

Trifexis. (spinosad+milbemycin oxime)

'She seems fine,' but you see pain

There's a fine line to walk when talking about pets' pain.



page 34



FLEAS
HEARTWORM
HOOKWORM
ROUNDWORM
WHIPWORM

ALL-IN-ONE PROTECTION FOR THE ONE WHO COUNTS ON YOU

Close gaps in protection with all-in-one Trifexis. With one convenient tablet administered monthly, it's simple for owners, so you can continue to be confident your patients get the protection they need.

INDICATIONS

Trifexis is indicated for the prevention of heartworm disease (*Dirofilaria immitis*). Trifexis kills fleas and is indicated for the prevention and treatment of flea infestations (*Ctenocephalides felis*), and the treatment and control of adult hookworm (*Ancylostoma caninum*), adult roundworm (*Toxocara canis* and *Toxascaris leonina*) and adult whipworm (*Trichuris vulpis*) infections in dogs and puppies 8 weeks of age or older and 5 pounds of body weight or greater.

IMPORTANT SAFETY INFORMATION

Serious adverse reactions have been reported following concomitant extra-label use of ivermectin with spinosad alone, one of the components of Trifexis. Treatment with fewer than three monthly doses after the last exposure to mosquitoes may not provide complete heartworm prevention. Prior to administration of Trifexis, dogs should be tested for existing heartworm infection. Use with caution in breeding females. The safe use of Trifexis in breeding males has not been evaluated. Use with caution in dogs with pre-existing epilepsy. The most common adverse reactions reported are vomiting, lethargy, pruritus, anorexia and diarrhea. To ensure heartworm prevention, dogs should be observed for one hour after administration. If vomiting occurs within one hour, redose. Puppies less than 14 weeks of age may experience a higher rate of vomiting. For product information, including complete safety information, see inside front cover.

Trifexis, Elanco and the diagonal bar logo are trademarks of Elanco or its affiliates. @ 2019 Elanco. PM-US-19-1101



Trifexis[™] (spinosad + milbemycin oxime) Chewable Tablets

Caution: Federal (USA) law restricts this drug to use by or on the order of a licensed veterinarian. Before using Trifexis, please consult the product insert, a summary of which follows: Indications:

TRIFEXIS is indicated for the prevention of heartworm disease (Dirofilaria immitis).

TRIFEXIS kills fleas and is indicated for the prevention and treatment of flea infestations (*Ctenocephalides felis*), and the treatment and control of adult hookworm (*Ancylostoma caninum*), adult roundworm (*Toxocara canis* and *Toxascaris leonina*) and adult whipworm (*Trichuris vulpis*) infections in dogs and puppies 8 weeks of age or older and 5 pounds of body weight or greater. **Dosage and Administration:**

TRIFEXIS is given orally, once a month at the minimum dosage of 13.5 mg/lb (30 mg/kg) spinosad and 0.2 mg/lb (0.5 mg/kg) milbemycin oxime body weight. For heartworm prevention, give once monthly for at least 3 months after exposure to mosquitoes (see **EFFECTIVENESS**). *Dosage Schedule:*

2000ge concate			
Body Weight	Spinosad	Milbemycin oxime	Tablets
	Per Tablet (mg)	Per Tablet (mg)	Administered
5 to 10 lbs	140	2.3	One
10.1 to 20 lbs	270	4.5	One
20.1 to 40 lbs	560	9.3	One
40.1 to 60 lbs	810	13.5	One
60.1 to 120 lbs	1620	27	One
Over 120 lbs	Administer the appropriate combination of tablets		

Administer TRIFEXIS with food for maximum effectiveness. To ensure heartworm prevention, owners should observe the dog for one hour after dosing. If vomiting occurs within an hour of administration, redose with another full dose. If a dose is missed and a monthly interval between doses is exceeded, then immediate administration of TRIFEXIS with food and resumption of monthly dosing will minimize the opportunity for the development of adult heartworm infections and flea reinfestations.

See product insert for complete dosing and administration information.

Heartworm Prevention:

TRIFEXIS should be administered at monthly intervals beginning within 1 month of the dog's first seasonal exposure and continuing until at least 3 months after the dog's last seasonal exposure to mosquitoes (see **EFFECTIVENESS**). TRIFEXIS may be administered year round without interruption. When replacing another heartworm preventative product, the first dose of TRIFEXIS should be given within a month of the last dose of the former medication.

Flea Treatment and Prevention:

Treatment with TRIFEXIS may begin at any time of the year, preferably starting one month before fleas become active and continuing monthly through the end of flea season. In areas where fleas are common year-round, monthly treatment with TRIFEXIS should continue the entire year without interruption.

To minimize the likelihood of flea reinfestation, it is important to treat all animals within a household with an approved flea protection product.

Intestinal Nematode Treatment and Control:

TRIFEXIS also provides treatment and control of roundworms (*T. canis, T. leonina*), hookworms (*A. caninum*) and whipworms (*T. vulpis*). Dogs may be exposed to and can become infected with roundworms, whipworms and hookworms throughout the year, regardless of season or climate. Clients should be advised of measures to be taken to prevent reinfection with intestinal parasites.

Contraindications:

There are no known contraindications to the use of TRIFEXIS.

Warnings:

Not for human use. Keep this and all drugs out of the reach of children.

Serious adverse reactions have been reported following concomitant extra-label use of ivermectin with spinosad alone, a component of TRIFEXIS (see **ADVERSE REACTIONS**). **Precautions:**

Treatment with fewer than 3 monthly doses after the last exposure to mosquitoes may not provide complete heartworm prevention (see **EFFECTIVENESS**).

Prior to administration of TRIFEXIS, dogs should be tested for existing heartworm infection. At the discretion of the veterinarian, infected dogs should be treated with an adulticide to remove adult heartworms. TRIFEXIS is not effective against adult *D. immitis*. While the number of circulating microfilariae may decrease following treatment, TRIFEXIS is not indicated for microfilariae clearance (see **ANIMAL SAFETY**).

Mild, transient hypersensitivity reactions manifested as labored respiration, vomiting, salivation and lethargy, have been noted in some dogs treated with milbemycin oxime carrying a high number of circulating microfilariae. These reactions are presumably caused by release of protein from dead or dying microfilariae.

Use with caution in breeding females (see **ANIMAL SAFETY**). The safe use of TRIFEXIS in breeding males has not been evaluated.

Use with caution in dogs with pre-existing epilepsy (see ADVERSE REACTIONS)

Puppies less than 14 weeks of age may experience a higher rate of vomiting (see **ANIMAL SAFETY**). Adverse **Reactions**:

In a well-controlled US field study, which included a total of 352 dogs (176 treated with TRIFEXIS and 176 treated with an active control), no serious adverse reactions were attributed to administration of TRIFEXIS. All reactions were regarded as mild.

Over the 180-day study period, all observations of potential adverse reactions were recorded. Reactions that occurred at an incidence >1% (average monthly rate) within any of the 6 months of observation are presented in the following table. The most frequently reported adverse reaction in dogs in the TRIFEXIS group was vomiting.

Average Monthly Rate (%) of Dogs With Adverse Reactions

Adverse Reaction	TRIFEXIS Chewable Tablets ^a	Active Control Tablets ^a
Vomiting	6.13	3.08
Pruritus	4.00	4.91
Lethargy	2.63	1.54
Diarrhea	2.25	1.54
Dermatitis	1.47	1.45
Skin Reddening	1.37	1.26
Decreased appetite	1.27	1.35
Pinnal Reddening	1.18	0.87

an=176 dogs

In the US field study, one dog administered TRIFEXIS experienced a single mild seizure 2 ½ hours after receiving the second monthly dose. The dog remained enrolled and received four additional monthly doses after the event and completed the study without further incident.

Following concomitant extra-label use of ivermectin with spinosad alone, a component of TRIFEXIS, some dogs have experienced the following clinical signs: *trembling/twitching, salivation/drooling, seizures, ataxia, mydriasis, blindness and disorientation.* Spinosad alone has been shown to be safe when administered concurrently with heartworm preventatives at label directions.

In US and European field studies, no dogs experienced seizures when dosed with spinosad alone at the therapeutic dose range of 13.5-27.3 mg/lb (30-60 mg/kg), including 4 dogs with pre-existing epilepsy. Four epileptic dogs that received higher than the maximum recommended dose of 27.3 mg/lb (60 mg/kg) experienced at least one seizure within the week following the second dose of spinosad, but no seizures following the first and third doses. The cause of the seizures observed in the field studies could not be determined.

For technical assistance or to report suspected adverse drug events, contact Elanco US Inc. at 1-888-545-5973. For additional information about adverse drug experience reporting for animal vugs, contact FDA at 1-888-FDA-VETS or http://www.fda.gov/AnimalVeterinary/SafetyHealth

Effectiveness: Heartworm Prevention:

In a well-controlled laboratory study, TRIFEXIS was 100% effective against induced heartworm infections when administered for 3 consecutive monthly doses. Two consecutive monthly doses did not provide 100% effectiveness against heartworm infection. In another well-controlled laboratory study, a single dose of TRIFEXIS was 100% effective against induced heartworm infections.

In a well-controlled six-month US field study conducted with TRIFEXIS, no dogs were positive for heartworm infection as determined by heartworm antigen testing performed at the end of the study and again three months later.

Flea Treatment and Prevention:

In a well-controlled laboratory study, TRIFEXIS demonstrated 100% effectiveness on the first day following treatment and 100% effectiveness on Day 30. In a well-controlled laboratory study, spinosad, a component of TRIFEXIS, began to kill fleas 30 minutes after administration and demonstrated 100% effectiveness within 4 hours. Spinosad, a component of TRIFEXIS, kills fleas before they can lay eggs. If a severe environmental infestation exists, fleas may persist for a period of time after dose administration due to the emergence of adult fleas from pupae already in the environment. In field studies conducted in households with existing flea infestations of varying severity, flea reductions of 98.0% to 99.8% were observed over the course of 3 monthly treatments with spinosad alone. Dogs with signs of flea allergy dermatitis showed improvement in erythema, papules, scaling, alopecia, dermatitis/pyodermatitis and pruritus as a direct result of eliminating the fleas.

Treatment and Control of Intestinal Nematode Infections:

In well-controlled laboratory studies, TRIFEXIS was \geq 90% effective in removing naturally and experimentally induced adult roundworm, whipworm and hookworm infections. *Palatability*:

TRIFEXIS is a flavored chewable tablet. In a field study of client-owned dogs where 175 dogs were each offered TRIFEXIS once a month for 6 months, dogs voluntarily consumed 54% of the doses when offered plain as if a treat, and 33% of the doses when offered in or on food. The remaining 13% of doses were administered like other tablet medications.

Storage Information:

Store at 20-25°C (68-77°F), excursions permitted between 15-30°C (59-86°F).

How Supplied:

TRIFEXIS is available in five tablet sizes. Each tablet size is available in color-coded packages of 6 tablets.

5-10 lbs (140 mg spinosad and 2.3 mg milbemycin oxime)

10.1-20 lbs (270 mg spinosad and 4.5 mg milbemycin oxime)

20.1-40 lbs (560 mg spinosad and 9.3 mg milberrycin oxime)

40.1-60 lbs (810 mg spinosad and 13.5 mg milbemycin oxime)

60.1-120 lbs (1620 mg spinosad and 27 mg milbemycin oxime)

NADA 141-321, Approved by the FDA

Manufactured for:

Elanco US Inc.

Greenfield, IN 46140

www.trifexis.com

Elanco, Trifexis and the diagonal bar are trademarks owned or licensed by Eli Lilly and Company, its subsidiaries or affiliates.





'She seems fine,' but you see pain

There's a fine line to walk when talking about pets' pain.



page 34

July 2019 | Volume 50 | Number 7 | dvm360.com

Too many pets, too little care

Once thought to be an eccentric hobby, animal hoarding is beginning to get the attention it deserves. *By Sarah Mouton Dowdy*

he definition of animal hoarding may surprise you. That's because the crux of what classifies a person as a hoarder isn't a particular number of animals—it's whether or not those animals are provided with sufficient care, says Fetch dvm360 conference educator Kirk Miller, DVM.



This means that someone with 20 cats who's able to meet all of their needs wouldn't classify as a hoarder. But a person with only seven cats who's overwhelmed by the situation and unable to provide a minimum level of care would.

As a clinical instructor of small animal primary care and shelter medicine at Oregon State University College of Veterinary Medicine and a practic-See page 19>



B ack in the mid-1990s, a pharmaceutical company was investigating a new drug called sildenafil as a potential treatment for heart disease. The drug did not improve anyone's cardiac function, so the company began the standard procedures to discontinue the clinical trial. When investigators told the

How David Bruyette's biotech startup is changing the way veterinary products come to market. By Jessica Vogelsang, DVM, CVJ

> participants the trial was over, they refused to return the drug. Confounded, the doctors asked why the men would want to keep a drug that didn't do anything for their heart condition.

Thus began the development of Viagra, perhaps the most successful serendipitous discovery in pharmaceutical industry history. Viagra follows the typical development arc for new pharmaceuticals: Scientists determine what a chemical compound does in the body, then see where it can be applied to human medicine. Lead with the solution, then find the problem. If a pharma company thinks a drug has potential, it launches a four-stage clinical trial. See page 18>



Notorious catkilling veterinarian loses appeal page 12



How tired are veterinary students, exactly? page 16



Do cameras belong in a veterinary hospital? page 28



Is ace not so ace for patients with fear aggression? page M6

Boehringer Ingelheim

The first solution for hypertension

- Semintra[®] (telmisartan oral solution) is the first FDA-approved angiotensin receptor blocker for first-line treatment of cats with hypertension¹
- Easy-to-use syringe allows for accurate dosing and flexible dosing²
- Safe for long-term administration, with once-daily dosing after 14 days¹

IMPORTANT SAFETY INFORMATION

SEMINTRA is an angiotensin II antagonist/angiotensin receptor blocker (ARB). Pregnant women should avoid contact with SEMINTRA because it can cause fetal and neonatal morbidity and death during pregnancy in humans. Pregnant women should avoid contact with SEMINTRA because other similar drugs have been found to harm the unborn baby during pregnancy. **Precautions:** SEMINTRA can cause mild anemia or non-regenerative anemia. Cats should be monitored for anemia when initiating treatment. Cats should be monitored for weight loss when initiating treatment with SEMINTRA. Use with caution in cats with a history of vomiting, inappetence, or weight loss. The safe use of SEMINTRA in cats with hepatic disease has not been evaluated. SEMINTRA is metabolized by the liver. SEMINTRA has not been evaluated in cats with systolic blood pressure > 200 mmHg. The safe use of SEMINTRA has not been evaluated in cats less than 9 months of age, or in cats that are pregnant, lactating, or intended for breeding. The safe use with other anti-hypertensive medications has not been evaluated. For more information, please see full prescribing information on page 03.

References: 1. Semintra® (telmisartan oral solution) Prescribing Information. Boehringer Ingelheim Vetmedica, Inc. 2018. 2. Zimmering T. Ease of use of Semintra® and its effects on quality of life—update on cat owner feedback ("EASY Programme") [abstract]. In: Proceedings from the 21st Federation of European Companion Animal Veterinary Associations (FECAVA); October 15–17, 2015; Barcelona, Spain. Poster.

Semintra® is a registered trademark of Boehringer Ingelheim Vetmedica GmbH, used under license. ©2019 Boehringer Ingelheim Animal Health USA Inc., Duluth, GA. All rights reserved. PET-0833-SEMI0319 18201





Mission

Through its extensive network of news sources, dvm360 provides unbiased multimedia reporting on all issues affecting the veterinary profession.

Content

News Channel Director | Kristi Reimer Fender kfender@mmhgroup.com

Business Channel Director | Brendan Howard Content Marketing Director | Adrienne Wagner Associate Editorial Director | Maureen McKinney Associate Content Specialists | Katie James, Hannah Wagle Clinical Techniques Course Manager | Jennifer Vossman, RVT, CMP Digital Content Director | Jessica Zemler Digital Design Director | Ryan Krame Associate Art Director | Nicholette Haigle Content Marketing Manager | Gabrielle Roman

Contributing Authors | Advisory Board

Christopher J. Allen, DVM, JD | Jan Bellows, DVM, DAVDC Bo Brock, DVM I Jeremy Campfield, DVM Ed Kane, PhD | Robert M. Miller, DVM Michael Paul, DVM | Marc Rosenberg, VMD

Account Manager | Angie Homann (913) 871-3917 | ahomann@mmhgroup.com Account Manager | Kelly Main (913) 871-3872 | kmain@mmhgroup.com Account Manager | Emma Pierce (913) 871-3873 | epierce@mmhgroup.com Account Manager | Terry Reilly (913) 871-3871 | treilly@mmhgroup.com Account Manager | Yousef Elhussein (609) 716-7777 | yelhusseini@mmhgroup.com Sales/Projects Coordinator | Anne Belcher (913) 871-3876 abelcher@mmhgroup.com Books/Resource Guide Sales | Kristina Bildeaux (507) 895-6758 | kbildeaux@mmhgroup.com

MultiMedia Healthcare LLC

President | Tom Ehardt Vice President & Managing Director | Christie McFall 913-871-3810 | cmcfall@mmhgroup.com Vice President, Digital Product Management | Mark Eisler Executive Creative Director | Marnette Falley Medical Director | Theresa Entriken, DVM Fetch dvm360 Director | Peggy Shandy Lane Business Manager | Chris Holston

Subscriber Services: Visit dvm360.com to request or change a subscription, or call our Customer Service Department toll-free at (888) 527-7008. Reprints: Call 877-652-5295 ext 121, or write to bkolb@wrightsmedia.com. Outside the U.S. and U.K., direct-dial (281) 419-5727 ext. 121. Books and Resource Guides: Visit industrymatter.com. List Rental Sales: Call Anne Belcher at (913) 871-3876, or write abelcher@mmharoup.com, Editorial Offices: MultiMedia Healthcare LLC, 11140 Thompson Ave., Lenexa, KS 66219; 913-871-3800. Websites: dvm360.com; fetchdvm360.com

Fetch dvm360 conference partners with Roark's Uncharted in Kansas City

Partnership brings an opportunity for attendees to join a live podcast taping with well-known veterinarian Dr. Andy Roark.

he upcoming Fetch dvm360 conference in Kansas City, Missouri, will partner with the Uncharted Veterinary Conference created by Andy Roark, DVM, the groups announced recently. Both conferences are designed to provide veterinary professionals with the latest clinical information, patient care tips, and practice management content in a live format.

The founder of the Uncharted Veterinary Conference, Dr. Roark has been a premier speaker at



dvm360 conferences and a contributor to dvm360. com for manv

Fetch

years. "Fetch has a great, fun vibe, just like Uncharted," says Dr. Roark, a practicing veterinarian and international speaker, in a dvm360 release. "I'm so excited for managers, practice owners and veterinary staff to attend Uncharted and Fetch and return home fired up, ready to make changes in the practice together."

The 2019 Uncharted Veterinary Conference, which will be held from Wednesday, Aug. 21, to Saturday, Aug. 24, offers attendees a special discount to attend Fetch dvm360 conference sessions from Friday, Aug. 23, to Monday, Aug. 26, with continuing education hours available. In addition, both conferences invite all attendees to join the first live Uncharted Veterinary Conference Podcast taping event Friday, Aug. 24, co-hosted by Dr. Roark and Practice Manager Stephanie Goss.

To find out more information, visit fetchdvm360.com/kansascity.

Semintra® (telmisartan oral solution) 10 mg/mL For oral use in cats only

Angiotensin II Receptor Blocker

Brief Summary: Before using SEMINTRA, please consult the product insert, a summary of which foll Caution: Federal law restricts this drug to use by or on the order of a licensed veterinarian

Description: SEMINTRA (telmisartan oral solution) is a clear, colorless to yellowish viscous solution containing 10 mg/mL telmisartan.

Indication and Usage: SEMINTRA is indicated for the control of systemic hypertension in cats. The initial dose of SEMINTRA is 1.5 mg/kg (0.68 mg/lb) orally twice daily for 14 days, followed by 2 mg/kg (0.91 mg/lb) orally once daily. The dose may be reduced by 0.5 mg/kg (0.23 mg/lb) increments to a minimum of 0.5 mg/kg (0.23 mg/lb) orally once daily to manage SEMINTRA-induced hypotension. SEMINTRA can be administered directly into the mouth, or next to or on top of a small amount of food. Do not mix into food.

SEMINTRA should be administered using the dosing syringe provided in the package. The dosing syringe fits onto the bottle and has 0.1 mL incremental marks. The dose should be rounded to the nearest 0.1 mL. After administration close the bottle tightly with the cap. Rinse the dosing syringe with water and let air dry.

If the cat vomits within 30 minutes of dosing, the cat may be re-dosed.

Information for Cat Owners: Adverse reactions can occur with use of SEMINTRA. The most common adverse reactions reported during the field studies included vomiting, diarrhea, lethargy, weight loss, anemia, and dehydration. Contraindications: Do not use in cats with a hypersensitivity to telmisartan.

Human Warnings: Not for human use. Keep out of reach of children.

SEMINTRA is an angiotensin II antagonist/angiotensin receptor blocker (ARB). Pregnant women should avoid contact with SEMINTRA because substances that act on the renin-angiotensin-aldosterone system (RAAS) such as angiotensin receptor blockers (ARBs) can cause fetal and neonatal morbidity and death during pregnancy in humans. Precautions: SEMINTRA can cause mild anemia or non-regenerative anemia. Cats should be monitored for anemia when initiating treatment with SEMINTRA.

SEMINTRA may cause inappetence and weight loss in some cats. Cats should be monitored for weight loss when initiating treatment with SEMINTRA. Use with caution in cats with a history of vomiting, inappetence, or weight loss. SEMINTRA has not been evaluated in cats with systolic blood pressure >200 mmHg.

The safe use of SEMINTRA in cats with hepatic disease has not been evaluated. SEMINTRA is metabolized by the liver. The safe use of SEMINTRA has not been evaluated in cats less than 9 months of age, or in cats that are pregnant, lactating, or intended for breeding. See Human Warnings.

The safe use with other anti-hypertensive medications has not been evaluated.

Adverse Reactions: The safety of SEMINTRA was evaluated in a 28-day field study in 192 cats. Adverse reactions that occurred include vomiting 46 (24.0%), diarrhea 18 (9.4%), lethargy 13 (6.8%), weight loss 13 (6.8%), decreased appetite/inappetence 13 (6.8%), non-regenerative anemia 11 (5.7%), dehydration 10 (5.2%), retinal lesions (target organ damage) 4 (2 1%). organ damage) 4 (2.1%).

The long-term safety of SEMINTRA was evaluated in an open-label, 5-month field effectiveness and safety study in 107 cats that received at least one dose of SEMINTRA. Adverse reactions that occurred in this study are weight loss 37 (34.6%), vomiting 32 (29.9%), dehydration 18 (16.8%), non-regenerative anemia 17 (15.8%), anorexia 14 (13.1%), diarrhea 12 (11.2%), lethargy 12 (11.2%), decreased appetite/inappetence 11 (10.3%), heart murmur 10 (9.3%), death euthanasia, found dead 9 (8.4%), cough 8 (7.5%), and retinal lesions (target organ damage) 6 (5.6%).

Nine cats died or were euthanized during the study. Three cats had progressive chronic kidney disease that may have been affected by telmisartan treatment, concurrent disease, or inadequate control of hypertension. The other six cats died of causes unrelated to treatment (e.g. neoplasia).

To report suspected adverse drug events, for technical assistance, or to obtain a copy of the Safety Data Sheet (SDS), contact Boehringer Ingelheim Vetmedica, Inc. at 1-866-638-2226. For additional information about adverse drug experience reporting for animal drugs, contact FDA at 1-888-FDA-VETS or at http://www.fda.gov/AnimalVeterinary/ SafetyHealth.

Effectiveness: Effectiveness was demonstrated in a 28-day multi-center, controlled, randomized and masked field study in client-owned cats with hypertension, and in an open-label 5-month field study. 28-Day Field Study

28-Day Field Study In a 28-day study, 288 cats with hypertension (systolic blood pressure [SBP] 160-200 mmHg) were enrolled in the study and randomized to treatment with SEMINTRA (telmisartan oral solution) (n=192) or vehicle control (n=96). The study population included cats with hypertension associated with chronic kidney disease or controlled hyperthyroidism, or idiopathic hypertension. The per protocol population for effectiveness was 141 SEMINTRA treated cats and 79 control cats. SEMINTRA was administered orally at 1.5 mg/kg twice daily for 14 days, then 2 mg/kg once daily until study end; the vehicle control was administered at a mL/kg volume equivalent to SEMINTRA. The two primary variables for effectiveness were comparison of the SEMINTRA group from baseline to Day 28. Cats with SBP >180 mmHg at Days 14 or 28 were rescued and removed from the study. There was a statistically significant difference between the mSBP for the SEMINTRA group mSBP decreased by 23.2 mmHg, and the control group mSBP decreased by 7.3 mmHg. At Day 28, the SEMINTRA group mSBP decreased 12.9 mmHg compared to baseline.

5-Month Field Study

5-Month Field Study One hundred-seven cats from the SEMINTRA group that had successfully completed the 28-day study were enrolled in a 5-month open-label study. At the beginning of the 5-month study most cats were administered SEMINTRA at 2 mg/k kg once daily. Cats that experienced hypotension (defined as SBP <120 mmHg) at 2 mg/kg once daily could have the SEMINTRA dose reduced to 1 mg/kg once daily. Cats that experienced hypotension at 1 mg/kg once daily could have the SEMINTRA dose reduced again to 0.5 mg/kg once daily. Cats were evaluated for SBP target organ damage (TOD; primarily assessed by retinal photographs), clinical pathology and adverse reactions. SBP was measured on Days 28, 56, 98, 140 and 182 and retinal photographs and clinical pathology were collected on Days 28, 98 and 182. Seventy-three (68.2%) cats completed the study (Day 182), 8 cats were removed for hypertension (SBP >180 mmHg), 2 cats were removed for hypotension, 10 cats were removed for adverse reactions unrelated to TOD. Twenty-six cats had dose reductions to 1 mg/kg once daily to manage hypotension. Of these 26 cats, 10 had an additional dose reduction to 0.5 mg/kg once daily. NADA 141-501, Approved by FDA

NADA 141-501, Approved by FDA Manufactured for:

Boehringer Ingelheim Vetmedica, Inc St. Joseph, MO 64506, U.S.A.

SEMINTRA is a registered trademark of Boehringer Ingelheim Vetmedica GmbH, used under license

© 2018 Boehringer Ingelheim Vetmedica, Inc. All Rights Reserved.

Reference: Package Insert 449201-00 Revised 03/2018 09/2018



GETTHE BESSE VETERINARY CE

Connect with like-minded animal care professionals!

A Fetch dvm360[®] conference offers you the opportunity to network, brainstorm and learn from expert speakers and other veterinary professionals. With evidence-based continuing education opportunities and hundreds of exhibitors, Fetch dvm360[®] has something for everyone in your practice.

Kansas City, MO | Aug. 23-26



Inside | CONTENT



NEWS 3 | Fetch dvm360

- » Fetch dvm360 conference partners with Roark's Uncharted in KC
 » Christie McFall named
- 'Top Woman in Media'



8 | Veterinary headlines

- » N.Y. state poised to ban declaws» CAPC study: Dogs can predict Lyme
- disease risk for humans

10 | Education

12 | Lone Star State

- » Notorious cat-killing veterinarian loses appeal
- » Texas Tech takes a \$17 million step toward new veterinary school

14 | Veterinary headlines

- » 'Luna' overtakes 'Bella' as top puppy name
- » Kansas State University names Bonnie Rush dean of veterinary school

15 | Endocrinology AAFP releases feline diabetes toolkit

16 | Emotional well-being How tired are veterinary students, exactly?

22 | Hospital design Minimal clutter, maximum efficiency





ON THE COVER A drug's life cont on pg 18

PLUS: Too many pets, too little care cont on pg 19

MEDICINE360

The small animal section begins after **page 34**.

M1 | Infectious disease

Fun with feline flu: Can cats get influenza? *Jenifer Chatfield, DVM, DACZM*

M4 | Surgery STAT Pinch and flush: Relieving urethral obstructions in male dogs *Andrew Jackson, DVM, DACVS*

M6 | Behavior Is ace not so ace for examining patients with fear aggression? *Julia Albright, MA, DVM, DACVB*

M8 | Nephrology

Do we *really* know what we think we know about feline CKD? *Hilal Dogan, BVSc, CCTP*

PRODUCTS360 40 | Dentistry

The dental dozen: 12 products that improve oral health *Jan Bellows, DVM, DAVDC, DABVP, FAVD*

43 | The latest veterinary products

33 | Alternative medicine Let's talk cannabidiol

35 | Business Banfield develops telehealth service

36 | Microchipping Comparison chart: Pet identification microchips

38 | Equine medicine When to REACT: Colic in horses



COMMUNITY 34 | Commentary 'She seems fine,' but you seen pain *Gina Singleton, DVM*

SPECIAL CONTRIBUTORS 26 | AVMA Eye on Economics

Will the feds forgive your student loans? Matthew Salois, PhD Caroline Cantner, VMD

28 | The Dilemma

Do cameras belong in a veternary hospital? *Marc Rosenberg, VMD*

30 | Letter of the Law 8 steps in a practice sale *Christopher J. Allen, DVM, JD*

32 | Can We Talk?

The most important things are simple—but they're not easy *Michael Paul, DVM*

50 | Stampede His one weakness *Bo Brock, DVM*

READER SERVICES 49 | Calendar







NO TIME TO WASTE WHEN CARE IS CRITICAL



NUTRITIONAL SUPPORT CAN SPEED UP RECOVERY AND IMPROVE PATIENT OUTCOMES* Introducing the most comprehensive range of liquid diets designed for tube feeding.

EASY TO USE

Start feeding in less than a minute-

blenderizing for NE and NG tubes

no mixing, reconstituting or

✓ INNOVATIVE CAP DESIGN

Specialized cap for quick and easy syringe withdrawal and usage

✓ CRITICAL NUTRITION

Also includes EPA+DHA and an antioxidant complex

*Brunetto MA et al. Effects of nutritional support on hospital outcome in dogs and cats. J Vet Emerg Crit Care. 2010; 20: 224–231. Mohr AJ et at. Effect of early enteral nutrition on intestinal permeability, intestinal protein loss, and outcome in dogs with severe parvoviral enteritis. J Vet Int Med. 2003; 17: 791–798.

N.Y. state poised to ban declaws

If Gov. Cuomo signs the bill, New York will impose a civil penalty of \$1,000 on people who perform onychectomies, partial or complete phalangectomies, or tendonectomies on cats without 'a therapeutic purpose.' *By Brendan Howard*

ew York could become the first state to ban feline declaws if Gov. Andrew Cuomo signs a new bill, passed on June 4, on its way to his office.

The bill (A1303B and S5532B), first sponsored by New York State Assemblymember Linda Rosenthal (D-Manhattan), would create a civil penalty of \$1,000 for anyone who performs "an onychectomy, partial or complete phalangectomy or tendonectomy procedure by any means on a cat within the state of New York, except when necessary for a therapeutic purpose."

The bill goes on to state that the procedure can only be performed for

the cat's medical needs: "Therapeutic purpose means the necessity to address the physical medical condition of the cat, such as an existing or recurring illness, infection, disease, injury or abnormal condition in the claw that compromises the cat's health. Therapeutic purpose does not include cosmetic or aesthetic reasons or reasons of convenience in keeping or handling the cat."

Gov. Cuomo will review the bill before deciding whether to sign it, according to an AP report.

The state's veterinary association the New York State Veterinary Medical Society—opposed the law in a recent memo, stating that the declaw decision should be in the hands of veterinarians: "[We] strongly encourage client education prior to consideration of declawing and believe the decision to declaw or not declaw a pet should be made by the pet owner in consultation with his or her veterinarian."

Other groups and governments have banned feline declaws, including many European countries, most of Canada's provinces (and VCA of Canada) and a handful of cities across the United States (including Denver, Los Angeles and San Francisco).

Rosenthal had introduced a bill in 2015 to ban declaws, but it died in



committee in 2016. Other declaw bans have been introduced in state legislatures in the past few years, including California, Hawaii, Rhode Island and New Jersey, but none have passed.

CAPC study: Proactive surveillance means dogs can predict Lyme disease risk for humans

According to new research from parasite council, regular monitoring of canine seroprevalence shows where people are at highest risk of contracting tick-borne disease.

dvocates of the One Health model focus on how veterinary medicine can positively impact other areas of health and vice versa. A new study from the Companion Animal Parasite Council (CAPC) gives credence to this idea. It found that regularly testing dogs for tick-borne illness can help predict where humans are at risk of Lyme disease.

The study quantifies the association between canine seroprevalence for *Borrelia burgdorferi* and human incidence of Lyme disease, according to a release from CAPC. As seroprevalence for *B. burgdorferi* in dogs increases, so does human incidence of Lyme disease.

Using data from dogs is less expensive and logistically challenging than monitoring Lyme disease rates in people, the release states. Canine seroprevalence monitoring is active and data are reported monthly at the county, state and national levels. In contrast, human Lyme disease surveillance is conducted passively, and it's difficult to gather contemporary data, researchers say.

"Unlike human medicine, veterinarians are fortunate to have the advances and commonality of annual testing and

vaccination for Lyme disease in dogs," says Karen Fling, DVM, president of East Lake Veterinary Hospital in Dallas, Texas, in the release.

Human risk of exposure now goes beyond the traditional realm of the northeastern United States. States that include mostly high-incidence areas (10 cases



CAPC maps (available at capcvet.org or petsandparasites.org) show disease prevalence in pets down to the county level

or more per 100,000 humans) include Minnesota, Wisconsin and Virginia. Bordering states with some high-incidence areas include Michigan, Iowa, Illinois, West Virginia and North Carolina, according to the release.

Veterinarians, physicians and pet owners can access canine data on the CAPC website (petsandparasites.org) to assess risk for exposure.

The key to a safer practice is right in front of you.



Most pracitces struggle with controlled

substances. Time consuming and inaccurate logs, missing lockbox keys, and unresolved discrepancies are all threats to practice health.

CUBEX[®] can help. Key features:

- Single-item access for maximum safety
 - Fingerprint ID no more lost keys
- Automated controlled substance logs
- Electronic invoicing (with most PIMS)

Charging a small **controlled substance handling fee** of \$3 to \$5 will typically offset the cost of CUBEX, and can even create a new profit center for your practice. Solutions start at **just \$15 per day.**

Get started at **cubex.com/mini** or by calling 866-930-9251







Recomended by #4EyesSaveLives Keep your staff safe with the option to require a witness for each narcotic transaction



CBD epilepsy trial results 'encouraging'

The team behind the research at CSU found that 89% of dogs in study experienced a reduction in seizure frequency.

ew findings from a pilot study to assess the use of cannabidiol (CBD) oil for dogs with epilepsy are "promising and exciting," according to a recent release from Colorado State University.

The study, led by Stephanie Mc-Grath, MS, DVM, DACVIM, a neurologist at Colorado State University's James L. Voss Veterinary Teaching Hospital, and sponsored by Applied Basic Science Co., assessed the short-term effects of CBD on seizure frequency in dogs. Of the patients that received CBD in the clinical trial, 89% had a reduction in the frequency of seizures, the release states.

In this blinded study, 26 clientowned dogs with idiopathic epilepsy were assigned randomly to either the treatment or placebo (control) group for 12 weeks; 12 dogs were treated with CBD-infused oil, while 14 were given noninfused oil. All dogs remained on standard anticonvulsant medications, including phenobarbital and potassium bromide. After exclusions, nine dogs in the CBD group and seven in the control group were included in the analysis.

The CBD oil used in the study was derived from hemp, which has 0.3% or less of the psychoactive component of cannabis (THC), the release states. The compound is not considered to be marijuana and can be used for research purposes based on the 2014 Farm Bill. In addition to the distinct reduction

in seizure frequency in the dogs that received CBD, there was

a significant association between the degree of seizure reduction and the concentration of CBD in the blood. "We saw a correlation between how high the levels of CBD oil were in these dogs with how great the seizure reduction was," Dr. McGrath says in the release.

Based on the results of this study, Dr. McGrath adjusted the dose of CBD oil for dogs in an ongoing clinical trial that aims to enroll 60 client-owned dogs with epilepsy. She also hopes to launch a new study later this year to determine the optimal dose of CBD to treat epilepsy in

dogs.

Penn Vet announces new entrepreneurship program

This immersive program is designed to build entrepreneurial skills and affect public health on a larger scale. *By Maureen McKinney*

he veterinary profession's influence on public health is becoming ever more evident. Veterinarians can offer insight and ideas that address complex societal issues ranging from public health to human and animal well-being.

That's why the University of Pennsylvania School of Veterinary Medicine has added the Leading Veterinary Entrepreneurs to its continuing education platform.

The intensive executive program, which is intended for veterinarians, scientists, technologists, academic leaders and innovators, covers topics like entrepreneurship fundamentals, global challenges for veterinarians, the landscape of healthcare, utilizing resources, and fostering partnerships, sociopolitics and leadership. The first session took place in June.

"This program is designed to prepare individuals to take on an entrepreneurial mindset that may be outside their areas of education and experience," Andrew Hoffman, DVM, DVSc, Gilbert S. Kahn Dean of Veterinary Medicine at Penn Vet and the program's academic director, says in a release from the university. It's intended to introduce the foundational skills needed to develop a new product, service or to identify new organizational opportunities, says Dr. Hoffman.

Veterinarians are uniquely situated to conceptualize solutions that can enhance the quality of animal and human lives, from appliances that improve pet mobility to devices that monitor our food supply to new medical treatments to treat disease, Dr. Hoffman says.

"It is our role as educators to make sure our students and alumni are well equipped to identify market opportunities that could lead to entrepreneurial careers that parallel, or go beyond, the practice of medicine," he says.

entyce® (capromorelin oral solution)

30 mg/mL

BRIEF SUMMARY: Before using this product, please consult the full product insert for more information.

For oral use in dogs only Appetite Stimulant

Caution: Federal (USA) law restricts this drug to use by or on the order of a licensed veterinarian.

Description: ENTYCE® (capromorelin oral solution) is a selective ghrelin receptor agonist that binds to receptors and affects signaling in the hypothalamus to cause appetite stimulation and binds to the growth hormone secretagogue receptor in the pituitary gland to increase growth hormone secretion.

Indication: ENTYCE (capromorelin oral solution) is indicated for appetite stimulation in dogs.

Contraindications: ENTYCE should not be used in dogs that have a hypersensitivity to capromorelin.

Warnings: Not for use in humans. Keep this and all medications out of reach of children and pets. Consult a physician in case of accidental ingestion by humans. For use in dags only

Precautions: Use with caution in dogs with hepatic dysfunction. ENTYCE is metabolized by CYP3A4 and CYP3A5 enzymes (See Clinical Pharmacology). Use with caution in dogs with renal insufficiency. ENTYCE is excreted approximately 37% in urine and 62% in feces (See Adverse Reactions and Clinical Pharmacology). The safe use of ENTYCE has not been

The safe use of ENTYCE has not been evaluated in dogs used for breeding or pregnant or lactating bitches.

or pregnant or lactating bitches. Adverse Reactions: Field safety was evaluated in 244 dogs. The most common adverse reactions were diarrhea and vomiting. Of the dogs that received ENTVCE (n = 171), 12 experienced diarrhea and 11 experienced vomiting. Of the dogs treated with placebo (n = 73), 5 experienced diarrhea and 4 experienced vomiting.

To report suspected adverse drug events and/or obtain a copy of the Safety Data Sheet (SDS) or for technical assistance, call Aratana Therapeutics at 1-844-640-5500.

For additional information about adverse drug experience reporting for animal drugs, contact FDA at 1-888-FDA-VETS or online at http://www.fda.gov/Animal Veterinary/SafetyHealth NADA 141-457, Approved by FDA

US Patent: 6,673,929 US Patent: 9,700,591

Made in Canada



Manufactured for: Aratana Therapeutics, Inc. Leawood, KS 66211 ENTYCE is a trademark of Aratana Therapeutics, Inc © Aratana Therapeutics, Inc.

AT2-051-1 February 2018

WITH REDUCED APPETITE, THERE'S MORE THAN MEETS THE EYE



Don't wait for weight loss.

Stimulate appetite early to treat the whole picture.

Long before you see physical changes, small reductions in eating can deprive patients with chronic medical conditions of the essential nutrition they need to support strength and energy, healing and immune response.

Take a closer look at entyce.aratana.com

Add ENTYCE® (capromorelin oral solution) at the first sign of decreased eating as part of your overall treatment plan.

entüce

- ✓ Proven safe for long-term use¹
- Seffectively stimulates appetite to help improve food consumption
- The ONLY FDA-approved appetite stimulant for dogs

¹ Zollers B, Huebner M, Armintrout G, Rausch-Derra LC, Rhodes L. Evaluation of the safety in dogs of long-term, daily oral administration of capromorelin, a novel drug for stimulation of appetite. J Vet Pharmacol Ther. 2017 Jun;40(3):248-255. doi: 10.1111/jvp.12358. Epub 2016 Sep 25.

IMPORTANT SAFETY INFORMATION: ENTYCE[®] (capromorelin oral solution) is for use in dogs only. Do not use in breeding, pregnant or lactating dogs. Use with caution in dogs with hepatic dysfunction or renal insufficiency. Adverse reactions in dogs may include diarrhea, vomiting, polydipsia, and hypersalivation. Should not be used in dogs that have a hypersensitivity to capromorelin. Please see the full Prescribing Information on page 10 for more detail.

©2019 Aratana Therapeutics, Inc. ENTYCE is a registered trademark of Aratana Therapeutics, Inc.

ENT-0364



Cat-killing veterinarian loses appeal in court

The Texas Supreme Court has reaffirmed the decision to hold Kristen Lindsey, DVM, accountable for her actions in 2015 that sparked international outrage. *By Maureen McKinney*

n April 15, 2015, Texas veterinarian Kristen Lindsey, DVM, made the fateful decision to post a photo of herself on Facebook holding a cat that she had just shot with a bow and arrow. The image, accompanied by boastful comments about the kill, including "My first bow kill ... lol," quickly went viral and incited the wrath of pet lovers and veterinary professionals around the world.

Shortly after the incident occurred, Dr. Lindsey was fired from her position at the Washington Animal Clinic in Brenham and her actions were denounced by the AVMA, the Texas Veterinary Medical Association and her alma mater, Colorado State University.

In 2016, citing ethics violations and animal cruelty, the Texas Board of Veterinary Medical Examiners suspended Dr. Lindsey's veterinary license for one year to be followed immediately by four years of probation.

According to court records, Dr.

Lindsey's appeal to the Texas Supreme Court to revoke her punishment was denied late last week. She remains permitted to practice veterinary medicine only on a probationary basis until February 2020.

Although Dr. Lindsey admitted to killing the animal, she said the feral cat had been on her property, which gave her the right to kill it. But neighbors said the cat was a pet named Tiger.

"This was a case of a veterinarian not only ignoring her responsibility to relieve suffering, but actually rejoicing in the suffering she was inflicting on Tiger," said Becky Robinson, president and founder of Alley Cat Allies in a statement on the group's website. "The Texas Supreme Court now becomes the highest authority in the state to confirm what we've known all along that Kristen Lindsey is wholly deserving of punishment for her brutal killing of Tiger."

Prior to appealing to the Texas Supreme Court, Dr. Lindsey made several



Lindsey testifying at an administrative hearing in 2016.

failed attempts in lower courts to have her punishment revoked, claiming that it negated the right of property owners to protect their home and land against damage caused by animals.

According to a report on the Veterinary Information Network, Dr. Lindsey will not pursue further appeals in her case. It is unclear whether she is practicing veterinary medicine at this time.

Texas Tech takes a \$17.4 million step toward new veterinary school Funding in state budget-now approved by governor-is

more than four times previous amounts allotted by legislators.

Texas state legislative committee voted in May to include \$17.4 million in the state budget to establish a new veterinary school at Texas Tech University. The amount is a significant increase from the roughly \$4 million included in the first budget, according to a story from the *Lubbock Avalanche-Journal*.

Seven Texas congresspeople announced the funding to help "address the shortage of large and mixed animal veterinarians in rural parts of the state" and "to secure the food supply." "The school will address the hundreds of students who are leaving the state of Texas for a more costly education, then coming back to practice in their home state with upwards of \$250,000 in debt due to out-of-state tuition," the legislators' release states.

Texas Tech first announced plans to develop the school in Amarillo, Texas, in 2015, forming a steering committee the next year. Two years later, plans for the school inspired a local economic development group to pledge up to \$69 million to help with construction. The new college of veterinary medicine would join Texas A&M University as the second Texas school to educate veterinarians. The two schools squabbled back in 2016 about the need for the school, with Texas A&M against a new veterinary school at the time and arguing that their off-campus partnerships would take care of the state's needs for food animal and agricultural veterinarians.

Gov. Greg Abott signed the full \$250 million state budget on June 15 with no line-item vetoes.



All the news you need Get updates in the veterinary industry as they happen at dvm360.com/news.



When urinary issues make him act out of character, look to the comprehensive nutrition of c/d[®] Multicare.

TOTAL URINARY CARE - INCLUDING STONES AND FIC



The ONLY nutrition shown in a controlled study to reduce the rate of recurring feline idiopathic cystitis (FIC) signs by 89%

1000

Dissolves struvite stones in as little as 7 days (average 27 days)²

Reduces urine calcium and the risk of calcium oxalate crystal formation 2X better than leading competitor³⁴

¹Kruger JM, Lulich JP, MacLeay J, et al. Comparison of foods with differing nutritional profiles for long-term management of acute nonobstructive idiopathic cystitis in cats. J Am Vet Med Assoc. 2015;247(5):508-517. ²Lulich JP, Kruger JM, MacLeay JM, et al. Efficacy of two commercially available, low-magnesium, urine acidifying dry foods for the dissolution of struvite uroliths in cats. J Am Vet Med Assoc. 2013;243(8):1147-1153. ²Gluhek T, Bartges JW, Callens A, et al. Evaluation of 3 struvite-oxalate preventative diets in healthy cats. J Vet Intern Med. 2012;26:801. ⁴Data on file. Hill's Pet Nutrition, Inc. 2017. Urine calcium directly measured and risk of calcium oxalate crystal formation measured by Hill's COT test vs. US ROYAL CANIN VETERINARY DIET[®] Feline Urinary S0[®] dry formula.

©2018 Hill's Pet Nutrition, Inc. ®/* Hill's, Prescription Diet and c/d Multicare are trademarks owned by Hill's Pet Nutrition, Inc. The referenced Royal Canin products are trademarks of Royal Canin.



Urinary Care



HillsVet.com



'Luna' overtakes 'Bella' as top name for puppies

What are the most common puppy names you might be seeing at your veterinary practice? Nationwide says a *Harry Potter*-inspired name beat out *Twilight*.

hat are people naming puppies these days? Nationwide shared its list of names of dogs 2 years or younger drawn from a database of more than 750,000 insured pets.

The top five most popular puppy names and in what states are:

1. "Luna" (from fan-favorite character Luna Lovegood in the *Harry Potter* books) was tops in California, Colorado, Connecticut, Delaware, Florida, Indiana, Massachusetts, Michigan, Minnesota, New Jersey, New York, Ohio, Pennsylvania, South Dakota, Utah, Virginia, Washington, Wisconsin and Wyoming.

2. "Bello" (from the main character in the *Twilight* series—a name that has spent years atop lists for both dogs and cats of all ages) was most popular in Alabama, Arizona, Georgia, Hawaii, Idaho, Iowa, Kansas, Mississippi, Nevada, New Hampshire, North Carolina, Oklahoma, Oregon, South Carolina, Tennessee and Texas.

3. "Charlie" was the favorite puppy name in Illinois.

4. "Bailey" was tops in Kentucky and Maryland.

5. "Cooper" won in Maine, Missouri and Rhode Island.

Other state-by-state winners include these classics:

"Buddy" (New Mexico)
"Duke" (Arkansas)
"Louie" (North Dakota)
"Lucy" (Alaska, Ohio)
"Max" (Nebraska)
"Molly" (West Virginia)
"Penny" (Washington, D.C.)
"Ruger" (Vermont)
"Sadie" (Montana)
"Stella" (Louisiana).

Kansas State University announces Bonnie Rush as dean of vet school

Dr. Rush has been at K-State since 1993 and interim dean since 2017.

fter a national search, Bonnie Rush, DVM, MS, DACVIM, has been selected as the new dean of the College of Veterinary Medicine at Kansas State University. Rush has been serving as interim dean since 2017.

"With her strong history of leadership for the College of Veterinary Medicine, Dr. Rush is the right choice to lead this college and its vital teaching, research, service and outreach programs into the future," says Charles Tabor, MS, PhD, provost and executive vice president of Kansas State University, in a release from the university.

Dr. Rush became a faculty member

at Kansas State University in 1993 and head of the clinical sciences department in 2006, where she coordinated core courses, led curriculum reform and maintained responsibility for clinical outcome assessment, according to the release. As a professor of equine internal medicine, Dr. Rush specializes in equine respiratory disease with an emphasis on respiratory physiology, immunology and aerosol drug therapy.

As dean, she will be tasked with program development, faculty and student development, research, teaching and extension, program accreditation, diversity and the 2025 plans for both the college and the university, according to the release. The College of Veterinary Medicine has three academic departments and two service units, and provides broad training opportunities across companion and exotic animals and livestock species.

"It has been an honor to serve as the interim dean," Dr. Rush says in the release. "The students, faculty and staff of the College of Veterinary Medicine are tremendously talented and committed to advancing the missions to strengthen animal health and well-being through research, education and service."

Her appointment began June 16.



Bonnie Rush, DVM, MS, DACVIM

Endocrinology | NEWS



Resource aims to make treatment of diabetes in cats more effective.



iagnosing, treating and monitoring diabetes in cats is challenging, in part because every patient requires a customized treatment plan that must be reassessed and adjusted on an ongoing basis.

To help veterinary professionals make the best diagnostic and treatment decisions for their feline patients, the American Association of Feline Practitioners (AAFP) has released a Diabetes Educational Toolkit.

This digital resource is intended to help veterinary professionals access and gather information quickly from clients, according to an AAFP release. The toolkit focuses on diagnosis, treatment, remission strategy, troubleshooting and frequently asked questions. Each section of the toolkit can be downloaded and printed for easy accessibility in the practice.

The release notes that effective treatment of diabetes in cats is based on a combination of patient goals, client finances, implementation of the treatment plan and the patient's response. A strong partnership between the veterinarian and the cat owner is key.

"We are excited to release this digital resource to the veterinary community in the hopes that we can help veterinary professionals in the diagnosis and treatment of their diabetic feline patients," Apryl Steele, DVM, president of the AAFP Board of Directors, says in the release.

The toolkit was made possible by an educational grant from Boehringer Ingelheim and developed by Audrey Cook, BVM&S, Msc VetEd, DACVIM-SAIM, DECVIM-CA, DABVP (feline); Kelly St. Denis, DVM, DABVP (feline); Sonnya Dennis, DVM, DABVP (canine/feline); and Elaine Wexler-Mitchell, DVM, DABVP (feline), chair.

Access the toolkit at catvets.com/ diabetes-toolkit.

Another resource dvm

Visit us online to find more feline care content dvm360.com/felinecenter.



Why treat just the signs of canine osteoarthritis when you can proactively treat the disease?

Only Adequan® Canine (polysulfated glycosaminoglycan) empowers you to proactively treat the disease and not just the signs of canine osteoarthritis (OA). In fact, it's the only FDA-approved diseasemodifying osteoarthritis drug (DMOAD) that inhibits cartilage loss in a dog's joint.* It may also help to:¹

• restore joint lubrication • relieve inflammation • renew the building blocks of healthy cartilage *The specific mechanism of action of Adequan® in canine joints is not known. Discover if Adequan[®] Canine is the right choice for your patients.

The difference between feeling better and getting better.® Visit adequancanine.com or contact your distributor.



polysulfated glycosaminoglycan

Adequan® Canine brand of polysulfated glycosaminoglycan (PSGAG)

INDICATIONS Adequan® Canine is recommended for intramuscular injection for the control of signs associated with non-infectious degenerative and/or traumatic arthritis of canine synovial joints. IMPORTANT SAFETY INFORMATION Adequar[®] Canine should not be used in dogs who are hypersensitive to PSGAG or who have

a known or suspected bleeding disorder. It should be used with caution in dogs with renal or hepatic impairment. Adverse reactions in clinical studies (transient pain at injection site, transient diarrhea, and abnormal bleeding) were mild and self-limiting. In post approval experience, death has been reported in some cases; vomiting, anorexia, depression/lethargy and diarrhea have also been reported. The safe use of PSGAG in breeding, pregnant or lactating dogs has not been evaluated. **Caution:** Federal law restricts this drug to use by or on the order of a licensed veterinarian. For additional safety information, **please see Full Prescribing Information at**

adequancanine.com. 1. Adequan® Canine Package Insert, Rev. 1/19. Adequan and the Dog Head design are registered trademarks of American Regent, Inc. © 2019, American Regent, Inc. PP-AC-US-0119 6/2019

NEWS | Emotional well-being

From our readers

We got some great personal feedback on this study on Facebook. A few highlights:

"The pinnacle for me was my surgery rotation. There were supposed to be eight students, but there was an outbreak of MRSA on the surgery ward, so four dropped it last minute. So we had the case load for eight, with four students. I was there every day until 11 p.m., and had to be back the next morning for 5 a.m. to have all my patients written up before rounds. Let's just say that is not the ideal way to learn. Definitely nearly passed out holding a leg for the surgeon. I lost 10 pounds in two weeks."

—Teresa Bousquet

"I was super sleepy, and still am 12 years later. In vet school I used to stay at school until sometimes 8 or 9 at night, study until 1 a.m. then set my alarm for 4, study for a bit then go back to school. I can't believe I did it. Then 10 years of on call. Needless to say, my sleep is now permanently screwed." *—Heather James*

"Just because it's the way it's always been, doesn't mean it has to be that way forever. Even if that's how it is in practice, no reason schools can't have it be better. I'm sure someone will reply with something along the lines of 'spoiled millennials,' and 'we had to put in our time, so should you.' But if that's true, and you suffered, why not let that motivate you to affect change?

"IDK. I survived clinics despite the lack of sleep. I know there's sleepless nights ahead. But if students after me can have it easier? Great. I want that for them." *—Lucy Rose*



Veterinary students sleep like babies ... as in definitely not enough and they usually wake up crying.

How tired are vet students, exactly?

No shocker, veterinary students are tired. This new study proves it and raises a new question: Now what? By Brendan Howard

ee, it all started when Michael Nappier, DVM, DABVP, was making the argument that checklists built from Partners for Healthy Pets material could help veterinary students perform better, more consistent wellness exams. He was surprised at the pushback.

"Believe it or not, I got this feedback: 'We know checklists are useful in situations where people are under stress or sleep-deprived, like airline pilots or human-medicine surgeons, but we have no data that veterinary students are stressed or sleep-deprived," Dr. Nappier says. "It was one of the most confoundingly ridiculous statements I'd heard in a long time, especially with all the talk in the profession about wellness."

So, Dr. Nappier and three other study coauthors surveyed veterinary students at the Virginia-Maryland College of Veterinary Medicine in Blacksburg, Virginia, at five points (September, November, December, February and May) over the course of an academic year to quantify their perceived sleep quality and sleepiness during activities. The study used the Pittsburgh Sleep Quality Index and Epworth Sleepiness Scale, and the results showed that the 312 students participating had poor sleep quality and above-average to excessive daytime sleepiness. (See Table 1.)

Table 1: Means across 5 time points for sleep quality and sleepiness

Month	Sleep Quality	Sleepiness
September	7.05	9.24
November	7.43	9.79
December	7.38	9.68
February	7.37	9.41
Мау	6.78	8.63

Dr. Nappier hopes the research will spur critical examination of veterinary school curriculum and evaluation of how students spend time in school. One possible takeaway for Dr. Nappier: "I remember my own time as a veterinary student. I'd be in the hospital 24 hours straight. As I review this data about how tired students are, I'm thinking hey, if you're going to work overnight in ICU, maybe you shouldn't have to be on the next day."

Adjusting the curriculum and pace of assessments is another change the research could support, he says. "We're asking students to digest so much, and we cram in back-to-back assessments during their education. Let's step back. Why are we doing it this way? Is everything we're teaching truly material they need as veterinarians? How many hours are we physically expecting them to be there and learning?"

It's easy to say veterinary school is just stressful. Veterinary students will survive, graduate and get out in the real world, where, in theory, they'll be more well-rested. "Veterinary school is their real world for a number of years, though," says Dr. Nappier. "Yes, we produce excellent clinicians—but at what personal cost?"

What's your vision for the future of your business?



Questions to ask as you enter discussions with potential partners.



<u>NO.</u>01

Is it the right culture fit for your team?

As you begin considering your options for selling your pet hospital business, it's important to find a partner aligned with your values, respectful of the individuality of what you've built, and equipped to grow your business, while your team and culture remain intact.

Ask around to find out which buyers have the best reputation for caring for pets and the people who love them.

NO. 02Are there flexible

deal structures?

Because selling your pet hospital is such a personal decision, you'll want to understand what types of options are available, and to what level they can tailor the terms to

ASK IF THE BUYER CAN:

meet your needs.

- Make all cash offers with no finance contingency
- Offer Joint Venture partnerships for growth and flexibility
- Buy the real estate outright or lease from you

<u>NO.</u>03

How comprehensive are the support services?

As you contemplate transitioning your business, you'll want to know every aspect is covered. Seek out a partner with a dedicated team seasoned in marketing (including digital advertising and social media strategy), web development and hosting, client satisfaction surveys, IT, HR, accounting, taxes, legal and more.

We're confident that we can care for and grow your practice like no one else. We'd be more than happy to talk through your questions. You can reach us at: 888.767.7755 | NVA.com | info@NVA.com



NEWS | Cover story

A drug's life

> Continued from the cover

Ten years and \$100 million later, about 14% of those drugs make it through the FDA approval process to market. The FDA mandates a drug be safe and effective. The pharmaceutical company that spends the \$100 million mandates it be profitable.

Somewhere in another part of the building, the animal health divisions of large pharma companies wait on the sidelines. "What typically happens in these big pharma companies is that a drug bombs on the human side and they give it to the vet side," says David Bruyette, DVM, DACVIM, chief medical officer at Anivive Lifesciences. "Then they say, 'See if you can make something happen with it.""

If there's potential, the process starts all over again with a new veterinary trial. This laborious, timeconsuming and expensive series of steps may explain why FDA-approved veterinary drugs are so sparse. But Dr. Bruyette thinks Anivive can change all that.

"It's not really surprising that 85% of the diseases that veterinarians face either don't have any treatment, or veterinarians tend to use human drugs off label," says Dr. Bruyette. "It just doesn't make financial sense to spend 10 years and \$100 million on a product that may only sell \$10 million a year. And that doesn't mean that that product and that disease aren't important. It just means there are probably better ways to invest your capital."

The intro that almost didn't happen

Dr. Bruyette's entrance into the startup world began three and a half years ago, with a random email sent through LinkedIn. At the time, he was medical director at VCA West Los Angeles. Before that, he was head of internal medicine at Kansas State. Well-entrenched in traditional clinical practice, Dr. Bruyette almost ignored the LinkedIn message from a 20-something entrepreneur asking if he knew anything about dog diabetes. Dr. Bruyette, a diplomate of the American College of Veterinary Internal Medicine, replied that he did. Eventually.

"I wrote him back. I said, who are you? I don't know you," Dr. Bruyette says, laughing. "I couldn't find him on the Internet anywhere."

The entrepreneur in question was Dylan Balsz, who had already launched

several successful companies, including International Pet Solutions, which sells a "pet potty" called PetLawn. Impressed by Balsz's success, Dr. Bruyette agreed to meet him. Balsz shared that he'd been approached by a pharma company wondering if he had any ideas for determining whether one of its shelved drugs might be of use in the veterinary space. Although the drug wasn't applicable on the human side, much of the preliminary testing had already been performed.

"On the human side, to get a drug approved, you show that it's safe in rodents and then typically you move it into something larger," says Dr. Bruyette. "The larger animal could be a primate or a pig. A lot of times, it's a dog." Much of this research is in pharma-

cokinetics, Dr. Bruyette continues: "Do dogs absorb it? What concentrations? Does it get in their blood? Is it safe?"

In a large company, this would be where the handoff to animal health would take place if the drug had no human application. But in smaller companies with no easy way to access the veterinary market, the products are simply shuttered.

The company that contacted Balsz hoped he might know how to discover whether any of those drugs might improve the lives of animals. Balsz knew business, but he had no background in veterinary medicine—hence his out-of-the-blue LinkedIn message to a prominent veterinary endocrinologist.

Dr. Bruyette was in. Although he and Balsz did not end up developing the original drug they explored, things were about to get more interesting.

Re-inventing drug discovery

In talking about the drug approval process, Balsz and Dr. Bruyette questioned whether there was a way to more make it more efficient and streamlined. "Does it really need to take 10 years and \$100 million to get a drug approved?" says Dr. Bruyette. Making the process more cost-effective would remove a huge barrier to new drugs entering the veterinary market. "Is there a way to leverage existing data and target an unmet need?"

His and Balsz's goal became even loftier than their original idea of taking human medicine's castoffs and trying them on animals. What if, they asked, they could use software platforms to develop potential new therapies more efficiently?

Fast-forward to today. If you look at the who's-who on the Anivive homepage, you'll notice that many are software engineers and computer scientists. How does this jibe with the stereotypical image of the lab-coatwearing, beaker-holding scientist we associate with pharma research? "The best way to develop a lead," says Dr. Bruyette, "is to develop software."

"It's not really surprising that 85% of the diseases that veterinarians face either don't have any treatment, or veterinarians tend to use human drugs off label." —Dr. David Bruyette

Turns out that software development has kicked off a new golden era of drug discovery, and it's all thanks to the approach.

"We look for an unmet need—for instance, lymphoma," says Dr. Bruyette. "And then we ask, OK, what's really needed for lymphoma patients? What we would like to have for treatment is a veterinary-approved drug with a good safety margin that can be administered orally, that works through a mechanism of action that's different from other chemotherapeutics that are out there." Anivive takes a veterinarian's therapeutic wish list and, through specially developed software platforms, starts sorting through existing data to see if such a compound might exist.

The software delivers an initial set of compounds. Then the process of elimination begins. "Do those compounds interact with a target that we know is present in lymphoma?" Dr. Bruyette says. "Is there a mutation in dog lymphoma cells and human lymphoma cells that would generate a target, and would this drug interact with that target?" The list of 20,000 becomes 10,000.

"Then we ask how many of those 10,000 compounds have data," says Dr. Bruyette. The team also researches whether any of the compounds are already protected by a patent. Eventually, the list is whittled down to just a handful. With that list in hand, Anivive approaches the groups working with the drugs.

"We go out to whoever those people are, whether they're universities or pharma companies. We take an option so we can learn a little bit more about the drug. And if we like it, then we end-license it for veterinary use," says Dr. Bruyette.

Anivive's internal regulatory team has experience taking therapeutics through both the FDA and USDA approval processes and eventually to market. The importance of the regulatory component can't be underestimated—particularly when it comes to determining whether a new product falls under the auspices of the FDA or USDA. In human medicine, it's easy: it all falls to the FDA. In animal medicine, there used to be a clear delineation: FDA for drugs that treat, USDA for vaccines that prevent. But today's newest biomedical technologies can blur the lines.

"The FDA has ruled that viral vector gene therapies are therapeutics. They're not biologic in nature," says Dr. Bruyette. "But Cytopoint is a monoclonal antibody that went through USDA. Things that rely on the host to elicit the response, like a biological response modifier or monoclonal antibody those are USDA products."

Sometimes not even the agencies themselves are sure where to file a product. What if something is therapeutic by virtue of its immune-modulating properties? One product under investigation by Anivive is just such a compound. "We actually had a joint meeting with the USDA and FDA and presented our information to them and said, 'Where does this go?'"

At the moment, the product is available only through clinical trials under the FDA's pre-approval compassionate use provision.

'We're an unmet needs company'

Nowhere is the need for novel drugs more apparent than in veterinary on-

cology. Before Tanovea's initial approval in 2017, there was no FDA-approved treatment for canine lymphoma. Patients were presented with the same offlabel treatment options for decades: chemotherapy protocols like CHOP (cyclophosphamide, hydroxydaunorubicin [doxorubicin], Oncovin [vincristine], and prednisolone), corticosteroids or imminent death. Options are similarly sparse with other neoplasias.

In its short time in existence, Anivive has launched investigations into 14 compounds; two are nearing the final stages of the approval process. The first is an oral product for lymphoma treatment. Imagine, for a moment, instead of the weekly IV infusions, telling clients about an effective oral medication. What might that mean for the thousands of afflicted pets diagnosed with lymphoma every year? And that's just the first product on the list.

Dr. Bruyette says Anivive's approach of starting with the end goal instead of the drug itself is unique among companies. "I think that's the thing that separates us," he says. "We're not an oncology company; we're not an infectious disease company. We're an unmet needs company."

Starting with the unmet needs of the field allows Anivive to target heavy-hitting diseases often considered a death sentence. In addition to the lymphoma treatment, Anivive plans to introduce a coccidiomycosis (valley fever) vaccine licensed from the University of Arizona, a feline infectious peritonitis (FIP) antiviral product licensed from Kansas State University and a recombinant angiotoxin-targeting hemangiosarcoma treatment currently in trials at the University of Minnesota. Any one of those treatments would be a major victory in veterinary medicine, but to move all of them forward at once—well, that's unheard of.

These partnerships have the benefit of streamlining both cost and time to approval. "It's significantly less money because we'll be able to leverage things like manufacturing. A lot of the time these companies already have worked out how to make it," says Dr. Bruyette. "There'll be clinical studies they've already performed that may help us offset the costs of safety and toxicity studies." This allows Anivive to produce drugs for smaller, often-ignored markets. Dr. Bruyette estimates that the time needed for their first drug's development and approval process will be shrunk from 10 years to somewhere between three and five.

What frustrates you the most?

While Anivive's current drugs are limited in availability to clinical trials through universities, Dr. Bruyette notes that general practitioners will be able to participate in future trials. "Cancer studies typically are going to be done at private practices or universities with oncologists," he says, noting that participants must be willing to follow the stringent requirements of the FDA. The FIP treatment, however, "will be a general-practice-driven product." Anivive's software platform has an arm specifically designed to identify and recruit general practitioners for clinical trial participation when the time comes.

Dr. Bruyette emphasizes that they view every practitioner, both specialist and GP, as a part of this new process. "We want to hear from them. What are the diseases that you see that are the most frustrating to you?" he says. "What are the diseases that you want to see successful therapies for, either because they're associated with a very poor prognosis or the treatments are difficult or expensive? We really want to partner with the general practice doctor to bring things into the clinic that they'll actually use and that they need."

Imagine the possibilities.

Dr. Jessica Vogelsang is a certified veterinary journalist, a regular contributing writer for a number of publications, author of the memoir All Dogs Go to Kevin, and creator of the blog Pawcurious.com.

Too many pets, too little care > Continued from the cover

ing veterinarian with the Oregon Humane Society in Portland, Dr. Miller is no stranger to the world of animal hoarding—a world that includes an estimated 250,000 animals per year in the United States alone.

With so many affected animals, there's unfortunately a good chance that if you haven't witnessed animal hoarding yet, you will in the future.

"According to the Animal Legal Defense Fund and the Pet Abuse Database, the animal hoarding trend seems to be going upward, especially in the past 10 years," says Dr. Miller. "But it's hard to say if that's because there's more hoarding going on or if awareness is simply growing. Thanks to television shows on the topic, the problem is more top of mind."

Animal hoarder typology

Building on the definition of hoarding we started with, Dr. Miller says animal hoarders are often

characterized by obsessive attempts to accumulate or maintain a collection of animals in the face of progressively deteriorating conditions.

"Even though things are bad or going downhill, they're still trying to get more animals or keep the ones they've got," he explains.

Animal hoarders fail to provide their pets with minimal standards of sanitation, space, nutrition and veterinary care, and they are unable to recognize the effects of this failure on the welfare of the animals, themselves and other people who live in the household, says Dr. Miller.

Though he stresses that there can be a lot of overlap and gray area, Dr. Miller explains that it can be helpful to know the three types of hoarders, as the typology can be used to guide authorities on the most appropriate intervention approach.

The overwhelmed caregiver. According to Dr.

JORVET SPECIALTY PRODUCTS

CARE, CLEANING AND HANDLING OF SURGICAL INSTRUMENTS

Instrument Cleaning Intro Kit all of the essentials for instrument cleaning and care.

Kit includes:

J0649F - FOAM-MAX Pump System J0647 - pH Neutral Instrument Cleaning Detergent J0648 - Instrument Milk, Concentrate J0646P - Medi-Sheen[™] Polish Powder J0364 - Nylon Instrument Cleaning Brush Product Code: J0647K



- Decontamination
- Lubrication
- Manual Cleaning
- Sterilization
- Ultrasonic Cleaning
- Troubleshooting corrosion vs stain
- Rinsing



Miller, this is a person with good intentions who's trying to take care of their animals but eventually becomes overwhelmed. Pets in this situation are often passively acquired, he explainsconsider the "neighborhood cat lady" who keeps getting cats brought to her until the situation spins out of control.

"Overwhelmed caregivers are more likely to understand there's a problem and thus typically have fewer issues with authority and accepting intervention," Dr. Miller says.

The rescue hoarder. Rescue hoarders, on the other hand, have a compulsive need to rescue animals from euthanasia and tend to see humane organizations as the enemy—in their eyes, they're the only ones who can help these animals, explains Dr. Miller. Unlike overwhelmed caregivers, they actively acquire pets and will avoid authority.

"They're not amenable to help because they believe they're the only ones who can help," he says.

The exploiter hoarder. The exploiter hoarder, explains Dr. Miller, is indifferent to the animals they acquire.

"Accumulating animals satisfies some need they have," he says. "Sometimes it's just to have a bunch of animals."

This category can include those who run puppy mills and who illegally sell animals into research. Exploiter

hoarders have an extreme need for control and will lie, cheat and steal to achieve their ends.

A detriment to pets and people

Malnutrition, neglect, stress and infectious diseases are common with these animals. Dr. Miller says hoarded pets are sometimes too far gone-medically, behaviorally or both—to be adopted out after being rescued.

The people involved in these situations don't go unscathed either-risk of zoonotic disease is high and sanitation concerns and self-neglect are common. To illustrate his point, Dr. Miller describes a case in which a woman lived in a one-bedroom apartment with 48 cats. When her toilet stopped working, she was unable to ask for help from her landlord (due to violating the conditions of her lease) and started using her bathtub as a toilet.

That's not the worst of it. "Sometimes, the hoarder's home is so bad that it has to be destroyed," he says.

From an eccentricity to a disorder

While the effects are obvious, the causes of animal hoarding are less clear. When animal hoarding was first reported in the early 1980s, it was referred to as "animal collecting." Such a term made it sound more like an eccentric hobby, says Dr. Miller.

Hoarding disorder is now a separate listing in the American Psychiatric Association's Diagnostic and Statistical Manual of Mental Disorders, and theories regarding the cause abound. Some speculate that it's linked to a traumatic event or an attachment disorder developed in childhood (i.e. a person who wasn't cared for properly as a child may turn to animals and develop unhealthy dependencies). Others have pointed to addiction models, delusional disorder, borderline personality disorder, obsessive compulsive disorder and insistent caregiving—none of which adequately describes every hoarder, says Dr. Miller. Dementia has also been documented in many hoarders, but not all of them.

Problematic prosecution

Prosecuting animal hoarders and getting them the long-term monitoring and therapy they need is difficult, Dr. Miller says. Animal hoarding is typically prosecuted under state animal cruelty laws as a crime of omission or neglect, though some states have developed hoarding-specific legislation.

Forfeiture laws are often used but can have a dramatic effect on the shelters that must house the seized animals while the case moves through the legal system. Bond laws, which require the animals' owner to post a security or

bond to pay for the care of the seized animals, can also be used. According to Dr. Miller, this approach can either help defray the costs associated with caring for these animals or can be used as a negotiating tool for getting hoarders to sign over their animals so they can be fostered and adopted out.

The penalties for animal hoarding are often inconsistent and ineffective at deterring the crime. For one, district attorneys may try to lump everything into one charge to avoid clogging the court system, says Dr. Miller.

"These are individual animals and should be treated as individual cases," he continues. "Having all of those separate charges really helps during the penalty phase."

Moreover, because the causes of animal hoarding are not well understood, and because hoarders are usually in denial that they have a problem, therapy is rarely mandated or followed through on, Dr. Miller explains. Monitored probation is also uncommon.

In cases that do go to trial, Dr. Miller highlights the importance of having veterinarians serve as expert witnesses.

"Someone with a white coat who can tell it like it is carries a lot of weight," he says. "The defense is going to have their own medical expert witnesses, so it's really important that the prosecution has expert witnesses as well."

Hope for hoarding?

According to Dr. Miller, the recidivism rate for animal hoarding is estimated to be 100 percent.

"The old adage that an animal hoarder is going to leave the courthouse and pick up another animal on the way home likely has a lot of truth to it," he says.

But that doesn't mean Dr. Miller doesn't think things can improve.

"Overall, the legal system needs to treat the problem more seriously," he explains. "The biggest thing we can do is to mandate therapy for these people so we can start collecting data to learn what's behind animal hoarding. And we need to institute monitored probation to make sure offenders don't leave the area and keep doing what they're doing elsewhere."

Sarah Mouton Dowdy, a former associate content specialist for dvm360. com, is a freelance writer and editor in Kansas City, Missouri.

Brief Summary: Before using please consult the product onsert, a summary of which follows. ANADA 200-595, Approved by FDA

Carprieve[®] (carprofen) **Chewable Tablets**

Non-steroidal anti-inflan torv drua

For oral use in dogs only

CAUTION: Federal law restricts this drug to use by or on the order of a licensed veterinarian INDICATIONS: Carprive is indicated for the relief of pain and infla associated with osteoarthritis and for the control of postoperative associated with soft tissue and orthopedic surgeries in dogs.

associated with sort associate and or include say genes in logs. CONTRAINDICATIONS: Carprieve should not be used in dogs exhibiting previous hypersensitivity to carprofen. WARNINGS: Keep out of reach of children. Not for human use. Consult a physician in cases of accidental ingestion by humans. For use in dogs only. Do

iot use in cats

not use in cats. All dogs should undergo a thorough history and physical examination before initiation of NSAID therapy. Appropriate laboratory tests to establish hematological and serum biochemical baseline data prior to, and periodically during, administration of any NSAID should be considered. **Owners should be** advised to observe for signs of potential drug toxicity.

tating, administration of any rGAM should be considered. Where is notified a divised to observe for signs of potential any circitizity. **PRECAUTIONS:** As a class, cyclooxygenase inhibitory NSAIDs may be associated with gastorintestinal, renal, and hepatic toxicity. The most frequently reported effects have been gastrointestinal signs. Events involving suspected renal, hematologic, neurologic, dermatologic, and hepatic effects have also been reported. Patients at greatest risk for renal toxicity are those that are dehydrated, on concomitant divine's the rayp, or those with renal, cardiovascular, and/or hepatic dysfunction. Concurrent administration of potentially nephrotoxic drugs should be approached cautiouxly, with appropriate monitoring. Concomitant use of carprofen with other anti-inflammatory drugs, such as other NSAIDS or corticosteroids, should be avoided because of the potential increase of adverse reactions, including gastrointestinal ulcerations and/or perforations. Carprieve is not recommended for use in dogs with bleeding disorders (e.g., Von Willebrand's disease), as safety has not been established in dogs with these disorders. The safe use of Carprieve in amimals less than 6 veeks of age, pregnant dogs, dogs used for breeding purpose, or in lactating bitches has not been established.

Deep in tably toge set of the result purposes, of initial and putches has not been established. Due to the liver flavoring contained in Carprieve chewable tablets, store out of the reach of dogs and in a secured area. **INFORMATION FOR DOG OWNERS:** Carprieve, like other drugs of its class, is not free from adverse reactions. Owners should be advised of the potential for adverse reactions and be informed of the clinical signs associated with drug intolerance. Adverse reactions may include decreased appetity, vomiting, diarrhea, afak or tarry stools, increased water consumption, increased urination, pale gums due to anemia, vellowing of gums, skin or white of the eye due to jaunice, lethargy, incoordination, seizure, or behavioral changes. Serious adverse reactions associated with this drug class can occur without varning and in are situations result in death (see Adverse Reactions). Owners should be advised to discontinue Carprieve therapy and contact their veterinarian immediately if signs of intolerance are observed.

During investigational studies for the chewable tablet formulation, gastrointestinal signs were observed in some dogs. These signs included voniting and soft stools. Post-Approval Experience:

ADVERSE REACTIONS: Du Iministration of 1 mg/lb, no clinically significant adverse reactions he clinical signs were observed during field studies (=27) which profen caplet: and placebo-travated dogs. Incidences of the follow d in both groups: vomiting (4%), diarrhea (4%), changes in appetit), behavioral changes (1%), and constipation (0.2%). The product rous adverse events reported during clinical f in of 2 mg/lb. The following categories of reported. The product vehicle served as contro ntage of Dogs with Abnormal Health Observation Study ons Reported in Clinical Field



experience reporting. The categories of adverse reactions are listed in decreasing order of frequency by body system. Gastrointestinal. Vomiting, diarrhea, constipation, inappetence, melena hematemesis, gastrointestinal ulceration, gastrointestinal bleeding, pancreatitis. Hepatic: Inappetence, vomiting, jaundice, acute hepatic toxicity, hepatic enzyme elevation, abnormal liver function test(s), hyperbilirubinemia, bilirubinuri, hypeabluminemia. Approximate one-fourth of hepatic reports were in Labrador Retrievers. nximatelı

Neurologic: Ataxia, paresis, paralysis, seizures, vestibular signs, aisorientation. Urinary: Hematuria, polyuria, polydipsia, urinary incontinence, urin tract infection, azotemia, acute renal failure, tubular abnormalities including acute tubular necrosis, renal tubular acidosis, glucosuria Behavioral: Sedation, lethargy, hyperactivity, restlessness, aggressiveness.

Although not all adverse reactions are reported, the following adverse reactions are based on voluntary post-approval adverse drug

aggressiveness. Hematologic: Immune-mediated hemolytic anemia, immune-mediated thrombocytopenia, blood loss anemia, epistaxis. Dermatologic: Pruritus, increased shedding, alopecia, pyotraumatic moist dermatitis (hot spots), necrotizing panniculitis/vasculitis, ventra

crymoso. munologic or hypersensitivity: Facial swelling, hives, erythema. rare situations, death has been associated with some of the adverse actions listed above.

pected adverse reaction call 1-866-591-5777 To report a sus In report a suspected adverse reaction call i -boo-sti-3/77. **DOSAGE AND ADMINISTRATION:** Always provide Client Information Sheet with prescription. Carefully consider the potential benefits and risk of Carprieve and other treatment options before deciding to use Carprieve. Use the lowest effective does for the shortest duration consistent with individual response. The recommended dosage for oral administration to dogs is 2 mg/lb of body weight cance daily or divided and administered as 2 mg/lb of body weight, For the control of postoperative pain, administer approximately 2 hours before the procedure

See product insert for complete dosing and administration

STORAGE: Store 25 mg and 75 mg Carprieve chewable tablets at 59.86°F (15-30°C). Store 100 mg Carprieve chewable tablets at controlled room temperature, 68-77°F (20-25°C). Use half-tablet within 30

HOW SUPPLIED: Carprieve chewable tablets are scored, and cor 25 mg, 75 mg, or 100 mg of carprofen per tablet. Each tablet size is packaged in bottles containing 30, 60, or 180 tablets.

package in bottles containing JU, 60, or 160 table Made in the UK. Manufactured by: Norbrook Laboratories Limited, Newry, BT35 6PU, Co. Down, Northern Ireland Carprieve® and the Norbrook logos are registered trademarks of Norbrook

101 March 2017





PALATABLE. PROFITABLE. PROVEN. CARPRIEVE® (carprofen) CHEWABLE TABLETS FOR DOGS

Man's best friend deserves readily accepted and effective pain management. In a recent study¹, Carprieve[®] Chewable Tablets were found to be equally accepted by dogs as Rimadyl[®] (carprofen) Chewable Tablets. Additionally, a survey of veterinarians², 100% rated Carprieve[®] Chewable Tablets as either similar in palatability or more palatable than their currently recommended chewable NSAID.

Discover Carprieve® Chewable Tablets – an FDA-approved, liver-flavored NSAID to help you maintain your practice's high standards of care at a reduced cost to you and your clients.

To read the full study or for more information on Carprieve[®], visit norbook.com or call (866) 591-5777. Please see Brief Summary on page 20.



^{2.} Carprieve Challenge Survey Results - December 2018, Brief Media, data on file.

IMPORTANT SAFETY INFORMATION: As a class, NSAIDs may be associated with gastrointestinal, kidney and liver side effects. These are usually mild but may be serious. Dog owners should discontinue therapy and contact their veterinarian immediately if side effects occur. Evaluation for pre-existing conditions and regular monitoring are recommended for dogs on any medication, including Carprieve. Use with other NSAIDs or corticosteroids should be avoided. See full product labeling for full product information.

© 2019 Norbrook Laboratories Limited. All rights reserved. Norbrook logo and Carprieve are registered trademarks of Norbrook Laboratories Limited. Rimadyl is a registered trademark of Zoetis, Inc.

NEWS | Hospital Design



Minimal clutter, maximum efficiency

Using her work as an associate and then locum tenens, this Hospital Design Competition Merit Award winner knew what she wanted: good-looking and clutter-free, with a much-needed break room for team members to decompress. *By Sarah Moser*



By the numbers

Goose Creek Veterinary Hospital

Owner: Dr. Margaret Fortier Number of doctors: 1 Exam rooms: 3 Total cost: \$2,255,461 Cost per square foot: \$120 Square footage: 3,000 Structure type: New, leasehold Architect: Charles Joch, CHJ3 Architecture xperience is a great teacher. After 10 years practicing veterinary medicine in Washington, D.C., in a four-story row house, Margaret Fortier, DVM, moved to the suburbs with a dream of opening her own veterinary practice. She had served as hospital director at her previous facility, and now her work as a relief veterinarian was invaluable to thinking over exactly what her practice would look like, she says.

"I saw a lot of what I liked and didn't like, and I was able to learn what size practice I was hoping for," says Dr. Fortier.

Her No. 1 design objective turned out to be neatness: "Clean, no clutter, every object has a purpose, and everything is easy to clean," she says. "A minimalist, industrial design element was the look I wanted. It was extremely important to me to have an appealing visual aesthetic, especially since I hope to be working and thriving in this space for the next 20 years."

In March 2018, Goose Creek Veterinary Hospital in Ashburn, Virginia, was born. The 3,000-square-foot small animal hospital earned a 2019 Hospital Design Competition Merit Award for its clean, open and airy design and uncluttered style.

'l'm a clean, minimalist person'

"Veterinary clinics tend to accumulate stuff over time," says Dr. Fortier. "Personally, I'm a clean, minimalist person, and I wanted that reflected in my practice."

Her design objectives were to have everything off the ground, have a place and a purpose for everything in the hospital, for everything to be easy to clean, and for the practice to look and smell clean at all times.

These objectives led every design decision. For example, in the dental area, the counter was built higher than usual to store the dental compressor underneath. Dr. Fortier says the area doesn't feel as crowded thanks to this detail.

Custom-built shelves in the pharmacy give a home for each and every drug and supply, making inventory management easier.

"I've practiced in places where drugs and supplies were all over the building; we couldn't find anything," Dr. Fortier says. She also focused on building spaces for as many items as possible to go under counters, leaving countertops clear. This included designing a space for the centrifuge to sit under the cabinet with a hole in the counter for access. An added benefit, besides a clear counter, is that it helps muffle the noise of running the centrifuge. Even small details—like not putting too many trash cans in treatment caught Dr. Fortier's attention. She has only one trash can on the floor in the treatment area, and staff members have been trained to take the few extra steps to keep the area clean.

Giving everything its own space extends to the staff members, too.

"I've worked in a practice before that was a 'U' shape, with doctors sitting at high-top bars in the middle of the treatment area, with no personal space," says Dr. Fortier. "I felt like we could never get away from the animals, never had privacy or a place to breathe."

This led to Goose Creek's staff area



FIND WHAT YOU LOVE. LOVE WHAT YOU DO.

With more than 700 community-based animal hospitals across the U.S.—each as unique as you are— VCA has the right fit to meet your personal and professional needs.

When you make VCA your new home, you'll have access to the resources and opportunities that can only come from America's leader in veterinary care.

- Tap into the expertise of 4,500+ doctors, including more than 600 Specialists.
- Expand your medical horizons through our post-graduate Internship Program and Sponsored Residencies.
- Keep your edge—and learn some new skills—through our award-winning WOOF University[™], and free full-day CE events with Specialists.
- Help make the next important medical discovery by participating in our Clinical Studies program.
- Enjoy unparalleled opportunities for transfers and career growth.
- Give back through strong Shelter partnerships and VCA Charities.

To start your journey with VCA, e-mail us at recruiting@vca.com.

Or visit us at VCAJobs.com



NEWS | Hospital Design

at the back of the hospital featuring a full kitchen area, a separate desk for technicians to sit and a beautiful view of the Blue Ridge Mountains out the large windows.

'lf you don't ask, you don't get'

Obviously, Dr. Fortier had clear thoughts on what she wanted in a practice. And as a first-time practice owner and builder, it would have been easy for her to let others dictate how the process should go.

"In the beginning, I felt shy to ask for what I wanted, but that soon faded and I developed the philosophy that this is my life's dream and that it's going to look the way I want it to look," says Dr. Fortier. "I'm not afraid to ask for what I want and speak up. This applied to getting good prices, fixing mistakes and getting stuff for free when things didn't go smoothly. If you don't ask, you don't get."

Dr. Fortier says she's been undermined in her job in the past, and she wasn't about to let that happen to her again, especially in her very own



Attack your project from every angle at HospitalDesign360

Plan to attend the 2019 HospitalDesign360 conference in Kansas City, Missouri, Aug. 21-23. Gather ideas, learn from the profession's most noted veterinary design experts, and compare your options for design, construction, equipment, financing and more with our exclusive hospital design exhibit hall. Visit **fetchdvm360.com/hd** for more information. Bonus! Practice owners from

Bonus! Practice owners from both of this year's Hospitals of the Year will be on hand to share their secrets.



practice—the place she spends most of her days.

"Life knocks you down from time to time, and as women we might feel that we don't deserve things," she says. "But If I have to be pushy or aggressive to get what I want, I won't apologize for it. It's my money, my dream, and ultimately me working to make it work."

Exam rooms feature whimsical artwork, decorative benches and glass-paned doors that let light flow in



When it comes to **fast** relief from allergic itch without the common side effects of steroids*

IT WOULD BE A SHAME TO MAKE THEM WAIT

APOQUEL (oclacitinib tablet) gives dogs fast, effective allergic itch relief that **starts working within 4 hours**¹



*Common side effects of steroids include polyuria, polydipsia and polyphagia.^{4,5} Side effects of APOQUEL reported most often are vomiting and diarrhea.⁶ †Based on survey data from veterinarians (n=250) and pet owners (n=150).²³

INDICATIONS

Control of pruritus associated with allergic dermatitis and control of atopic dermatitis in dogs at least 12 months of age.

IMPORTANT SAFETY INFORMATION

Do not use APOQUEL® (oclacitinib tablet) in dogs less than 12 months of age or those with serious infections. APOQUEL may increase the chances of developing serious infections, and may cause existing parasitic skin infestations or pre-existing cancers to get worse. APOQUEL has not been tested in dogs receiving some medications including some commonly used to treat skin conditions such as corticosteroids and cyclosporine. Do not use in breeding, pregnant, or lactating dogs. Most common side effects are vomiting and diarrhea. APOQUEL has been used safely with many common medications including parasiticides, antibiotics and vaccines.

For more information, please see Brief Summary of full Prescribing Information on adjacent page.

References: 1. Gadeyne C, Little P, King VL, et al. Efficacy of oclacitinib (APOQUEL[®]) compared with prednisolone for the control of pruritus and clinical signs associated with allergic dermatitis in client-owned dogs in Australia. *Vet Dermatol.* 2014;25(6):512-518. doi:10.1111/vde.12166. **2.** Data on file, APOQUEL/CYTOPOINT Vet Tracker, Wave 11, 2018, Zoetis Inc. **3.** Data on file, APOQUEL/CYTOPOINT Pet Tracker, Wave 6, 2019, Zoetis Inc. **4.** Edwards SH. *The Merck Veterinary Manual.* 11th ed. Kenilworth, NJ: Merck Sharp & Dohme Corp; 2014. http://merckvetmanual.com/pharmacology/anti-inflammatory-agents/corticosteroids?qt=antiinflammatoryagents&alt=sh. Accessed January 4, 2018. **5.** Sousa CA. Glucocosteroids in veterinary dermatology. In: Bonagura JD, Twedt DC, eds. *Kirk's Current Veterinary Therapy.* 14th ed. St. Louis, MO: Saunders Elsevier; 2009:400-404. **6.** Cosgrove SB, Wren JA, Cleaver DM, et al. Efficacy and safety of oclacitinib for the control of pruritus and associated skin lesions in dogs with canine allergic dermatitis. *Vet Dermatol.* 2013;24(5):479-e114. doi:10.1111/vde.12047.

All trademarks are the property of Zoetis Services LLC or a related company or a licensor unless otherwise noted. © 2019 Zoetis Services LLC. All rights reserved. APQ-00654R2

ZOETIS PETCARE

The treatment area has heated cages and clear countertops



A walk through

Goose Creek Veterinary Hospital is in a newly constructed leasehold space. The neutral color exterior with a pop of red on the awning sets the tone for what awaits inside.

Crisp white greets pet owners when they first walk in. To tie into the red in the logo, Dr. Fortier had a bold-redprinted commercial-grade steel panel applied to the front of the reception desk. The piece "makes a statement," she says, and people see the pop of red when driving up.

The lobby is sparsely decorated on purpose, with only a magnetic chalkboard labeled with the day's incoming



The surgery suite features equipment including a Baxter IV pump and surgical table from VSSI



The designated staff room gives the team a break from the chaos



In the lab and pharmacy, all equipment is up and out of the way but still accessible.

patient names, which kids can also write and draw on.

The three exam rooms hold to Dr. Fortier's less-is-more philosophy. A simple aesthetic with minimal decor makes the rooms easy to clean.

The treatment area features heated cages, one of Dr. Fortier's favorite splurges for her patients. And all of the equipment is given a home off the top of counters, keeping clutter to a minimum.

A designated break room gives staff members a breather from the chaos. The room includes a full kitchen, desks for technicians and a view out the back windows of the Blue Ridge Mountains.

Sarah A. Moser is a freelance writer in Lenexa, Kansas.

apoquel (oclacitinib tablet)

Brief Summary of Prescribing Information

For oral use in dogs only

Caution: Federal (USA) Law restricts this drug to use by or on the order of a licensed veterinarian. Indications: Control of pruritus associated with allergic dermatitis and control of atopic dermatitis in dogs at least 12 months of age.

Dosage and Administration: The dose of APOQUEL (oclacitinib maleate) tablets is 0.18 to 0.27 mg oclacitinib/lb (0.4 to 0.6 mg oclacitinib/kg) body weight, administered orally, twice daily for up to 14 days, and then administered once daily for maintenance therapy. APOQUEL may be administered with or without food.

Dosing Chart

	-						
Weight Range Weight (in lb) (in k		jht Range in Kg)	Number of Tablets to be Administered				
	Low	High	Low	High	3.6 mg Tablets	5.4 mg Tablets	16 mg Tablets
	6.6	9.9	3.0	4.4	0.5	-	-
	10.0	14.9	4.5	5.9	-	0.5	-
	15.0	19.9	6.0	8.9	1	-	-
	20.0	29.9	9.0	13.4	-	1	-
	30.0	44.9	13.5	19.9	-	-	0.5
	45.0	59.9	20.0	26.9	-	2	-
	60.0	89.9	27.0	39.9	-	-	1
	90.0	129.9	40.0	54.9	-	-	1.5
	130.0	175.9	55.0	80.0	-	-	2

Warnings: APOQUEL is not for use in dogs less than 12 months of age (see Animal Safety). APOQUEL is not for use in dogs with serious infections. APOQUEL may increase susceptibility to infection, including demodicosis, and exacerbate in a subject to a degree Paretiens and Animal Safety). neoplastic conditions (see Adverse Reactions and Animal Safety)

Human Warnings:

This product is not for human use. Keep this and all drugs out of reach of children. For use in dogs In by block is that immediately after handling the tablets. In case of accidentative econtact, flush immediately with water or saline for at least 15 minutes and then seek medical attention. In case of accidental ingestion, seek medical attention immediately

Precautions:

APOQUEL is not for use in breeding dogs, or pregnant or lactating bitches. The use of APOQUEL has not been evaluated in combination with glucocorticoids, cyclosporine, or

other systemic immunosuppressive agents. Dogs receiving APOQUEL should be monitored for the development of infections, including demodicosis, and neoplasia.

Adverse Reactions:

Control of Atopic Dermatitis

In a masked field study to assess the effectiveness and safety of oclacitinib for the control of atopic dermatitis in dogs, 152 dogs treated with APOQUEL and 147 dogs treated with placebo (vehicle dermatitis in dogs, 152 dogs treated with APUQUEL and 147 dogs treated with placebo (vehicle control) were evaluated for safety. The majority of dogs in the placebo group withdrew from the 112-day study by Day 16. Adverse reactions reported (and percent of dogs affected) during Days 0-16 included diarrhea (4.6% APOQUEL, 3.4% placebo), vomiting (3.9% APOQUEL, 4.1% placebo), anorexia (2.6% APOQUEL, 0% placebo), new cutaneous or subcutaneous lump (2.6% APOQUEL, 2.7% placebo), and lethargy (2.0% APOQUEL, 1.4% placebo). In most cases, diarrhea, vomiting, anorexia, and lethargy spontaneously resolved with continued dosing. Dogs on APOQUEL had decreased leukocytes (neutrophil, eosinophil, and monocyte counts) and serum olohulin, and increased chelestorial and lingse compared to the placebo group but group. serum globulin, and increased cholesterol and lipase compared to the placebo group but group nained within the normal range. Mean lymphocyte counts were transiently increased at Day 14 in the APOQUEL group.

Dogs that withdrew from the masked field study could enter an unmasked study where all dogs received APOQUEL. Between the masked and unmasked study, 283 dogs received at least one dose of APOQUEL. Of these 283 dogs, two dogs were withdrawn from study due to suspected treatment-related adverse reactions: on dog that had an intense flare-up of dematitis and se-vere secondary pyoderma after 19 days of APOQUEL administration, and one dog that developed generalized demodicosis after 28 days of APOQUEL administration. Two other dogs on APOQUEL were withdrawn from study due to suspected or confirmed malignant neoplasia and subsequently euthanized, including one dog that developed signs associated with a heart base mass after 21 days of APOQUEL administration, and one dogs that developed a Grade Martin mast cell tumor after 60 days of APOQUEL administration. One of the 147 dogs in the placebo group developed a Grade I mast cell tumor and was withdrawn from the masked study. Additional dogs receiving APOQUEL were hospitalized for diagnosis and treatment of pneumonia (one dog), transient bloody vomiting and stool (one dog), and cystitis with urolithiasis (one dog). In the 283 dogs that received APOQUEL, the following additional clinical signs were reported after beginning APOQUEL (percentage of dogs with at least one report of the clinical sign as a non-pre-existing finding): pyoderma (12.0%), non-specified dermal lumps (12.0%), otitis (9.9%), vomiting (9.2%), diarrhea (6.0%), histicocytoma (3.9%), cystitis (3.5%), anorexia (3.2%), lethargy (2.8%), yeast skin infections (2.5%), pododermatitis (2.5%), lipoma (2.1%), polydipsia (1.4%), lymphadenopathy (1.1%), nausea (1.1%), increased appetite (1.1%), aggression (1.1%), and weight loss (0.7)

16 mg

Control of Pruritus Associated with Allergic Dermatitis

5.4

Control of Pruritus Associated with Allergic Dermatitis In a masked field study to assess the effectiveness and safety of oclacitinib for the control of pruritus associated with allergic dermatitis in dogs, 216 dogs treated with APOQUEL and 220 dogs treated with placebo (vehicle control) were evaluated for safety. During the 30-day study, there were no fatalities and no adverse reactions requiring hospital care. Adverse reactions reported (and percent of dogs affected) during Days 0-7 included diarrhea (2.3% APOQUEL, 0.9% placebo), vomiting (2.3% APOQUEL, 1.8% placebo), lethargy (1.8% APOQUEL, 0.4% placebo), anorexia (1.4% APOQUEL, 0% placebo), and polydipsia (1.4% APOQUEL, 0.9% placebo). In most of these cases, signs spontaneously resolved with continued dosing. Five APOQUEL group dogs were withdrawn from study because of: darkening areas of skin and fur (1 dog); and diarrhea, vomiting, lethargy and cystitis (1 dog); an inflamed footpad and vomiting (1 dog); and diarrhea, vomiting, and lethargy (1 dool). Doos in the APOQUEL group had a slight decrease in mean white blood cell and lethargy (1 dog). Dogs in the APOQUEL group had a slight decrease in mean white blood cell counts (neutrophil, eosinophil, and monocyte counts) that remained within the normal reference range. Mean lymphocyte count for dogs in the APOQUEL group increased at Day 7, but returned to pretreatment levels by study end without a break in APOQUEL administration. Serum cholesterol increased in 25% of APOQUEL group dogs, but mean cholesterol remained within the reference range.

3.6

Continuation Field Study After completing APOQUEL field studies, 239 dogs enrolled in an unmasked (no placebo control), continuation therapy study receiving APOQUEL for an unrestricted period of time. Mean time on this study was 372 days (range 1 to 610 days). Of these 239 dogs, one dog developed demodicosis following 273 days of APOQUEL administration. One dog developed dermal pigmented viral plaques following 266 days of APOQUEL administration. One dog developed a moderately severe bronchopneumonia after 272 days of APOQUEL administration; this infection resolved with antimicrobial treatment and temporary discontinuation of APOQUEL. One dog was euthanized after developing abdominal ascites and pleural effusion of unknown etiology after 450 days of APOQUEL administration. Six dogs were euthanized because of suspected malignant neoplasms: including thoracic metastatic, abdominal metastatic, splenic, frontal sinus, and intracranial neoplasms, and transitional cell carcinoma after 17, 120, 175, 49, 141, and 286 days of APOQUEL administration, respectively. Two dogs each developed a Grade II mast cell tumor after 52 and 91 days of APOQUEL administration, respectively. One dog developed low grade B-cell lymphoma after 392 days of APOQUEL administration. Two dogs each developed an apocrine gland adenocarcinoma (one dermal, one anal sac) after approximately 210 and 320 days of APOQUEL administration, respectively. One dog developed a low grade oral spindle cell sarcoma after 320 days of APOQUEL administration

To report suspected adverse events, for technical assistance or to obtain a copy of the MSDS, contact Zoetis Inc. at 1-888-963-8471 or www.zoetis.com.

For additional information about adverse drug experience reporting for animal drugs, contact FDA at 1-888-FDA-VETS or online at http://www.fda.gov/AnimalVeterinary/SafetyHealth

Storage Conditions:

eXPOQUEL should be stored at controlled room temperature between 20° to 25°C (68° to 77°F) with excursions between 15° to 40°C (59° to 104°F).

How Supplied:

APOQUEL tablets contain 3.6 mg, 5.4 mg, or 16 mg of oclacitinib as oclacitinib maleate per tablet. Each strength tablets are packaged in 20 and 100 count bottles. Each tablet is scored and marked with AQ and either an S, M, or L that correspond to the different tablet strengths on both sides. NADA #141-345, Approved by FDA

Made in Italy

zoetis

Distributed by: Zoetis Inc. Kalamazoo, MI 49007 February 2013

428007800A&P

AVMA EYE ON ECONOMICS | Matthew Salois, PhD

Will the feds **forgive** your student loans?

A primer on the Public Service Loan Forgiveness program from the AVMA Economics team.

Editor's note: Caroline Cantner, VMD, contributed to this column. She is assistant director for student initiatives with the Association of American Veterinary Medical Colleges.

ere at the AVMA, we're often asked by association members about the federal government's Public Service Loan Forgiveness (PSLF) program as a strategy to pay student debt. This program, administered by the U.S. government, forgives the remaining debt on eligible loans for borrowers who have worked at least 10 years in public service or the nonprofit sector.

PSLF has proven to be a critical resource for veterinarians who otherwise would be unable to work in public health or other public service fields. It's a viable option for many, but there are strict rules about who qualifies. If you're wondering whether PSLF is right for you, here's what you need to know.

How to qualify

Eligibility for PSLF is based on three criteria:

1. Employment. Qualifying for PSLF isn't about the specific job you do, but rather who you do it for. Essentially, it's intended for government employees and people who work for a 501(c)3 nonprofit organization. There also are nonprofits that aren't 501(c)3 organizations that can qualify for PSLF—if their "primary purpose is to provide certain types of qualifying public services."

Aside from your employer, other employment-related details also may affect your eligibility—for example, whether you are working full or part time and if you are employed as a contractor. This is especially important for veterinarians working in academia or other sectors where their position may be funded in such a way that they are not technically classified as full-time employees.

2. Loan type. Only direct loans from the government qualify for PSLF. Private loans do not qualify. For example, direct loans that have been consolidated into private loans no longer count toward PSLF. On the other hand, consolidating a nonqualifying loan, such as a Perkins loan, into a direct government loan will allow it to qualify from the time of consolidation.

3. Payment. The final requirement for PSLF eligibility is that you have made 120 on-time payments in a qualifying repayment plan. In general, this means an income-driven repayment plan (IDR). IDRs are repayment plans based on your income and family size. They're especially useful for high-debt, low-income borrowers who are looking to make lower monthly payments than they would with a standard 10-year plan. If your debt isn't repaid at the end of the plan term—either 20 or 25 years—the IDR will forgive the remaining balance, which will be taxed as income in the year it's forgiven.

An important note is that the required 120 payments do not need to be made consecutively. They do, however, need to be scheduled. That means you can't accelerate payments, and overpaying won't help you reach forgiveness faster. In fact, extra payments will only decrease the forgiven amount.

Working to preserve PSLF

Recently, PSLF has come under scrutiny, and concerns about its potential cost continue to be discussed by Congress. Adding to the uncertainty is the low approval rate—just over 1% on the applications processed since 2017. For people who are counting on PSLF, we know that questions about its status and approval rating can be especially stressful. Among the questions we hear are whether PSLF will be "guaranteed" for existing borrowers and whether forgiveness amounts will be capped. We don't yet have the answers, but when we do, we'll make them available at avma.org/PSLF.

If you were denied PSLF eligibility because you weren't in the correct repayment plan, you may be eligible to receive funds under a Temporary Expanded Public Service Loan Forgiveness program. Learn more at studentaid.ed.gov.

Making PSLF work for you

You can only apply for PSLF after you've made 120 qualifying payments. But if you're considering the program, there are things you can be doing now:

File an Employment Certification Form annually. This will help you (and the federal government) confirm that you meet PSLF employment criteria. Anyone interested in PSLF should file this form every year. It's the only PSLF-specific paper trail you'll have on file with the government while you're working toward forgiveness.

Recertify your IDR annually. Document every conversation you have with your loan servicer, including reference numbers or employee IDs for each call. Also, double-check any information or recommendation provided to you, and keep a spreadsheet of all your payment amounts with dates and confirmation numbers.

Be informed and be prepared. It's wise to have a backup plan in case PSLF doesn't work for you. An income-driven repayment plan—which you may already be enrolled in if you're working toward PSLF—can be a good option. Be sure to understand what this will look like if you need to use IDR—that it will affect your finances for a longer period and require saving for the added taxes that come with IDR's forgiveness.

In conclusion

IDRs and PSLF both offer debt forgiveness, but they are very different programs. PSLF is not a loan repayment plan itself. You are required to make monthly payments through your IDR while you're working toward PSLF. Here are a few more key distinctions:

PSLF

> Debt is forgiven after 120 qualifying payments, or 10 years if the payments are made consecutively.

> Forgiveness is tax-free.

> An Employer Certification Form is recommended annually.

IDR

> Debt is forgiven after 20 or 25 years, depending on the specific plan.
> Forgiveness is taxed. Borrowers would have to plan for a potentially high tax bill in the year their debt balance is forgiven.

> Recertification is required annually.

Matthew Salois, PhD, is chief economist and Veterinary Economics Division director at the AVMA.



HELPING YOU SOLVE THE PUZZLE OF JOINT HEALTH

Choose from a range of multimodal products from Boehringer Ingelheim.

 Order now from your Boehringer Ingelheim representative.

Metacam[®] (meloxicam oral suspension) For use in dogs only

Metacam[®] (meloxicam)

Solution for Injection

METACAM and PREVICOX are indicated for the control of pain

and inflammation associated with osteoarthritis in dogs.

For use in dogs



For use in dogs only

Antinol.

For use in dogs and cats

ANTINOL is a joint health supplement.



MOBILITY SOLUTIONS

PREVICOX® is a registered trademark of Boehringer Ing a registered trademark of Pharmalink International Limi Boehringer Ingelheim Vetmedica GmbH, licensed to Bo © 2019 Boehringer Ingelheim Animal Health USA Inc. F nal Health USA Inc. ANTINOL[®] is AM[®] is a registered trademark of Jelheim Animal Health USA Inc.

IMPORTANT SAFETY INFORMATION: METACAM (meloxicam oral suspension) and PREVICOX (firocoxib) are for use in dogs only. METACAM (meloxicam) Solution for Injection is approved for use in dogs or cats. Repeated use of meloxicam in cats has been associated with acute renal failure and death. Do not administer additional injectable or oral meloxicam to cats. As a class, cyclooxygenase inhibitory NSAIDs like METACAM and PREVICOX may be associated with gastrointestinal, kidney, or liver side effects. Dogs should be evaluated for pre-existing conditions and currently prescribed medications prior to treatment with METACAM or PREVICOX, then monitored regularly while on therapy. Concurrent use with another NSAID, corticosteroid, or nephrotoxic medication should be avoided or monitored closely.

For more information on products mentioned in this ad, please see full prescribing information on page 28-29.



Boehringer

Ingelheim

Do cameras belong in a veterinary hospital?

When medications go missing in a veterinary practice, this owner opts to install a watchful eye in the form of video surveillance.

hree years ago, Dr. Jim Ray opened a veterinary clinic after working as an associate for eight years at a facility in the next town. His staff quickly grew from six to 17 in just 36 months.

That's when the trouble started. Dr. Ray's clinic administrator came to him with some troubling news: The drug inventory and controlled substances logs showed missing medications.

Dr. Ray was devastated. Police were called because some of the missing drugs were narcotics.



28 | July 2019 | dvm360

Brief Summarv NADA 141-213. Approved by FDA

Metacam[®]

(meloxicam oral suspension) 1.5 mg/mL (equivalent to 0.05 mg per drop) /0.5 mg/mL (equivalent to 0.02 mg per drop) Non-steroidal anti-inflammatory drug for oral use in dogs only

Caution: Federal law restricts this drug to use by or on the order of a licensed veterinarian

Warning: Repeated use of meloxicam in cats has been associated with acute renal failure and death. Do not administer additional injectable or oral meloxicam to cats. See Contraindications, Warnings, and Precautions for detailed information.

Description: Meloxicam is a non-steroidal anti-inflammatory drug (NSAID) of the oxicam class. Each milliliter of METACAM Oral Suspension contains meloxicam equivalent to 0.5 or 1.5 milligrams and sodium benzoate (1.5 milligrams) as a preservative. The chemical name for Meloxicam is 4-Hydroxy-2-methyl-N-(5-methyl-2-thiazolyl):2H-1,2 benzothiazine-3-carboxamide-1, 1-dioxide. The formulation is a yellowish viscous suspension with the odor of honey.

Indications: METACAM Oral Suspension is indicated for the control of pain and inflammation associated with osteoarthritis in dogs.

Contraindications: Dogs with known hypersensitivity to meloxicam should not receive METACAM Oral Suspension. Do not use METACAM Oral Suspension in cats. Acute renal failure and death have been associated with the use of meloxicam in cats.

Warnings: Not for use in humans. Keep this and all medications out of reach of children. Consult a physician in case of accidental ingestion by humans. For oral use in dogs only.

As with any NSAID all dogs should undergo a thorough history and physical examination before the initiation of NSAID therapy. Appropriate laboratory testing to establish hematological and serum biochemical baseline data is recommended prior to and periodically during administration. Owner should be advised to observe their dog for signs of potential drug toxicity and be given a client information sheet about METACAM.

should be advised to observe their dog for signs of potential drug toxicity and be given a client information sheet about METACAM. **Precautions:** The safe use of METACAM Oral Suspension in dogs younger than 6 months of age, dogs used for breeding, or in pregnant or lactating dogs has not been evaluated. Meloxicam is not recommended for use in dogs with bleeding disorders, as safety has not been evaluated. Meloxicam is not recommended for use in dogs with bleeding disorders, as safety has not been evaluated. Meloxicam is not recommended hey activity to drug-associated adverse events varies with the individual patient. Dogs that have experienced adverse reactions from one NSAID may experience adverse reactions from another NSAID. Patients at greatest risk for renal toxicity are those that are dehydrated, on concomitant diuretic therapy, or those with existing renal, cardiovascular, and/or hepatic dysfunction. Concurrent administration of potentially nephrotoxic drugs should be carefully approached. NSAIDs may inhibit the prostaglandins that maintain normal homeostatic function. Such anti-prostaglandin effects may result in clinically significant disease in patients with underlying or pre-existing disease that has not been previously diagnosed. Since NSAIDs possess the potential to induce gastrointestinal ulcerations and/or perforations, concomitant use with other anti-inflammatory drugs, such as NSAIDs or corticosteroids, should be avoided. If additional pain medication is needed after administration of the total daily dose of METACAM Oral Suspension, a non -NSAID or non-corticosteroid class of analgesia should be considered. The use of another NSAID is not recommended. Consider appropriate washout times when switching from corticosteroid use or from one NSAID or non-corticosteroid class of analgesia should be considered. The use of another NSAID is not recommended. Consider appropriate washout times when switching from corticosteroid use or from one NSAID to another in dogs. The use of concom

Adverse Reactions: Field safety was evaluated in 306 dogs.¹ Based on the results of two studies, GI abnormalities (vomiting, soft stools, diarrhea, and inappetance) were the most common advers reactions associated with the administration of meloxicam.

The following adverse events are based on post-approval adverse drug experience reporting. Not all adverse reactions are reported to FDA/CVM. It is not always possible to reliably estimate the adverse event frequency or establish a causal relationship to product exposure using these data. The following adverse events are listed in decreasing order of frequency by body system.

Gastrointestinal: vomiting, anorexia, diarrhea, melena, gastrointestinal ulceratior Urinary: azotemia, elevated creatinine, renal failure Neurological/Behavioral: lethargy, depression Hepatic: elevated liver enzymes Dermatologic: pruritus

Death has been reported as an outcome of the adverse events listed above. Acute renal failure and death have been associated with use of meloxicam in cats.

death have been associated with use of meloxicam in cats. Information for Dog Owners: METACAM, like other drugs of its class, is not free from adverse reactions. Owners should be advised of the potential for adverse reactions and be informed of the clinical signs associated with drug intolerance. Adverse reactions may include vomiting, diarrhea, decreased appetite, dark or tarry stools, increased water consumption, increased urination, pale gums due to anemia, yellowing of gums, skin or white of the eye due to jaundice, lethargy, incoordination, seizure, or behavioral changes. Serious adverse reactions associated with this drug class can occur without warning and in rare situations result in death (see Adverse Reactions). Owners should be advised to discontinue METACAM and contact their veterinarian immediately if signs of intolerance are observed. The vast majority of patients with drug related adverse reactions have recovered when the signs are recognized, the drug is withdrawn, and veterinary care, if appropriate, is initiated. Owners should be advised of the importance of periodic follow up for all dogs during administration of any NSAID. Effectiveness: The effectiveness of meloxicam was demonstrated in two field studies involving a total

advised of the importance of periodic follow up for all dogs during administration of any NSAID. Effectiveness: The effectiveness of meloxicam was demonstrated in two field studies involving a total of 277 dogs representing various breeds, between six months and sixteen years of age, all diagnosed with osteoarthritis. Both of the placebo-controlled, masked studies were conducted for 14 days. All dogs received 0.2 mg/kg meloxicam on day 1. All dogs were maintained on 0.1 mg/kg oral meloxicam from days 2 through 14 of both studies. Parameters evaluated by veterinarians included lameness, weight-bearing, pain on palpation, and overall improvement. Parameters assessed by owners included mobility, ability to rise, limping, and overall improvement. In the first field study (n=109), dogs showed clinical improvement with statistical significance after 14 days of meloxicam treatment for all parameters. In the second field study (n=48), dogs receiving meloxicam showed a clinical improvement after 14 days of therapy for all parameters; however, statistical significance was demonstrated only for the overall investigator evaluation on day 7, and for the owner evaluation on day 14.¹

Reference: 1. FOI for NADA 141-213 METACAM (meloxicam oral suspension).

Manufactured for:

Boehringer Ingelheim Vetmedica, Inc. St. Joseph, MO 64506 U.S.A.

METACAM is a registered trademark of Boehringer Ingelheim Vetmedica GmbH, used under license. 601401-08/601413-04/6015161-10/6015268-04

Revised 07/2016



Metacam[®]

(meloxicam) 5 mg/mL Solution for Injection Non-steroidal anti-inflammatory drug for use in dogs and cats only

Caution: Federal law restricts this drug to use by or on the order of a licensed veterinarian.

Warning: Repeated use of meloxicam in cats has been associated with acute renal failure and death, Do not administer additional injectable or oral meloxicam to cats. See Contraindicatio Warnings, and Precautions for detailed information.

Description: Meloxicam is a non-steroidal anti-inflammatory drug (NSAID) of the oxicam class. Each mL of this sterile product for injection contains meloxicam 5.0 mg, alcohol 15%, glycofurol 10%, poloxamer 188 5%, sodium chloride 0.6%, glycine 0.5% and meglumine 0.3%, in water for injection, pH adjusted with sodium hydroxide and hydrochloric acid.

Indications: Dogs: METACAM (meloxicam) 5 mg/mL Solution for Injection is indicated in dogs for the control of pain and inflammation associated with osteoarthritis.

Contraindications: Dogs with known hypersensitivity to meloxicam should not receive METACAM 5 mg/mL Solution for Injection.

Warnings: Not for use in humans. Keep this and all medications out of reach of children. Consult a physician in case of accidental ingestion by humans. For IV or SQ injectable use in dogs. All dogs should undergo a thorough history and physical examination before administering any NSAID. Appropriate laboratory testing to establish hematological and serum biochemical baseline data is recommended prior to, and periodically during use of any NSAID in dogs.

Owner should be advised to observe their dogs for signs of potential drug toxicity.

Precautions: The safe use of METACAM 5 mg/mL Solution for Injection in dogs younger than 6 months of age, dogs used for breeding, or in pregnant or lactating bitches has not been evaluated. Meloxicam is not recommended for use in dogs with bleeding disorders, as safety has not been evaluated. Meloxicam is not hese disorders. Safety has not been established for intramuscular (IM) administration in dogs. When administering METACAM 5 mg/mL Solution for Injection, use a syringe of appropriate size to ensure precise dosing. As a class, cyclo-oxygenase inhibitory NSAIDs may be associated with gastrointestinal, renal and hepatic toxicity. Sensitivity to drug-associated adverse events varies with the individual patient. Dogs that have experienced adverse reactions from one NSAID may experience adverse advections from another NSID. Patients at creates tick for renal toxicity are those that are dehydrated or reactions from another NSAID. Patients at greatest risk for renal toxicity are those that are dehydrated, on concomitant diuretic therapy, or those with existing renal, cardiovascular, and/or hepatic dysfunction. Concurrent administration of potentially nephrotoxic drugs should be carefully approached. NSAIDs Concurrent administration of potentially nephrotoxic drugs should be carefully approached. NSAIDs may inhibit the prostaglandins that maintain normal homeostatic function. Such anti-prostaglandin effects may result in clinically significant disease in patients with underlying or preexisting disease that has not been previously diagnosed. Since NSAIDs possess the potential to induce gastrointestinal ulcerations and/or perforations, concomitant use with other anti-inflammatory drugs, such as NSAIDs or corticosteroids, should be avoided. If additional pain medication is needed after the administration of the total daily dose of METACAM Oral Suspension, a non-NSAID or noncorticosteroid class of analgesia should be considered. The use of another NSAID is not recommended. Consider appropriate washout times when switching from corticosteroid use or from one NSAID to another in dogs. The use of concomitantly protein-bound drugs with METACAM 5 mg/mL Solution for Injection has not been studied in dogs. Commonly used protein-bound drugs include cardiac, anticonvulsant and behavioral medications. The influence of concomitant drugs that may inhibit metabolism of METACAM 5 mg/mL Solution for Injection has not been evaluated. Drug compatibility should be monitored in patients requiring adjunctive therapy. The effect of cyclo-oxygenase inhibition and the potential for thromboembolic occurrence or a hypercoagulable state has not been studied. thromboembolic occurrence or a hypercoagulable state has not been studied.

Adverse Reactions

Dogs: A field study involving 224 dogs was conducted.¹ Based on the results of this study. GI abnormalities (vomiting, soft stools, diarrhea, and inappetance) were the most common adverse reactions associated with the administration of meloxicam.

The following adverse reactions are based on post-approval adverse drug event reporting. The categories are listed in decreasing order of frequency by body system:

Gastrointestinal: vomiting, diarrhea, melena, gastrointestinal ulceration

Urinary: azotemia, elevated creatinine, renal failure Neurological/Behavioral: lethargy, depression Hepatic: elevated liver enzymes

Dermatologic: pruritus

Death has been reported as an outcome of the adverse events listed above. Acute renal failure and death have been associated with the use of meloxicam in cats.

Information For Dog Owners: Meloxicam, like other NSAIDs, is not free from adverse reactions. Owners should be advised of the potential for adverse reactions and be informed of the clinical signs associated with NSAID intolerance. Adverse reactions may include vomiting, diarrhea, lethargy, decreased appetite and behavioral changes. Dog owners should be advised when their pet has received a meloxicam injection. Dog owners should contact their veterinarian immediately if possible adverse reactions are observed, and dog owners should be advised to discontinue METACAM therapy.

Effectiveness:

Effectiveness: Dogs: The effectiveness of METACAM 5 mg/mL Solution for Injection was demonstrated in a field study involving a total of 224 dogs representing various breeds, all diagnosed with osteoarthritis.¹ This placebo-controlled, masked study was conducted for 14 days. Dogs received a subcutaneous injection of 0.2 mg/kg METACAM 5 mg/mL Solution for Injection on day 1. The dogs were maintained on 0.1 mg/kg or all neloxicam from days 2 through 14. Variables evaluated by veterinarians included lameness, weight-bearing, pain on palpation, and overall improvement. Variables assessed by owne included mobility, ability to rise, limping, and overall improvement.

In this field study, dogs showed clinical improvement with statistical significance after 14 days of meloxicam treatment for all variables.

Reference: 1. FOI for NADA 141-219 METACAM (meloxicam) 5 mg/mL Solution for Injection

Manufactured for:

Boehringer Ingelheim Vetmedica, Inc. St. Joseph, MO 64506 U.S.A.

METACAM is a registered trademark of Boehringer Ingelheim Vetmedica GmbH, licensed to Boehringer Ingelheim Vetmedica, Inc.

601307-07 Revised 08/2014

18490 06/2018

Marc Rosenberg, VMD | THE DILEMMA

An investigation showed that Dr. Ray's security protocols were practically nonexistent, and the police recommended he install a video surveillance system. After ruminating about how this would never have happened when his clinic was smaller and the staff more intimate, Dr. Ray installed cameras throughout the clinic.

The new cameras saw in light and dark and were triggered by motion, and they collected up to 30 days' footage. Dr. Ray sent a memo to all staff members informing them that surveillance was now in place. He went on to say he was sorry he had to take these steps, but circumstances dictated that they were necessary. Finally, he attempted to lighten the mood by telling team members they should feel free to make faces at the camera.

Nevertheless, several of the staff members were concerned. They told Dr. Ray they were disappointed that he felt they couldn't be trusted. In addition, one of his staff doctors advised him of a law that prohibited him from



CHEWABLE TABLETS

Brief Summary: Before using PREVICOX, please consult the product insert, a summary of which follows: Caution: Federal law restricts this drug to use by or on the order of a licensed veterinarian.

Indications: PREVICOX (firecoxil) Chewable Tablets are indicated for the control of pain and inflammati associated with osteoarthritis and for the control of postoperative pain and inflammation associated with soft-tissue and orthopedic surgery in dogs.

Contraindications: Dogs with known hypersensitivity to firocoxib should not receive PREVICOX. Warnings: Not for use in humans. Keep this and all medications out of the reach of children. Consult a physician in case of accidental ingestion by humans.

in case of accidental ingestion by humans. For oral use in dogs only. Use of this product at doses above the recommended 2.27 mg/b (5.0 mg/kg) in puppies less than seven months of age has been associated with serious adverse reactions, including death (see Animal Safety). Due to tablet sizes and scoring, dogs weighing less than 12.5 lb (5.7 kg) cannot be dorough history and physical examination before the initiation of NSAID therapy. Appropriate laboratory testing to establish hematological and serum baseline data is recommended prior to and periodically during administration of any NSAID. Owners should be advised to observe for signs of potential drug toxicify (see Adverse Reactions and Animal Safety) and be given a Client Information Sheet about PREVICOX Chewable Tablets.

For technical assistance or to report suspected adverse events, call 1-877-217-3543. For additional information about adverse drug experience reporting for animal drugs, contact FDA at 1-888-FDAVETS or http://www.fda.gov/ AnimalVeterinary/SafetyHealth

Precautions: This product cannot be accurately dosed in dogs less than 12.5 pounds in body weight. Consider appropriate washout times when switching from one NSAID to another or when switching from corticosteroid use to NSAID use.

Consider appropriate Washout times when switching from the NSALD to another of when switching infom corticosteroid use to NSALD use. As a class, cyclooxygenase inhibitory NSALDs may be associated with renal, gastrointestinal and hepatic toxicity. Sensitivity to drug-associated adverse events varies with the individual patient. Dogs that have experienced adverse reactions from one NSALD may experience adverse reactions from another NSALD. Patients at greatest risk for adverse events are those that are dehydrated, on concomitant diuretic therapy, or those with existing renal, cardiovascular, and/or hepatic dysfunction. Concurrent administration of potentially nephrotoxic drugs should be carefully approached and monitored. NSALDs may inhibit the prostaglandins that maintain normal homeostatic function. Such anti-prostaglandin effects may result in clinically significant disease in patients with underlying or pre-existing disease that has not been previously diagnosed. Since NSALDs possess the potential to produce gastrointestinal ulceration and/or gastrointestinal perforation, concomitant use of PREVICOX Chewable Tablets with other anti-inflammatory drugs, such as NSALDs or corticosteroids, should be avoided. The concomitant use of protein-bound drugs with PREVICOX Chewable Tablets has not been studied in dogs. Commonly used protein-bound drugs liculde cardiac, anticonvulsant, and behavioral medications. The influence of concomitant drugs that may inhibit the metabolism of PREVICOX Chewable Tablets has not been evaluated. Drug compatibility should be monitored in patients requiring adjunctive therapy. If additional pain medication is needed after the daily dose of PREVICOX, a non-NSAID class of analgesic may be necessary. Appropriate monitoring procedures should be employed during all surgical procedures. Anethetic drugs may affect renal perfusion, approach concomitant use of anesthetics and NSAIDs cardiously. The use of parenteral fluids during surgery should be considered to decrease potential

Adverse Reactions:

Idverse Reactions: Isteoarthritis: In controlled field studies, 128 dogs (ages 11 months to 15 years) were evaluated for safety when given REVICOX Chewable Tablets at a dose of 2.27mg/lb (5.0 mg/kg) orally once daily for 30 days. The following adverse eactions were observed. Dogs may have experienced more than one of the observed adverse reactions during the study Adverse Reactions Seen in U.S. Field Studies

Adverse Reactions	PREVICOX (n=128)	Active Control (n=121)
Vomiting	5	8
Diarrhea	1	10
Decreased Appetite or Anorexia	3	3
Lethargy	1	3
Pain	2	1
Somnolence	1	1
Hyperactivity	1	0

PREVICOX (firocoxib) Chewable Tablets were safely used during field studies concomitantly with other therapies, including vaccines, anthelmintics, and antibiotics.

Soft-tissue Surgery: In controlled field studies evaluating soft-tissue postoperative pain and inflammation, 258 dogs (ages 10.5 weeks to 16 years) were evaluated for safety when given PREVICOX Chewable Tablets at a dose of 2.27 mg/ lb (5.0 mg/kg) orally approximately 2 hours prior to surgery and once daily thereafter for up to two days. The following adverse reactions were observed. Dogs may have experienced more than one of the observed reactions during the study.

Adverse Reactions Seen in the Soft-tissue Surgery Postoperative Pain Field Studies

Adverse Reactions	Firocoxib Group (n=127)	Control Group* (n=131)
Vomiting	5	6
Diarrhea	1	1
Bruising at Surgery Site	1	1
Respiratory Arrest	1	0
SQ Crepitus in Rear Leg and Flank	1	0
Swollen Paw	1	0
*01		

Orthopedic Surgery: In a controlled field study evaluating orthopedic postoperative pain and inflammation, 226 dogs of various breeds, ranging in age from 1 to 11.9 years in the PREVICOX-treated groups and 0.7 to 17 years in the control group were evaluated for safety. Of the 226 dogs, 118 were given PREVICOX Chewable Tablets at a doss of 2.27 mg/lb (5.0 mg/kg) orally approximately 2 hours prior to surgery and once daily thereafter for a total of three days. The following adverse reactions were observed. Dogs may have experienced more than one of the observed reactions during the study

Adverse Reactions Seen in the Orthopedic Surgery Postonerative Pain Field Study

i occipitatio i an riola otauj				
Adverse Reactions	Firocoxib Group (n=118)	Control Group* (n=108)		
Vomiting	1	0		
Diarrhea	2**	1		
Bruising at Surgery Site	2	3	_	
Inappetence/ Decreased Appetite	1	2		
Pyrexia	0	1	_	
Incision Swelling, Redness	9	5		
Oozing Incision	2	0	_	
A case may be represented in more	than one category.			

A case may be represented in more than on *Sham-dosed (pilled). **One dog had hemorrhagic gastroenteritis.

Post-Approval Experience (Rev. 2009): The following adverse reactions are based on post-approval adverse drug event reporting. The categories are listed in decreasing order of frequency by body system: <u>Gastrointestinal:</u> Vomiting, anorexia, diarrhea, melena, gastrointestinal perforation, hematemesis, hematachezia, weight loss, gastrointestinal ulceration, peritonitis, abdominal pain, hypersalivation, nausea

Urinary: Elevated BUN, elevated creatinine, polydypsia, polyuria, hematuria, urinary incontinence, proteinuria, ilure. azotemia. urinarv tract infectior

Noney ranno accente, unay lact intection of the second sec Hepatic: Elevated ALP, elevated ALT, elevated bilirubin, decreased albumin, elevated AST, icterus, decreased or increased total protein and globulin, pancreatitis, ascites, liver failure, decreased BUN

Hematological: Anemia, neutrophilia, thrombocytopenia, neutropenia

Cardiovascular/Respiratory: Tachypnea, dyspnea, tachycardia

Dermatologic/Immunologic: Pruritis, fever, alopecia, moist dermatitis, autoimmune hemolytic anemia, facial/ nuzzle edema. urticaria In some situations, death has been reported as an outcome of the adverse events listed above

For a complete listing of adverse reactions for firocoxib reported to the CVM see: http://www.fda.gov/downloads/AnimalVeterinary/SafetyHealth/ProductSafetyInformation/UCM055407.pdf

Animal/Veterinary/Safety/Health/ProductSafety/Information/UCM055407.pdf Information For Dog Owners: PREVICOX, like other drugs of its class, is not free from adverse reactions. Owners should be advised of the potential for adverse reactions and be informed of the clinical signs associated with drug intolerance. Adverse reactions may include vomiting, diarrhea, decreased appetite, dark or tarry stools, increased water consumption, increased urination, pale gums due to anemia, yellowing of gums, skin or white of the eye due to jaundice. Identary, incoordination, seizure, or behaviori changes. Serious adverse reactions associated with this drug class can occur without warning and in rare situations result in death (see Adverse Reactions). Owners should be advised to discontinue PREVICOX therapy and contact their veterinarian immediately if signs of intolerance are observed. The vast majority of patients with drug-related adverse reactions have recovered when the signs are recognized, the drug is withdrawn, and veterinary care, if appropriate, is initiated. Owners should be advised of the importance of periodic follow up for all dogs during administration of any NSAID. Effectionees: Two hundred and fork-ring dogs of various branes, ranging in age from 11 months to 20 years.

Recovered where the signs are recovered with a signs and seven and vector of the seven and vector of the seven and the seven and

The volume of the term of the top termingle. The scalar of the termination in the terms on the output of the study of the scalar of the terms of the scalar of

Made in France Marketed by: Merial, Inc., Duluth, GA 30096-4640, U.S.A. -877-217-3543 NADA 141-230, Approved by FDA Rev. 09-2015

recording or listening to any audio the cameras captured. In his state, video surveillance in the workplace was legal with the permission of one party only, but audio recording was prohibited without the permission of all parties concerned. Furthermore, private areas such as restrooms and the break room

> were totally off limits. Dr. Ray started to feel like his practice growth was a double-edged sword. The intimate trust and collegiality of the small clinic had been replaced by the stricter workplace rules and regulations of a "bigger company." Dr. Ray reluctantly adjusted to the changes. He wondered if he would ever be able to reestablish his small clinic feeling of intimacy now that his facility had grown larger. He knew the answer was a resounding "no."

> Do you agree with Dr. Ray's choices? Have you had a similar experience? Let us know at dvm360@mmhgroup.com.

Dr. Rosenberg's response

Small veterinary practices—like other "mom and pop" businesses-are shrinking in number. There are lots of reasons for this. Progressive veterinary technology is expensive. The internet, online pharmacies, increasing healthcare costs and workers' compensation premiums have all stressed small-practice bottom lines.

In spite of all this, I agree with Dr. Ray's choice to install cameras. Safety protocols and theft deterrents assist everyone. In addition, the practice leader or leaders need to be ethical, moral and honest role models.

Coworkers are comforted when they can honestly respect practice leadership, and the collegiality that Dr. Ray had with a smaller team doesn't have to disappear with an increase in staff. Over time, morale may get even better, with informal protocols and thoughtless watercooler gossip replaced by interactions and procedures that everyone feels comfortable with.

Dr. Marc Rosenberg is director of the Voorhees Veterinary Center in Voorhees, New Jersey. Although many of his scenarios in "The Dilemma" are based on real-life events, the veterinary practices, doctors and employees described are fictional.



Steps in a practice sale

With consolidators and investors snapping up practices, owners who weren't thinking of selling wonder if now's the time. Here's how the process works.

t's no secret that the veterinary profession has entered a new world of rapid corporate acquisition, and practice owners are being lured by the robust sale prices. At the same time, associates are becoming more alert to any availability of successful practices, hoping they might be able to buy one before it's scarfed up by a consolidator.

In bygone days, word that a veterinary hospital might be available for purchase spread via ads in veterinary journals or word-of-mouth: whispers among former classmates, nearby competitors and drug reps. No longer. With prices soaring, owners are considering selling when they otherwise might have waited 10 years or more to pull the ripcord. Acquisition is on everyone's radar. Here's how the process typically plays out.

1. Initial outreach gets a practice owner thinking

Today, I rarely encounter a clinic partner or owner who hasn't been contacted by somebody who wants to discuss acquisition. Sometimes these entreaties are rebuffed, but that contact can still start the owner's gears turning. Even the attention of Dr. NeverSell will be, at least momentarily, drawn to outsized offers by corporate chains.

2. The sit-down may happen in secret

Not everybody who owns a practice is actively selling. But even the "extremely unlikely but marginally possible" potential seller may think, "What have I got to lose? It might be interesting to hear what that consolidator has in mind." So there's often an initial meeting—in secret at a coffee shop in a nearby town at a late hour.

3. A 'letter of intent' locks down confidentiality

Whether the suitor is a billion-dollar corporation or a pair of guys looking to get a better return on their IRAs, the deal is generally initiated with the drafting of a "letter of intent" (LOI), a document that describes the essential terms of a potential clinic purchase. LOIs generally mandate one or both of the following: (1) nondisclosure of the details of the deal, and (2) the obligation of the seller not to entertain other offers until expiration of the LOI.

My general feeling is that LOIs should be as detailed as possible. It's much less expensive for the deal to collapse during multiple redrafts of a three-page LOI than to discover a deal-breaker the night before closing after both sides have incurred substantial legal costs.

4. Due diligence shows where the money's at

If the deal survives the LOI process, there will be a far more specific set of terms set forth in a purchase-and-sale contract between buyer and seller. Regardless of whether the contract is signed shortly after finalization of the LOI or at closing (or any time between), the buyer must take a close look at the representations of the seller.

Is the gross revenue truly what's claimed? Are there liens on the equipment? Are associates likely to leave if the practice is sold? These and other facts need to be investigated by the buyer and his or her advisors. Also, if the clinic is operated on leased premises, it's likely the seller's job to secure a commitment from his landlord to continue to lease (or sometimes to sell) the premises to the potential purchaser. Truth be told, if the seller has any doubt that the landlord will offer the purchaser terms similar to the existing lease, the seller should probably work that angle before spending time or effort negotiating an LOI.

5. The reveal must be managed well

Now the tough part: At some point, the clinic team needs to be told the hospital is being sold. The way this news is revealed can determine whether the practice sells or the buyer walks away—leaving behind a hospital whose earth has been scorched by an employer now perceived as having blindsided or sacrificed the interests of his dedicated team.

There is no easy way to manage this reveal, and there are multiple techniques for carrying it out. Essentially, it's incumbent on the seller to figure out a way to get his people (particularly associate doctors) on board before the buyer will pay the purchase price.

6. The contract is crucial to secure financing

Ordinarily, in the case of larger practice sales, a final, definitive contract is prepared (if not executed) before the actual closing of the sale. The main reason is the need to secure the money to buy the practice. A contract may be necessary before a funding source bank, venture capitalist, the buyer's Uncle Fred—will commit to providing the funds for acquisition.

7. Contingencies cover what occurs after the sale

The LOI, the contract or both may contain preclosing contingencies specific requirements that must be met before closing occurs. One common contingency is that staff veterinarians must all sign commitments to remain with the practice for a minimum of (x) months after the closing. Another might be a requirement that the buyer be able to negotiate an acceptable lease for the use of the clinic property (either from the seller or from the seller's landlord).

8. The closing can be anticlimactic

For anyone who's bought a home, you

likely remember that closing was a nerve-wracking and exciting time. Maybe you had a table with seller and buyer present, flanked by representatives of the seller, the buyer, one or more banks,

] ###

a developer, a title insurer and more.

In what may seem counterintuitive, a practice sale closing (perhaps involving 10 times the cost of a typical home) may take place with nobody getting together. If all the legal preparations have been made and all last-minute misunderstandings have been addressed, the closing may occur 100% digitally with the buyer's and seller's attorneys exchanging signatures online. In such closings all signature pages are held in escrow pending the wiring of funds from the buyer's account to the seller's.

That's how it works

Those are the relatively universal stages involved in the transformation of Dr. NeverSell into the wealthiest worker bee on staff at a veterinary practice he used to own. Clearly there are many moving parts: The order in which the steps are carried out, and the flow of information among all those affected, can make or break the outcome.

It makes good sense, before moving forward, for a seller and a buyer to realistically assess whether the deal works emotionally, financially and practically in their individual circumstances. If so, then it's game on!

Dr. Christopher J. Allen is president of Associates in Veterinary Law PC, which provides legal and consulting services to veterinarians. He can be reached via email at info@veterinarylaw.com.

INFLAMMATION RUNNING WILD?

S Duralactin®

Why stock up? Only Duralactin helps tame inflammation throughout the whole body with MicroLactin®, a protein that helps manage inflammation and helps support joint health. Minimal side effects make Duralactin products suitable for high-risk patients under veterinarian care. Add this valuable tool to your treatment arsenal and save! Ask your sales representative for details.

SATISFACTION GUARANTEED

Duralactin[®] products come with a risk-free, 100% money-back guarantee. If your clients are not completely satisfied with any of the products, they are eligible for a refund or product replacement.

BUY ANY 3 Canine or Feline Duralactin® Products & GET ONE FREE!

Now is the perfect time to stock up on Duralactin[®] products. From **July 1, 2019 – August 31, 2019**, buy any three canine or feline Duralactin products and get one free. Mix and match all you want, as long as the free product is of equal or lesser value than the ones you buy.



Promotional Terms and Conditions: This promotion is restricted to veterinary practices where the veterinary-client-patient relationship (VCPR) exists as defined by the AVMA's Principles of Veterinary Medical Ethics. Other veterinary accounts such as shelters, animal care/control agencies and veterinary partner pharmacies, may be eligible on a case-by-case basis. Accounts with direct-to-consumer sales via internet website, catalog or other over-the-counter channels are ineligible. Qualifying orders must be on a single invoice. Free goods will be fulfilled by distribution. Free goods may not be returned for credit. PRN Pharmacal reserves the right to modify or withdraw this promotion at any time. Purchases must be invoiced between July 1, 2019 and August 31, 2019. Promotion excludes Canada and equine Duralactin products.

This product has not been approved by the FDA nor is it intended to diagnose, treat, cure, or prevent any disease. Should only be used through consultation of a veterinarian and in conjunction with an overall wellness program.

Microlactin is a registered trademark of Stolle Milk Biologics, Inc. Duralactin is a registered trademark of Pegasus Laboratories, Inc. ©2019 PRN Pharmacal, Inc. All rights reserved.

Duralactin.com 800-874.9764



UniversityPRN.com CE as needed, when needed.





The most important things are simple but they're not easy

Meaningful personal and professional growth may come at a level that seems easy as pie. Like, so basic that surely the veterinary profession succeeds at it already. But no.

ell-being author and speaker Mike Robbins tells us that the advice we give others is often the exact advice we need ourselves. As the Sermon on the Mount admonishes, "First remove the log out of your own eye, then you can see clearly to remove the speck from your brother's eye." Sort of like, "People who live in glass houses ... "

We all have the solution to our friends' problems. So, here's a thought: Maybe it's time we all listen to our own advice rather than doling it out like Halloween candy.

I don't know about you, but I struggle with seemingly universal issues. It isn't easy. Maybe that's why they're called struggles. Relationships, truthfulness, tolerance, compassion ... you get the idea. Where do you wish you could hold yourself to a higher ideal? In the quest to be your best, most amazing self, where would you want to dial up your effort just one more notch?

I think we can all grow by focusing on the simple and basic. For example:

Be honest. I know. We're all honest, right? Then why is the world so full of doubt, mistrust and accusations? The more open and honest we are with ourselves and about ourselves, the less likely we are to be arrogant, judgmental, self-righteous or defensive about our own need for love and support—and the more likely we are to be compassionate toward others.

Be compassionate. We are all doing the best we can at any moment. Having compassion is really simple, but it's not easy. Start by giving yourself a break. When we can get off our own back and forgive ourselves (not as easy as it sounds) then we are on the road to giving others that same gift.

Stop fighting for perfection.

Perfection doesn't exist. So, stop asking for perfection from yourself and others. We all screw up sometimes. Recognizing and accepting that is a first step toward acceptance in yourself and others. Turn down the heat under your burner and give yourself space to be you and impact others in a positive way.

Dr. Michael Paul is the former executive director of the Companion Animal Parasite Council and a former president of the American Animal Hospital Association. He is currently the principal of MAGPIE Veterinary Consulting. He is retired from practice and lives in Anguilla, British West Indies.

Let's talk cannabidiol

CBD in practice comes with many questions and legal concerns. Here's what you need to know. *By Michael Petty, DVM, CVPP, CVMA, CCRT, CAAPM*

Letter to *dvm360*: Some more about cannabis

In Dr. Marc Rosenberg's recent column (see box below) I was pleased to see Dr. Knox passionately and effectively defend his stance on cannabis for his veterinary patients. I was also very glad to see Dr. Rosenberg's progressive stance on the issue. As veterinarians in 2019, we need to support the need for change regarding the regulatory and legislative restraints surrounding cannabis use for veterinary (and all) patients. In order to best serve our patients, clients and the community as a whole, veterinarians need to be able to discuss and provide guidance regarding all available therapeutic options.

—Elizabeth Mironchik-Frankenberg, DVM, Founder, Veterinary Cannabis Consultants



Rosenberg on cannabis The above letter was in response to a scenario from Dr. Mark Rosenberg. Find the original at dvm360.com/ cannabisquestion. he use of cannabidiol (CBD) for medical conditions in veterinary medicine—most commonly for pain, anxiety and epilepsy seems to be the most talked-about area of medical therapy at the moment. And it's no wonder: in a recent survey published in *Frontiers in Veterinary Science*, 29% of veterinarians reported they got a weekly inquiry about CBD from their clients. Twenty-seven percent were asked about it monthly and 7% were asked daily.

Yet the same survey showed that less than half of these veterinarians were comfortable talking to their clients about CBD products. Since then, the number of people asking about CBD products has probably grown exponentially, especially after hemp-derived CBD was removed from the Schedule I list in December 2018.

What's the big deal?

First of all—and this is important— CBD products can come from either hemp or marijuana. Although they may look alike, those CBD products derived from marijuana are still Schedule I and illegal to use. In other words, they can put your DEA license at risk. (In California, veterinarians can legally discuss marijuana, but they can't prescribe it or use it in treatment.)

Always ask for the source of the CBD (licensed hemp grower, not marijuana grower) before buying, dispensing or recommending a particular product, should you be inclined to do so. On the human side, dispensers of marijuana-derived CBD are being pursued aggressively in some states—most notably Texas, Ohio and Nebraska.

Federally, CBD oil from hemp with less than 0.3% 19-tetrahydrocannabinol (THC), the psychotropic part of

The use of cannabidiol (CBD) for
medical conditions in veteri-
nary medicine—most com-
for pain, anxiety and epilepsy—
to be the most talked-about areamarijuana (and possibly hemp as it
contains small amounts), is legal. The
real issue is that many states have not
caught up with their own legislation
regarding the use of CBD from hemp
and some have been more aggressive
in enforcing their laws than others.

On the human side, it's usually OK to dispense CBD as long as it's not dispensed as a drug, no medical claims are made and it's not part of a dietary supplement or added to food. Of course, in some states, CBD from marijuana is a legal human drug. To make it more confusing, on the veterinary side, animal supplements are not regulated by the FDA, so there's no prohibition on the federal level against using CBD as an animal supplement.

Taking it state by state

The following is a list provided to me by Stacey Evans, JD, an independent legal consultant who works with Elle-Vet (a provider of hemp products that contain CBD) and individual veterinarians. Note: When a state veterinary medical association (VMA) says CBD is illegal or cautions against its use, the association might be wrong. The issue of whether the CBD comes from hemp or marijuana has muddled the declarations of several state VMAs, as has the fact that many prefer to err on the side of caution. This list could change at any moment. Please contact your state VMA for any updates.

- California VMA cautions veterinarians against selling or administering hemp.
- Michigan VMA cautions that veterinarians face increased legal risk if there is an adverse event.
- > Connecticut VMA states that it was told by the Connecticut Department of Consumer Affairs that

- CBD is illegal for animal use.
- Oregon VMA states that it shares with members the FDA's position that hemp products with CBD are unapproved animal drugs.
- > Illinois VMA provides an AVMA memo about not making any claims that CBD can treat, cure, prevent or mitigate a medical condition or disease.
- Oklahoma VMA states that although legal, veterinarians may face increased liability when CBD is used to treat animals.

These state VMAs have no comment: Colorado, New Jersey, Kentucky, Washington, Maryland, Minnesota, Florida, Texas, Louisiana, New York and Pennsylvania.

Want to consider one more layer of legal confusion? A product that doesn't make claims or intend to treat, mitigate or cure a medical condition doesn't automatically become a drug if a client or a veterinarian administers the product to an animal to treat, mitigate or cure a medical condition. Nor is a product a drug just because it contains an ingredient, such as CBD, that's also used in another FDA-approved drug. Such a product is an animal supplement, which the FDA does not regulate.

Once each state government actually passes legislation, most if not all legal issues should be resolved. My advice is to ask your state VMA to push for CBD legislation for animals so you don't accidentally break the law during these confusing early days. And for the time being, to be safe, never ever make a claim that it can treat a medical condition or disease or use a product whose packaging makes such a claim.

Dr. Michael Petty owns Arbor Pointe Veterinary Hospital in Canton, Michigan.

COMMUNITY | Commentary

Get in touch Contact us on Twitter: @ dvm360, on Facebook: facebook.com/ dvm360, via e-mail: dvm360@ mmhgroup.com or online at dvm360.com/ community.

'She seems fine,' but you see **pain**

There's a fine line to walk when talking about pets' discomfort without paining clients and, of course, yourself. *By Gina Singleton, DVM*

saw a dog for a rabies vaccine in my clinic a while ago. When I walked into the exam room, I was smacked in the face with the smell of rot. I looked down and saw a tiny, gray, quivering poodle in a cheetahprint faux-fur sweater. One of her eyes was draining pus and her tongue was hanging out. Her owner picked her up, unfolded her legs like a picnic chair and placed her on the table.

"She gets stiff," the owner explained. The younger, politer version of myself would gently ask if she was on any medications or being treated for any health conditions. The current version of myself isn't as mild: "Are you giving her anything for pain?"

I've found this to be an effective, time-saving phrase in my life. It might be a little blunt, but I'm done with the careful, don'twant-to-hurt-anyone's-feelingsor-god-forbid-make-a-clientupset approach to medicine. The bottom line: This poor dog was in pain and her owner was blind to it. Her answer to my question? "No, she seems fine." *Sigh.* So, we talked about pain in animals (not my best educational session, as it was the fourth exam that day) and afterwards, she left with the trembling poodle under her arm.

The following week, she returned with Poopsie, the poodle, as well as her daughter's dog, Smoochie. She thought they both might be painful. Luckily for us, it was a morning appointment, so I had only talked about pain once that day. Poopsie and Smoochie both had a little bloodwork done and left with some meloxicam.



Hurrah! Relief of an animal suffering needless pain achieved!

As you can probably tell from my jaded tone, this whole scenario is causing me pain. There are many versions of this story:

> The fat, happy shepherd mix whose tail never stops wagging with stifles that palpate like bubble wrap. "He's fine," his owner tells me. "He still wants to eat and play."

> The active young Lab who tore her cranial cruciate ligament six months ago and whose owner couldn't afford surgery, but seemed dedicated to physical therapy and gabapentin. You can actually see the tibia sliding forward while she's gimping across the

34 July 2019 J dvm360

room. You naively ask, "How are the meds going?"

"Oh, I stopped giving them," her owner says. "She seems fine."

I've come to realize that many owners define "fine" as eating, drinking, peeing, pooping and moving about in some fashion—in other words, still alive. And I know that it's not helpful to be cranky about this, because I've had an excessive amount of education regarding animal health and owners haven't. I know this.

However, is it crazy of me to assume that a human can make the mental leap that limping equals pain? When is the last time you limped when some part of you didn't hurt? What creates this obstacle in the minds of otherwise intelligent people? Denial? Distraction? Just not thinking at all?

My favorite pain quote of all time: "We can't take him for walks anymore because he's too stiff, but we stopped giving him the Rimadyl 'cause he seems fine." (Another observation somehow stiff does not equal pain.) Educating clients about pain is tricky. If we're too gentle, clients stay

firm in their belief that the pet is fine. If we're too firm, clients feel blamed or guilty and sometimes angry. You have to get it just right, and some days I don't have the patience for perfection.

So, hopefully without being a total jerk, I've become content with my question—"What are you giving for pain?"—which is really a backhanded way of saying, "Your pet is in pain."

However, if I have to be a jerk to help the poor Poopsies of the world, I guess I'm fine with that.

Gina Singleton is an associate veterinarian practicing at a small animal practice in Maine. If she had free time, she would love to make movies, travel the world and dance. For now she is devoted to being a mom, wife and vet.



Let's talk about pain, baby

Trying to get through to your clients on pet pain convos? See a sample script from one of our favorite pain experts at dvm360.com/talkpain.





Canine otitis externa: A common problem to test anyone's problem-solving skills

Itchy, smelly, irritated ears are one of the most common complaints that drive dogs to veterinary clinics, and ear disease is always among the top two reasons for pet insurance claims. So, what's the best way to uncover all of the factors that underlie a case of otitis externa? And what are best practices for helping treat these miserable dogs?

By Andrew Rosenberg, DVM, DACVD

No case of canine otitis externa is simple because it should be assumed that there are multiple causes and factors present. For your treatment to be successful, all the causes and factors must be addressed, not just some of them. Adopting the PSPP system—identifying and managing all the primary and secondary causes and predisposing and perpetuating factors¹ in dogs with otitis—supports an optimal treatment outcome.

PSPP: A system for recognizing all the factors in otitis externa

Primary causes of otitis externa directly damage or inflame the ear canal and typically lead to secondary infections. Identifying and managing primary causes prevents recurrence of otitis externa. Common primary causes of otitis externa include allergy (atopic dermatitis, cutaneous adverse food reaction, flea allergy dermatitis), autoimmune or immune-mediated disease (especially pemphigus foliaceus), foreign bodies, ceruminous gland disorders, endocrine diseases, epithelialization diseases, and parasites (*Otodectes, Demodex*).

Secondary causes of otitis externa do not create disease in a normal ear; however, they cause disease in ears affected by a primary cause or predisposing factor. Secondary causes are usually easy to eliminate, but unless the underlying primary causes are identified and treated, the secondary causes will return. Secondary causes include bacteria (cocci and rods), yeast (*Malassezia* and *Candida*), fungi, and medication reactions. The most common and important bacterial causes of otitis externa include *Staphylococcus*, *Enterococcus*, *Streptococcus and Pseudomonas* species; *Proteus mirabilis*; and *Escherichia coli*.

Perpetuating factors are changes in the anatomy and physiology of the external ear canal in response to otitis externa. These changes occur most commonly in chronic otitis externa cases. Perpetuating factors do not cause otitis externa initially, but they allow development of secondary infections and can prevent resolution of otitis externa. If perpetuating factors are left untreated, they can result in the majority of clinical signs seen in chronic cases. Perpetuating factors include epithelial changes (altered/failure of ear cleaning mechanism), ear canal changes (proliferative changes to the ear canal or tragal folds, stenosis, edema), a ruptured tympanic membrane leading to otitis media, glandular changes (dilated or blocked ceruminous glands, inflamed ceruminous glands, hyperplasia), mineralization due to chronic inflammation, or otitis media.

Predisposing factors are present before ear disease develops. They alone do not cause otitis, but they can predispose a dog to the development and persistence of otitis externa. Predisposing factors include abnormal conformation of the ear canal (sometimes breedspecific changes: excessive hair in canals, stenotic canals as seen in Chinese Shar-Pei dogs, pendulous pinnae), excessive moisture after swimming, or obstructive ear disease (polyps, neoplasia).

Your best diagnostic approach

When approaching ear disease, be systematic and strive to identify the primary cause or causes. Work up and rule out all possible primary causes. A good patient history and thorough physical and otoscopic examinations are important in identifying primary causes. Also look for secondary causes through cytologic examination and, when warranted, bacterial culture. Concurrently, address and manage all predisposing and perpetuating factors.

Cytology is the crucial diagnostic tool in cases of otitis externa. In my opinion, ear cytology should be performed in all otitis cases. Cytology allows you to evaluate the cellular makeup of the otic discharge, including microorganisms and inflammatory cells. It is inexpensive and can guide your treatment decisions. It can also help identify underlying causes or indicate a need for additional diagnostic tests. For example, if no inflammatory cells are present, the patient may be immunosuppressed (e.g., has hyperadrenocorticism), or if neoplastic cells are seen, aural neoplasia may be present.

Opinions differ on the diagnostic value of bacterial culture of ear swab samples because there may be different strains of the same bacterial species in an infected ear. Thus, the strain identified on a bacterial culture report may not be the only strain. In addition, susceptibility breakpoints on antimicrobial sensitivity profiles are based on in vivo serum antibiotic concentrations. However, topical medications provide much higher antibiotic concentrations at the affected site and often overpower bacterial resistance mechanisms. I recommend obtaining an ear swab sample for bacterial culture if 1) cytologic examination reveals rods or a mixed bacterial population, 2) otitis clinical signs do not improve after two or three weeks of treatment, or 3) you suspect otitis media. The culture results can be used to guide treatment and choose systemic antibiotics when warranted for middle ear disease or severe proliferative otitis.²⁻⁵

Your best treatment approach

Commercial ear cleansers provide numerous benefits in the treatment of otitis externa. These cleansers help break up organic debris and biofilms, help normalize epithelial turnover, decrease inflammation, and remove bacteria and yeast. Using commercial cleansers can hasten resolution of ear disease.

Many combination topical antimicrobial/ antifungal/corticosteroid products are marketed to treat otitis externa, and reviewing each one is beyond the scope of this article. Choose an appropriate medication based on its spectrum of antimicrobial efficacy and the results of a cytologic examination. Be cautious, because many products contain an aminoglycoside, which has been implicated in ototoxicity reactions. Also be aware that polymyxin is readily deactivated by organic or purulent debris. Adequately clean the ear canal before using any product that contains polymyxins. Topical ear medications are typically used for two to four weeks, once or twice daily, depending on the ingredients. I recommend rechecking the patient and performing cytology before discontinuing a medication.

Newer products such as Claro[®] (florfenicol, terbinafine, mometasone furoate) Otic Solution from Bayer and Osurnia[®] (florfenicol, terbinafine, betamethasone acetate) from Elanco are available to treat otitis externa. Both contain florfenicol, terbinafine, and a glucocorticoid. Claro[®] contains a higher concentration of both florfenicol and terbinafine. Claro® also contains mometasone, which is considered a soft corticosteroid; while it has potent local activity, it is not readily absorbed and does not typically cause systemic effects. Both products are indicated for the treatment of otitis externa in dogs affected with susceptible strains of Staphylococcus pseudintermedius and Malassezia pachydermatis. Claro® is a liquid-based product

with a 30-day duration of effect, whereas Osurnia[®] is a gel-based product labeled for initial administration followed by repeat administration in seven days. These long-acting products are superior to lanolin-based compounded products because they do not form concretions, they are administered by the veterinarian, and they are FDA-approved. Both products are good choices for uncomplicated otitis externa, especially for owners who may have medication compliance challenges and for aggressive dogs that are difficult to medicate. They should not be used for gram-negative rod bacterial infections, especially *Pseudomonas* species, as florfenicol has a poor spectrum of activity against those bacteria.

Schedule recheck examinations after application of these long-acting products to ensure improvement in clinical signs or resolution of otitis. If clinical signs are improved but the infection is not completely resolved (as noted cytologically), administer additional doses as labeled until complete resolution occurs. If there is not improvement and cocci or *Malassezia* are identified on cytology, consider submitting a sample for bacterial culture.

Compounded "leave-in" otic preparations that are not FDA-approved are also available. These typically have a lanolin base and contain enrofloxacin, ketoconazole, and triamcinolone. I have seen complications such as medication concretions that accumulate in the middle ear, so I do not recommend routine use of compounded products, especially if you do not know whether the patient's tympanic membrane is intact.

The takeaways

When treating dogs with otitis externa, identify and treat all primary and secondary causes of the ear disease. The secondary causes should be treated based on results of cytologic examination. Claro[®] is indicated in cases in which cytology shows cocci or yeast, not when large rods are identified.

Also address perpetuating and predisposing

References

- I. Miller W, Griffin C, Campbell K. Muller and Kirk's Small Animal Dermatology, 7th Ed. St. Louis, MO: Elsevier, 2013.
- Kowalski JJ. The microbial environment of the ear canal in health and disease. Vet Clin North Am Small Anim Pract 1988;18:743-754.
 Cole LK, Kwochka KW, Kowalski JJ, et al. Microbial flora and antimicrobial susceptibility patterns of isolated pathogens from the horizontal ear
- Cole LN, KWOCHKA KVY, KOWASKI JJ, et al. Incrobina for a and antimicrobina susceptionity patterns of isolated pathogens from the forizontal ear canal and middle ear in dogs with ottis media. J Am Vet Med Assoc 1998;212:534-538.
 Schick AE, Angus JC, Coyner KS. Variability of laboratory identification and antibiotic susceptibility reporting of Pseudomonas spb. isolates from
- dogs with chronic otilis external. Vet Dermatol 2007;18:120-126. 5. Graham-Mize CA, Rosser EJ, Jr. Comparison of microbial isolates and susceptibility patterns from the external ear canal of dogs with otitis
- Graham-Mize CA, Rosser EJ, Jr. Comparison of microbial isolates and susceptibility patterns from the external ear canal of dogs with otitis externa. J Am Anim Hosp Assoc 2004;40:102-108.

Footnotes

CAUTION: Federal (U.S.A.) law restricts Claro® to use by or on the order of a licensed veterinarian. CONTRAINDICATIONS: Claro® should not be used in dogs known or suspected to be allergic to Claro or any of its ingredients.

Bayer, the Bayer Cross and Claro are registered trademarks of Bayer. Elanco and Osurnia are registered trademarks of Elanco.

Andrew Rosenberg, DVM, DACVD

After earning his DVM degree from Cornell University, Dr. Rosenberg completed a three-year dermatology residency and achieved diplomate status with the American

College of Veterinary Dermatology. He is the practice owner of Animal Dermatology & Allergy Specialists, with two locations in Riverdale, NJ, and Westchester County, NY. Dr. Rosenberg is an active member of the ACVD and currently serves as chairman of the Education Committee. He received the ACVD Research Award for his work in cyclosporine-associated gingival overgrowth. Dr. Rosenberg has written for multiple publications, has appeared on television shows, and lectures nationally and internationally. He has a strong interest in both allergies and autoimmune skin diseases. When not at the clinic, he donates his time to treat skin conditions of animals in zoos and wildlife centers.

factors (in dogs with altered self-cleaning mechanism, excessive debris, stenotic or narrowed canals, excessive moisture in ears from swimming) through frequent ear cleaning that's timed appropriately so as not to reduce efficacy of any primary topical treatment, administration of systemic corticosteroids (in dogs with edematous or proliferative canals), or removal of growths (in dogs with obstructive ear disease). In severe cases, you may need to refer the patient to a veterinary dermatologist for video otoscopy and deep ear flush or advanced otic surgeries.

When managing a case of otitis externa, use the PSPP system to help identify all potential primary and secondary causes, and perpetuating and predisposing factors. Only when all causes and factors are addressed will management of chronic otitis externa be rewarding for both you and your patients. Recheck all patients before discontinuing therapy. A treatment such as Claro[®] can help you avoid pitfalls of otitis externa therapy such as poor owner compliance and difficulty medicating ears.



(florfenicol, terbinafine, mometasone furoate) Otic Solution

Antibacterial, antifungal, and anti-inflammatory For Otic Use in Dogs Only

CAUTION: Federal (U.S.A.) law restricts this drug to use by or on the order of a licensed veterinarian.

DESCRIPTION:

CLARO[®] contains 16.6 mg/mL florfenicol, 14.8 mg/mL terbinafine (equivalent to 16.6 mg/mL terbinafine hydrochloride) and 2.2 mg/mL mometasone furoate. Inactive ingredients include purified water, propylene carbonate, propylene glycol, ethyl alcohol, and polyethylene glycol.

INDICATIONS:

CLARO[®] is indicated for the treatment of otitis externa in dogs associated with susceptible strains of yeast (*Malassezia pachydermatis*) and bacteria (*Staphylococcus pseudintermedius*).

DOSAGE AND ADMINISTRATION:

Shake before use.

CLARO® should be administered by veterinary personnel. Administer one dose (1 dropperette) per affected ear. The duration of effect should

- last 30 days.
 - 1. Clean and dry the external ear canal before administering the product.
 - 2. Verify the tympanic membrane is intact prior to administration.
 - 3. Remove single dose dropperette from the package.
 - 4. While holding the dropperette in an upright position, remove the cap from the dropperette.
 - 5. Turn the cap over and push the other end of the cap onto the tip of the dropperette.
 - 6. Twist the cap to break the seal and then remove cap from the dropperette.
 - 7. Screw the applicator nozzle onto the dropperette.



8. Insert the tapered tip of the dropperette into the affected external ear canal and squeeze to instill the entire contents (1 ml) into the affected ear.



- 9. Gently massage the base of the ear to allow distribution of the solution.
- 10. Repeat with other ear as prescribed.

Cleaning the ear after dosing may affect product effectiveness.

CONTRAINDICATIONS:

Do not use in dogs with known tympanic membrane perforation (see **PRECAUTIONS**). CLARO[®] is contraindicated in dogs with known or suspected hypersensitivity to florfenicol, terbinafine hydrochloride, or mometasone furoate.

WARNINGS:

<u>Human Warnings:</u> Not for use in humans. Keep this and all drugs out of reach of children. In case of accidental ingestion by humans, contact a physician immediately. In case of accidental skin contact, wash area thoroughly with water. Avoid contact with eyes. Humans with known hypersensitivity to florfenicol, terbinafine hydrochloride, or mometasone furoate should not handle this product.

PRECAUTIONS:

Do not administer orally.

The use of CLARO[®] in dogs with perforated tympanic membranes has not been evaluated. The integrity of the tympanic membrane should be confirmed before administering the product. Reevaluate the dog if hearing loss or signs of vestibular dysfunction are observed during treatment. Use of topical otic corticosteroids has been associated with adrenocortical suppression and iatrogenic hyperadrenocorticism in dogs (see **ANIMAL SAFETY**).

Use with caution in dogs with impaired hepatic function (see **ANIMAL SAFETY**). The safe use of CLARO[®] in dogs used for breeding purposes, during pregnancy, or in lactating bitches has not been evaluated.

ADVERSE REACTIONS:

In a field study conducted in the United States (see **EFFECTIVENESS**), there were no directly attributable adverse reactions in 146 dogs administered CLARO[®].

To report suspected adverse drug events and/or obtain a copy of the Safety Data Sheet (SDS) or for technical assistance, contact Bayer HealthCare at 1-800-422-9874. For additional information about adverse drug experience reporting for animal drugs, contact FDA at 1-888-FDA-VETS or online at http://www.fda.gov//Apimal//dtoringsv/Cofth.khoeth

http://www.fda.gov/AnimalVeterinary/SafetyHealth.

PHARMACOLOGY:

CLARO[®] Otic Solution is a fixed combination of three active substances: florfenicol (antibacterial), terbinafine (antifungal), and mometasone furoate (steroidal antiinflammatory). Florfenicol is a bacteriostatic antibiotic which acts by inhibiting protein synthesis. Terbinafine is an antifungal which selectively inhibits the early synthesis of ergosterol. Mometasone furoate is a glucocorticosteroid with anti-inflammatory activity.

MICROBIOLOGY:

The compatibility and additive effect of each of the components in CLARO[®] solution was demonstrated in a component effectiveness and non-interference study. An *in vitro* study of organisms collected from clinical cases of otitis externa in dogs enrolled in the clinical effectiveness study determined that florfenicol and terbinafine hydrochloride inhibit the growth of bacteria and yeast commonly associated with otitis externa in dogs. No consistent synergistic or antagonistic effect of the two antimicrobials was demonstrated. The addition of mometasone furoate to the combination did not impair antimicrobial activity to any clinically significant extent. In a field study (see **EFFECTIVENESS**), at least 10 isolates from successfully treated cases were obtained for *S. pseudintermedius* and *M. pachydermatis*.

EFFECTIVENESS:

In a well-controlled, double-masked field study, CLARO[®] was evaluated against a vehicle control in 221 dogs with otitis externa. One hundred and forty six dogs were treated with CLARO[®] and 75 dogs were treated with the vehicle control. All dogs were evaluated for safety. Treatment (1 mL) was administered once on Day 0 to the affected ear(s). Prior to treatment, the ear(s) was cleaned with saline. The dogs were evaluated on Days 0, 7, 14, and 30. Blood work and urinalysis were obtained on Day 0 pre-treatment and Day 30 at study completion. Four clinical signs associated with otitis externa were evaluated: erythema, exudate, swelling, and ulceration. Success was based on clinical improvement at Day 30. Of the 183 dogs included in the effectiveness evaluation, 72.5% of dogs administered CLARO[®] solution were successfully treated, compared to 11.1% of the dogs in the vehicle-control group (p=0.0001).

ANIMAL SAFETY:

In a target animal safety study, CLARO[®] was administered aurally to 12-week-old Beagle puppies (4 dogs/sex/group) at 0X, 1X, 3X, and 5X the recommended dose once every 2 weeks for a total dosing period of 28 days (3 times the treatment duration). No clinically relevant treatment-related findings were noted in hearing tests, body weight, weight gain, or food consumption. CLARO[®] administration was associated with post-treatment ear wetness or clear aural exudate, increased absolute neutrophil count, decreased absolute lymphocyte and eosinophil counts, suppression of the adrenal cortical response to ACTH-stimulation, decreased adrenal weight and atrophy of the adrenal cortex, increased liver weight with hepatocellular enlargement/cytoplasmic change, and decreased thymus weight. Other potentially treatment-related effects included mild changes to AST, total protein, inorganic phosphorus, creatinine, and calcium.

STORAGE INFORMATION:

Store between $20^{\circ}C - 25^{\circ}C$ ($68^{\circ}F - 77^{\circ}F$), excursions are permitted $15^{\circ}C - 30^{\circ}C$ ($59^{\circ}F - 86^{\circ}F$).

HOW SUPPLIED:

 ${\rm CLAR0}^{\otimes}$ solution is supplied in a single-use dropperette in a blister. Each dropperette contains one 1 mL dose.

CLARO® is available in cartons of two, ten, or twenty dropperettes.

Manufactured for

Bayer HealthCare LLC, Animal Health Division P.O. Box 390 Shawnee Mission, Kansas 66201 USA.

Bayer, the Bayer Cross and CLARO are registered trademarks of Bayer

© 2018 Bayer

NADA 141-440, Approved by FDA

LV1802



(florfenicol, terbinafine, mometasone furoate) Otic Solution

READY. AIM. CLARO.

Fight canine otitis externa with one big dose of love. Claro[®] (florfenicol, terbinafine, mometasone furoate) Otic Solution is the only FDA-approved, single-dose treatment administered by you with guaranteed compliance and no at-home treatments.

SPREAD THE LOVE IN YOUR CLINIC. USE CLARO° FOR YOUR MOST COMMON OTITIS CASES.

Claro[®] is indicated for the treatment of otitis externa in dogs associated with susceptible strains of yeast (*Malassezia pachydermatis*) and bacteria (*Staphylococcus pseudintermedius*).

CAUTION: Federal (U.S.A.) law restricts this drug to use by or on the order of a licensed veterinarian. CONTRAINDICATIONS: Do not use in dogs with known tympanic membrane perforation. CLARO[®] is contraindicated in dogs with known or suspected hypersensitivity to florfenicol, terbinafine hydrochloride, or mometasone furoate.

©2019 Bayer, Shawnee Mission, Kansas 66201 Bayer, the Bayer Cross and Claro are registered trademarks of Bayer. CL191103

BayerDVM.com/Claro

dvm

MEDICINE | Infectious disease

medicine)()

Fun with feline flu: Can **cats** get **influenza?**

The short answer is 'yes,' and the long answer is 'sort of' and 'it depends.' What does that mean for you? *By Jenifer Chatfield, DVM, DACZM*

hile influenza has been around since the 1500s,¹ the virus caught the public's attention in a new way recently when the pandemic of 2009 emerged (H1N1, anyone?). Prior to "swine '09," bird flu was the big fear, giving us all a legitimate reason to look askance at seagulls and grackles, but interest seemed to fizzle after several years.

Avian influenza is certainly still a

threat, as we saw with the 2014-2015 highly pathogenic avian influenza (HPAI) outbreak that spread from the Pacific Northwest all the way to Iowa—still the largest foreign animal disease outbreak in the history of the United States. Moreover, a handful of people still die every year of avian influenza infections in Asia.²

And up until 2004, a coughing dog only meant an annoying bout with

kennel cough was likely. These days that cough could be a sign of anything from Bordetella to influenza to the catchall canine infectious respiratory disease complex.

Cats and influenza

But what about cats? Can they get influenza? The short answer is "yes."^{3,4} The long answer is "sort of" and "it depends."



FEATURE M4 Pinch and flush: Relieving urethral

Pinch and flush: Relieving urethral obstructions in male dogs

EXPERT Q&A M6

Is ace not so ace for examining patients with fear aggression?

M8

What do we really know about feline chronic kidney disease?

dvm360.com/medicine

Find interactive cases, expert answers to your questions, clinical research summaries and more. While there isn't a specific "feline influenza" adapted for maintenance in feline populations, influenza in cats has been documented.^{3,4} For example, some domestic cats and their more glamorous cousins (i.e. cheetahs) were confirmed infected with the H1N1 strain in 2009.⁵

The cheetahs were thought to have been infected by an animal park staff member who had flulike symptoms for a couple of days before going home sick. This person had come into contact with the cheetahs' food and environment but had not had direct contact with the cats themselves. Soon after, the cheetahs began exhibiting mild respiratory signs, including nasal and ocular discharge and lethargy your basic influenza-like signs.

The infected domestic cats had also come into contact with infected humans and displayed similar nonspecific

Not only were the cats able to transmit the flu to the humans, cat-to-cat transmission was also confirmed. This was a whole new ballgame.

respiratory signs. While all four of the infected big cats survived, a handful of the domestic cats died. It does bear mentioning here that ferrets were also confirmed to be infected by the 2009 H1N1 strain during the outbreak.⁶ Ferrets are feline-adjacent, aren't they?

Influenza in domestic animal species was monitored much more closely after the 2009 H1N1 pandemic. As canine influenza continued to spread across the United States, many pet owners began opting for vaccination to prevent illness in their dogs. And yet, despite being experimentally infected with the canine H3N8,⁷ cats were still not really addressed in either public messaging or by veterinarians at large.

Then a second novel canine influenza strain that had been circulating in Asia was identified in the United States: canine H3N2. The strain is more virulent in dogs and more easily transmitted among them than the original canine influenza, H3N8. Vaccines were quickly developed and implemented in areas experiencing outbreaks. But again, cats weren't really a part of the conversation.

A whole new ballgame

Once cat-to-cat transmission of H3N2 was confirmed, however (albeit in a shelter environment), people started to wonder about cats and influenza more vocally.⁸ Then, a veterinarian working in a shelter (again, read: unnatural population density) in the Northeast was infected with an avian influenza virus, H7N2, and it turned out the cats in the shelter were the source. Not only were the cats able to transmit the flu to the humans, cat-to-cat transmission was also confirmed. This was a whole new ballgame.

While the "H" and the "N" may vary, the fundamental concept that cats are susceptible to influenza and that transmission between cats and other animals (including people) is possible remains constant. There is one vaccine currently labeled for use in cats to prevent them from becoming infected with canine H3N2.9 Another vaccine has recently been shown to be efficacious against H3N2 in cats, though it's not labeled for use in the species. As the development of cross-protective immunity among similar strains of influenza is possible,¹⁰ the vaccine may be able to mitigate illness derived from other influenza strains.

It's important to note that vaccination recommendations should be made using a risk-based assessment rather than relying on blanket statements (e.g. "All cats should be vaccinated"). Understanding the mechanisms of transmission of infectious diseases combined with a patient's and owner's lifestyle are key to an accurate recommendation.

Is it time to fret about feline flu?

Do veterinarians need to practice saying "feline flu" five times fast without spitting? In my opinion, not yet. As far as we know, felids don't yet have an influenza that is endemic or maintained among cats. However, given how adaptable influenza is and how mobile humans continue to be, it seems inevitable that a feline influenza strain will appear in the future. That said, if I could predict the future, I would currently be in Las Vegas diversifying my income.

Bottom line, I implore all practitioners to talk to their clients about the real threat of influenza to people and their animals and to make appropriate risk assessments based on what we know—namely, that influenza is easily transmitted, that it sheds prior to the onset of clinical signs and that it can be prevented or the course of disease mitigated through vaccination.

References

 Potter CW. A history of influenza. J Appl Microbiol 2001;91(4):572-579.
 World Health Organization. Cumulative number of confirmed human cases for avian influenza, A(H5N1) reported to WHO, 2003-

2018. Available at: www.who.int/influenza/human_animal_interface/2018_12_13_tableH5N1. pdf?ua=1. 3. Hatta M, Zhong G, Gao Y, et al. Charac-

3. Hatta M, Zhong G, Gao Y, et al. Characterization of a feline influenza A(H7N2) virus. *Emerg Infect Dis* 2018;24(1):75-86.

4. Fiorentini L, Taddei R, Moreno A, et al. Influenza A pandemic (H1N1) 2009 virus outbreak in a cat colony in Italy. *Zoonoses Public Health* 2011;58:573-581.

5. Crossley B, Hietala S, Hunt T, et al. Pandemic (H1N1) 2009 in captive cheetah. *Emerg Infect Dis* 2012;18(2):315-317.

6. Lin HT, Wang CH, Wu WL, et al. Natural A(H1N1)pdm09 influenza virus infection case in a pet ferret in Taiwan. *Jpn J Vet Res* 2014;62(4):181-185.

7. Su S, Wang L, Fu X, et al. Equine influenza A(H3N8) virus infection in cats. *Emerg Infect Dis* 2014;20(12):2096-2099.

8. University of Wisconsin-Madison School of Veterinary Medicine. UW Shelter Medicine, WVDL find canine influenza transmitted to cats in Midwestern shelter. Available at: www uwsheltermedicine.com/news/2016/3/uw shelter-medicine-wvdl-find-canine-influenzatransmitted-to-cats-in-midwestern-shelter. 9. Product label, Nobivac Canine Flu H3N2, Merck Animal Health. Available at www. merck-animal-health-usa.com/product/canine/Nobivac-Canine-Flu-H3N2/1. 10. Fang Y, Banner D, Kelvin AA, et al. Seasonal H1N1 influenza virus infection induces crossprotective pandemic H1N1 virus immunity through a CD8-independent. B cell-dependent mechanism. J Virol 2012;86(4):2229-2238.

Dr. Jenifer Chatfield is staff veterinarian at 4J Conservation Center in Pasco, Florida, as well as an instructor for federal disaster management courses and a regional commander for the National Disaster Medicine System Team. She has also chaired the Florida Veterinary Medical Association's One Health Committee and co-chaired its Disaster Response Committee.



Cats, cats, cats If youv'e got a feline itch to scratch, we have an entire section of the site dedicated to feline medicine at dvm360. com/felinecenter.



Alpha-Stim is the drug-free, clinically proven treatment to relieve anxiety, stress, and fear.

Don't let fearful or aggressive behavior from stressed pets or horses get in the way of a successful visit to your hospital. Alpha-Stim is an FDA cleared, easy to use, handheld prescription medical device that improves mood conditions, often in less than 20 minutes, without side effects or use of medication.

Proven by more than 100 studies over the past 38 years, Alpha-Stim is a fast, safe and effective treatment to help you, your staff, and your patients have the best in-clinic experience possible!

LATEST RESEARCH: The University of Texas MD Anderson Cancer Center, "Cranial Electrotherapy Stimulation for the Management of Depression, Anxiety, Sleep Disturbance, and Pain in Patients with Advanced Cancer"



REFERENCE

Yennurajalingam S, Kang D-H, Hwu W-J, Padhye NS, Masino C, Dibaj SS, Liu DD, Williams JL, Lu Z, Bruera E. Cranial electrotherapy stimulation for the management of depression, anxiety, sleep disturbance, and pain in patients with advanced cancer: a preliminary study. Journal of Pain and Symptom Management. 2018 Feb; 55(2): 198-204.

HELP FOR YOUR PATIENTS IS HERE.

To get started and to see more clinical data, visit www.alphastimforanimals.com or call 855-900-3585.

Alpha-Stim and the Alpha-Stim logo are registered trademarks, and LET NOTHING STOP THEM is a trademark of Electromedical Products International, Inc. @ 2019 Electromedical Products International, Inc. All rights reserved. Read a full disclosure of the minor and self-limiting risks here: alpha-stim.com/risk



ALPHA-STIN





Pinch and flush: Relieving urethral obstructions in male dogs

By pinching the penis and flushing the urethra—plus a few more steps—you can relieve painful obstructions and avoid complicated surgical procedures. *By Andrew Jackson, DVM, DACVS,*

rethral obstructions in male dogs are common in veterinary practice. These obstructions can be difficult to relieve, and many patients are referred to emergency/specialty hospitals still obstructed. It doesn't have to be this way! With a few precise but straightforward steps, general practitioners can relieve most urethral obstructions with minimal fuss to the patient.

Background and diagnostic steps

Canine urethral obstruction is almost always due to urolithiasis. In most cases, the objective of treatment is to relieve the obstruction via retropulsion and extract the urolith via cystotomy. Urethrotomy can result in urine leakage into soft tissues, stricture, persistent hemorrhage and infection, both perioperatively and long-term, and should therefore be avoided. Scrotal urethrostomy, while more invasive than most patients need, may be appropriate in certain breeds (such as Dalmatians) or in dogs with multiple obstructions. It may also be a better long-term solution in cases of multiple urethral blockages.

Still, almost all urethral obstructions can be relieved and converted to a cystotomy procedure if appropriate treatment is provided. When a dog presents with urethral obstruction, the veterinary team should immediately be aware that this is a painful condition. It's important to consider pain relief medications right away and understand that general anesthesia will be completed to relieve the obstruction. Also, every urethral obstruction should be treated as an emergency because it can lead to urinary bladder rupture.

First, conduct a thorough physical examination, obtain a complete blood count with serum chemistry profile and urinalysis with culture, and take a set of radiographs. When you perform lateral abdominal radiography, be sure to capture the entire rear end of the dog so you can evaluate the entire

Surgery STAT | MEDICINE

urethra. In addition, take lateral radiographs with normal limb positioning and also with rear limbs pulled forward to help visualize the perineal urethra.

Also note that these dogs can be azotemic and will need appropriate therapy. In addition, hypercalcemia may be present, which will typically require further diagnostic tests, such as a parathyroid panel.

The pinch-and-flush procedure

General anesthesia with intubation, although it might not seem necessary, is always recommended because it eases passage of the obstruction and relieves discomfort. When the dog is asleep and relaxed and the airway is protected, you should be able to relieve the obstruction more easily. Give a premedication of a narcotic and sedative (e.g. hydromorphone and acepromazine) before inducing anesthesia.

Now the dog is ready for retropulsion of urethral stones. Remember that the premise of this procedure is to flush the stones into the bladder, not to push the stones into the bladder with the catheter. I recommend that three people be involved when available: one person is on the catheter, one person is flushing and one person is rectally occluding the urethra. See Figure 1 (page M4) for a review of canine anatomy relevant to this procedure.

Here are the procedure steps:

1. Select an appropriately sized red rubber catheter and a 60- or 30-ml catheter-tip syringe depending on the size of the dog. Prefill the syringes with sterile saline or a 50-50 mix of saline and sterile lubricant mixed vigorously.

2. Place the catheter at the level of the obstruction or just distal to it, adhering strictly to sterile technique.

3. Have a gloved assistant place a finger rectally and compress the urethra onto the floor of the pelvis (Figures 2A-2C).

4. Attach the saline-filled syringe to the red rubber catheter. Lube can be added to the saline for additional viscosity if needed.

5. Pinch the tip of the penis to make sure the urethra is distending while flushing 5 to 10 ml saline into the distal urethra via the catheter.

6. With the urethra distended with saline, double-check that the assistant is detecting pressure rectally while still compressing the urethra. The urethra



Figure 2A: With a red rubber catheter placed in the urethra, a gloved assistant places a gloved finger in the dog's rectum.



Figure 2B: The assistant presses his or her finger downward (ventrally) to occlude the urethra.



Figure 2C: From the rectum, the assistant compresses the urethra onto the floor of the pelvis. Another team member pinches the distal urethra at the tip of the penis to help distend the urethra while 5 to 10 ml saline is flushed into the catheter.



Figure 3: At the exact same moment, the assistant releases the compression and the doctor flushes saline upward into the urethra. The retropulsion pushes the obstruction back into the bladder, where it can be relieved with cystotomy.

will be taut and distended distally to the rectal compression.

7. As a timed procedure—for example, on the count of three—release the rectal urethral compression and flush the saline with pressure at the exact same moment (Figure 3). Most obstructions will be relieved with one or two attempts.

8. Confirm retropulsion of the stones with radiographs.

If the blockage doesn't budge

If this procedure doesn't work and you can't pass a catheter, check the urinary bladder. If the bladder is distended, relieve the pressure by manual expression or cystocentesis. Then create a 50-50 mix of saline and sterile lubricant mixed vigorously to increase the viscosity of the flush. The increased viscosity of this solution helps to increase the resistance and help with retropulsion.

If the obstruction is still not relieved, the next option to try is epidural anesthesia. Typically, placing a preservative-free morphine epidural is enough to help in this situation; bupivacaine can potentially be added for increased muscle relaxation. Repeat retropulsion as needed to relieve the obstruction.

This procedure should relieve almost all obstructions. If the obstruction is not addressed with retropulsion, you may need to perform a urethrotomy or urethrostomy. If the dog needs to be referred, perform a temporary cystocentesis first.

Conclusion

In surgery, avoiding complications is highly desirable. Cystotomy is associated with far fewer complications than urethrotomy or urethrostomy. Retropulsion of urethral calculi causing urethral obstruction accomplishes this goal and is a highly successful procedure when completed correctly. Relieving the obstruction with minimal inflammation and irritation means fewer attempts at catheterization. If you follow these steps to "pinch and flush," you should successfully relieve the obstruction with only a few attempts.

Dr. Andrew Jackson graduated from the University of Prince Edward Island's Atlantic Veterinary College, then completed an internship in Sacramento and surgical residency in Detroit. Dr. Jackson has been practicing at BluePearl Veterinary Partners in Minnesota for the last nine years. He has extensive experience in emergency, soft tissue and orthopedic surgery. He loves living in Minnesota even in the winter.

Surgery STAT is a collaborative column between the American College of Veterinary Surgeons (ACVS) and dvm360 magazine. To locate a diplomate, visit ACVS's online directory,

which includes practice setting, species emphasis and research interests, at acvs.org.







While acepromazine may make patients more tractable in the clinic, it's likely doing nothing to reduce their anxiety. *By Julia Albright, MA, DVM, DACVB*

Question: Why shouldn't acepromazine be a go-to sedative to help manage fear aggression in dogs during physical examinations? Which medications are good alternatives to consider?

Answer: Psychopharmacology can be a confusing and overwhelming subject in veterinary medicine, in large part due to the wide individual variation in observable effects and the overlap in clinical applications. Another factor is the current paradigm shift from drugs that simply produce behavioral suppression and decreased motor activity to those that have antianxiety properties as well.

Acepromazine is an antipsychotic, a class of drugs originally used to treat psychoses such as schizophrenia in humans by blocking the action of dopamine, a catecholamine neurotransmitter. More specifically, acepromazine is a low-potency phenothiazine neuroleptic drug and, like most of the older antipsychotics used in veterinary medicine (including haloperidol and fluphenazine as well as acepromazine), it blocks all the dopamine pathways responsible for cognition, motivation and motor coordination. Acepromazine affects other physiologic systems as well and can cause cardiovascular, motor and endocrine side effects. Though acepromazine is generally safe and can ease handling by blunting behavioral responses, it has fallen out of favor, especially as an oral monotherapy, due to numerous reports of sedation without acceptable reduction in signs of fear or anxiety.

So, to answer the specific question about the use of acepromazine to manage fearrelated aggression, acepromazine may make the animal more tractable for handling, but it's unlikely to be addressing the underlying fear. Other medications such as benzodiazepines, gabapentin, the atypical antidepressant trazodone, and norepinephrine release blockers like dexmedetomidine are more likely to create emotional calmness (again, primarily based on body language assessment) with or without sedation.

My clients and consulting general practitioners are looking for the silver bullet to help make visits go more smoothly. Unfortunately, fast-acting situational oral drugs can have variable effects due to several factors. Most of these drugs have reduced bioavailability compared to other administration routes due to the hepatic first pass effect. In addition, many of our patients are experiencing an extreme level of distress during the average clinic visit, and single administration of most of these medications is simply not effective in the face of such acute physiologic arousal. In my practice, once we've identified a fearful patient, I have the clients conduct a trial of two to three medications at home—usually some combination of those discussed above. We monitor for gastrointestinal or agitation side effects and adjust doses until we reach the desired clinic effect with few to no side effects. Acepromazine may be one of the medications we use in the cocktail, but that is rare these days.

For most of my aggressive patients, the goal of client-administered pre-visit medications is to produce enough sedation and relaxation to allow the team to administer a low-stress intramuscular injection of additional medications for a more thorough physical exam or other procedures. However, occasionally we feel the patient is comfortable enough to continue our visit with just the oral medications.

Either way, when the patient is calm in the veterinary clinic—and not just still—the team can do what it needs to do to optimize physical health without harming emotional wellbeing. And everyone feels better about that.

Dr. Julia Albright is assistant professor of veterinary behavior and PetSafe Chair of Small Animal Behavioral Research at the University of Tennessee's College of Veterinary Medicine.



A pet insurance plan that does its job so you can do yours

Nationwide's Whole Pet with Wellness® plan is the only pet insurance plan that pays back up to 90% on virtually everything^{*}—including preventive care.

If it doesn't cover preventive care, it doesn't cover the whole pet.

To learn more or to order materials for your practice, contact us today. 866-838-4874 • vets.petinsurance.com



*Some exclusions may apply. Certain coverages may be subject to pre-existing exclusion. See policy documents for a complete list of exclusions. Plans may not be available in all states. Insurance terms, definitions and explanations are intended for informational purposes only and do not in any way replace or modify the definitions and information contained in individual insurance contracts, policies or declaration pages, which are controlling. Such a and availability may vary by state and exclusions may apply. Underwritten by Veterinary Pet Insurance Company (CA), Columbus, OH, an AM Best A+ rated company (2018), National Casualty Company (all other states), Columbus, OH, an AM Best A+ rated company (2018). Agency of Record: DVM Insurance Agency. Nationwide, the Nationwide N and Eagle, and Nationwide is on your side are service marks of Nationwide Mutual Insurance Company. ©2019 Nationwide. 19VET5903

Do we *really* know what we **think we know** about feline CKD?

One study lays out all the elements of this common condition in cats. By Hilal Dogan, BVSc, CCTP

hronic kidney disease (CKD) is the most common metabolic disease of domesticated cats presented to veterinarians for evaluation. A recent journal article evaluates our current knowledge of feline CKD, discussing pathogenesis, initiation factors and progression factors.¹ The study involved a retrospective evaluation of scientific data available from both human and veterinary medicine.

How common is CKD?

Two consistent trends on the prevalence of CKD in cats have been identified: (1) The prevalence of CKD increases with advancing age from 5 to 6 years onward, and (2) overall prevalence of CKD in cats increased from 0.04% in the 1980s to 0.2% in the 1990s to 1% in the 2000s. It's unknown whether this increase reflects greater awareness and enhanced diagnostic acumen, an increase in median age in cat populations or a true increase in prevalence.

Pathologic findings

Most geriatric cats with CKD don't have histologic evidence of primary glomerular disease. Instead they have tubulointerstitial lesions with only mild secondary lesions within glomeruli.

Grossly, kidneys are decreased in size with surface pitting. Histologically, renal lesions are multifocal to segmental and include interstitial mononuclear cell inflammation, tubular degeneration and atrophy, interstitial fibrosis, mineralization of Bowman's capsule and tubular basement membranes, interstitial lipid, and glomerulosclerosis. The inflammatory infiltrate typically consists of lymphocytes, which may be mixed with plasma cells and macrophages; they are typically present in the interstitium surrounding atrophic tubules.

Pathogenesis

Chronic primary renal diseases found to cause CKD in cats include:

- > Amyloidosis
- > Juvenile renal dysplasia or glomerular disease

- > Lymphoma
- > Chronic feeding of unbalanced diets
- > Polycystic kidney disease
- Bacterial pyelonephritis
- > Nephro- and ureterolithiasis
- > Chronic infection of feline immunodeficiency virus, feline leukemia virus or feline infectious peritonitis
- > Immune complex glomerulonephritis
- > Acute kidney injury (AKI).

With the exception of AKI, most of these known primary renal diseases affect only specific breeds or produce histological changes inconsistent with the pathological changes of CKD. Thus, most cats with CKD lack an apparent inciting cause. It seems more likely that a combination of intrinsic (animal) factors, environmental factors and repeated intermittent AKI act in concert as initiating or causative factors.

Initiating factors

Factors associated with the onset of CKD include:

- > Aging. An abundance of evidence supports a link, perhaps causal, between aging and feline CKD. Aging itself does not initiate CKD, but it's plausible that age-associated changes enhance susceptibility to CKD development. These may include diseases that are more common in older cats, such as hyperthyroidism, dental disease, systemic hypertension and inflammatory bowel disease (IBD).
- > Hyperthyroidism. Convincing evidence is lacking, as most cats with CKD do not have overt hyperthyroidism. Consequences of hyperperfusion and direct effects of thyroid hormone on feline tubular cells are also not well understood.
- > Periodontal disease. This is a complex, possibly bidirectional relationship, but there is more evidence in people and dogs than in cats.
- > Systemic hypertension. While this condition is common in cats with CKD, it's not clear if it precedes or is coincident with CKD initiation.
- > IBD. This is an interesting but unsubstantiated hypothesis. People with

IBD may exhibit tubular dysfunction. Other initiating factors include

ischemia and other AKI. There is evidence that AKI, specifically ischemic, initiates changes that mimic CKD in cats, consistent with the suggestion that maladaptive repair mechanisms following an AKI can lead to CKD.

Husbandry factors discussed in conjunction with CKD include:

- > Ad lib feeding or high-protein diets there's a lack of supportive evidence.
- > Food additives such as ethoxyquin or genetically modified plants also lack real evidence.
- > Glyphosate, an herbicide, has some evidence of toxic renal effects, but the authors are unaware of studies in cats.
- > Routine vaccinations have been hypothesized to be an initiating factor,
- but further studies are needed. > Chronic stress due to confinement, cofeeding, litterbox sharing and living with other animals might lead to chronic overactivation of the hypothalamic-pituitary-adrenal (HPA) axis.
- > Renal hypoxia could be an initiation factor—potential causes are stress, aging, ischemia as a result of tubular hypermetabolism, anemia, transient systemic hypotension, systemic overactivity or activation of the reninangiotensin-aldosterone system (RAAS), and subclinical exposure to compounds with effects on renal vasculature (NSAIDs or melamine).

Progression factors

It's assumed that CKD is an inherently progressive disease, but this is difficult to demonstrate in lab models. Several factors have been associated with progression of feline CKD:

- > Phosphorus intake
- > Proteinuria
- > Anemia
- > Systemic hypertension
- > Intraglomerular hypertension
- > Activation of the RAAS
- > Sodium intake
- > Tubular hypoxia
- > Interstitial fibrosis.

Take-home points

This was an interesting review of an incredibly common disease with many moving parts. It's important to be reminded that cats are different from dogs and people and that the disease affects tubules in cats versus glomerulus in dogs and humans. Also, it's important to remember that CKD is not just one or two insults to the kidney; it's a combination of factors that form a cascade—almost like a domino effect.

Reference

1. Brown CA, Elliott J, Schmiedt CW, et al. Chronic kidney disease in aged cats: Clinical features, morphology, and proposed pathogeneses, Vet Pathol 2016 Mar:53(2):309-26.

Dr. Hilal Dogan practices in Denver, Colorado. She is the founder of the Veterinary Confessionals Project.



Business | NEWS

Banfield develops **telehealth** service

Jane Lynch has signed on to speak for the new on-demand

platform. By Brendan Howard

B anfield has introduced a telehealth service, Vet Chat, to the smartphone app designed for pet owners on their wellness plans. What's more, actress Jane Lynch has signed on to help warn people about the dangers of seeking advice about their pets' health from the internet.

"Vet Chat gives Banfield Optimum Wellness Plan clients on-demand access to a veterinarian, through the Banfield app, for immediate guidance," reads the new service's FAQ.

The website goes on to explain exactly what the veterinarians on the service can and will do (it's less than what other telemedicine apps operating under established veterinarianclient-patient relationships do): "Vet Chat doctors do not have access to pet medical records and do not treat, diagnose, prognose or prescribe/refill. They limit their interactions to general advice and recommending one of these next steps: refer to Banfield for an inperson visit, watch and wait, general information and refer to emergency."

That makes Vet Chat similar to other telemedicine triage services available to private practitioners, like Guardian-Vets, but unlike Anipanion, Petzam, TeleTails and TeleVet, which let practices directly manage cases virtually.

Jane Lynch, a dog-owning celebrity who supports pet causes, is helping Banfield raise awareness of the dangers of turning to the internet with pet health issues instead of seeking counsel from a veterinarian.

"As the proud owner of three rescue pups, I am all too familiar with the sounds of a dog vomiting at 3 in the morning—and the comfort and peace of mind that comes with having a veterinary team I can count on," says Lynch in a Banfield press release.

Banfield's app is not a way not to circumvent veterinary visits, the company says, but a method to counter bad pet health advice online and help folks figure out if they need to come in.

dvm360 | July 2019 | 35

CYTOPOINT is now approved for the treatment of allergic dermatitis!



For dogs with allergic or atopic dermatitis,

CYTOPOINT[®] offers 4 to 8 weeks of relief with a single in-office injection, helping to improve the quality of life for dogs and their families¹



TARGETED

Monoclonal antibody (mAb) that targets and neutralizes interleukin (IL)-31, a key itch-inducing cytokine²



WORKS FAST AND LASTS

Begins working within 1 day and delivers 4 to 8 weeks of relief*; in-office administration ensures compliance¹



Safe for dogs of all ages, even those with concomitant diseases, and can be used with many common medications^{3,4}

To learn more, please visit www.CYTOPOINT.com

ZOETIS PETCARE

Indications: CYTOPOINT has been shown to be effective for the treatment of dogs against allergic dermatitis and atopic dermatitis.

*Repeat administration every 4 to 8 weeks as needed in individual patients.

References: 1. Data on file, Study Report No. C863R-US-12-018, Zoetis Inc. 2. Gonzales AJ, Humphrey WR, Messamore JE, et al. Interleukin-31: its role in canine pruritus and naturally occurring canine atopic dermatitis. *Vet Dermatol.* 2013;24(1):48-53. doi:10.1111/j.1365-3164.2012.01098.x. 3. Data on file, Study Report No. C362N-US-13-042, Zoetis Inc. 4. Data on file, Study Report No. C961R-US-13-051, Zoetis Inc.

All trademarks are the property of Zoetis Services LLC or a related company or a licensor unless otherwise noted.

© 2019 Zoetis Services LLC. All rights reserved. CYT-00097R4



Comparison chart: Pet identification microchips

A few of the big pet microchip companies provided dvm360 with details about their current products. Curious if there's any reason to switch your choice? Check 'em out! *By Brendan Howard*

ome veterinary practices implant very few microchips and leave it all to rescue groups and animal shelters. Other hospitals use the, as a part of their packages for new adoptions, puppies and kittens. Whichever way your hospital swings, here are a few details on players in the market to compare ...

Veterinary microchips for pets

AKC Reunite		
Website	akcreunite.com	
	Varies according to number of chips or whether they're bundled with a scanner	
	Free registration and updates; other chips: \$17.50	
Designated code	956	
	24/7/365 call center; calls, emails, texts and/or snail mail to contact lost pet owners; broadcasts lost pet info to Reuniters Network	
BuddydD	Minichin	

BuddyID Minichip

	buddyid.com
	Free with registration
	One-time \$24.95
Designated code	933
	Lifetime warranty; nationwide search alerts; mobile app; text alerts; direct-to-owner lost pet recovery



HomeAgain

Website	Merck Animal Health	
	Free with registration	
	\$19.99 lifetime registration (includes lifetime profile updates)	
Designated code	985	
	Enhanced pet recovery; emergency medical hotline	
PetLink		
	petlink.com	
	\$15.50	
	Free registration for chips sold to veternarians	
Designated code	981	
	24/7/365 U.Sbased call center; lost-pet posters for print; library of resources; lunch-and-learn training for veterinary clients available.	
SmartTag		

	IDtag.com
	Data \$8.50, Mini Data \$9
	Free
Designated code	987
	24/7/365 call center; lost pet broadcast alerts; metal ID tag; smaller-gauge Mini Data chips; temperature-reading chips

rce: Companies self-reported



The chew dogs love. THE SCIENCE YOU CAN TRUST.



Fight plaque, calculus and halitosis with ORAVET[®] Dental Hygiene Chews - *the only chew with the power of delmopinol!*

- Unique dual-action mechanism
- Highly palatable¹
- Designed to provide an extended chew duration¹
- Proven technology ^{1, 2, 3}

UNIQUE DUAL-ACTION MECHANISM

Delmopinol creates a protective barrier against the bacteria that cause bad breath and are the basis for plaque

2. The scrubbing action of the chew works in parallel with the delmopinol to effectively remove plaque and calculus



¹ Data on file. ² Data on file. ³ Data on file.



ORAVET® and SERIOUS ORAL CARE MADE SIMPLE® are registered trademarks of Boehringer Ingelheim Animal Health USA Inc. All other marks are property of their respective owners. ©2019 Boehringer Ingelheim Animal Health USA Inc., Duluth, GA. All rights reserved. PET-1147-0VT0219.

NEWS | Equine medicine







When to REACT: **Colic** in **horses**

Check out this British-developed acronym you can use to educate your equine clients on signs of colic in a horse. It could just lead to a betterinformed, faster-responding and quicker-calling clientele. *By Ericka Cherry, Jennifer Vossman, RVT, CMP*

COURTESY OF BRITISH HORSE SOCIETY

Equine medicine | NEWS

ot all horses with colic present telltale signs of the disease (pawing the ground, kicking at the belly and rolling) but more subtle signs that can often be attributed to another issue. Colic can be more complicated than veterinary clients think, according to Sarah Freeman, BVetMed, PhD, DECVS, FHEA, FRCVS, who presented a session to veterinarians on better colic education for horse owners at the West Indies Veterinary Conference hosted by Ross University School of Veterinary Medicine last year. Dr. Freeman worked in collaboration with the British Horse Society and a group she leads—the Nottingham Equine Colic Project.

This evidence-based equine health initiative helps horse owners recognize colic in their horses earlier, so they can contact their veterinarians sooner. According to the British Horse Society's website, one in 10 colic cases may be critical and up to 80% of these critical cases can result in death or euthanasia.

REACT is an acronym-centered marketing effort to reduce the instance of critical cases by highlighting the early signs of the disease. Videos, handouts and educational material shares jargon-free language on colic signs like this:

Restless or agitated

- > Attempts to lie down
- > Repeatedly rolling
- > Unexplained sweating
- > Box-walking or circling

Eating less or droppings reduced

- > Eating less or nothing
- > Passing less or no droppings
- > Changes in the consistency of droppings

Abdominal pain

- > Flank watching
- > Pawing
- > Kicking at belly

Clinical changes

- > Increased heart rate
- > Reduced or absent gut sounds
- > Changes in the color of gums
- > Rapid breathing rate
- > Skin abrasions over eyes

Tired or lethargic

- > Lying down more
- > Lowered head position> Dull and depressed

1

Get more on colic and other conditions

Dig deeper into the British Horse Society's website on the topic, and you'll find resources including:

- "REACT Now to Beat Colic," a free video for horse owners
- "REACT to Colic," a longer version of the video
- More than a dozen PDF handouts related to colic, including "Recognizing the signs of colic,"
 "Emergency decision making" and

"Waiting for the vet to arrive." See a sample on the opposing page of one of the handouts.

With these resources literally at horse owners' fingertips, the chances of them catching colic sooner and quickly contacting veterinarians for solutions is better than ever. Find them all at **dvm360.com/react**.

Vmed Wireless Monitors with Remote Connect



Now Monitor your patients remotely on any WiFi enabled device

- Monitor on your mobile device and clinic computer at the same time
- Record and store vital signs automatically
- Store files on your computer or server
- Attach patient files to your practice management program
 * Requires Windows software installation

VetGard+[™] and VetChek[™] wireless monitors



Monitor surgeries on your computer and mobile device with the **VetGard+** multiparameter monitor.

Use the **VetChek** for routine ECGs, resurgical screens or postsurgical monitoring on your computer and mobile device.

Both products include free ECG electronic interpretation software.

Vmed blood pressure solutions

The **BP-AccuGard** automatic BP monitor with SunTech animal validated software minimizes motion artifact. Optional wireless link to your computer for display and automatic file storage.

For those really difficult patients the **VetDop2** with low noise and high sensitivity is the Doppler of choice for veterinarians.



vmed technology

www.vmedtechnology.com, johnb@vmedtech.com 800 926-9622

The dental dozen: **12 products** that improve oral health

Here are some of my favorite products that are making it easier for clients and veterinary practices to improve the oral health and well-being of cats and dogs. *By Jan Bellows, DVM, DAVDC, DABVP, FAVD*

ore and more veterinary clients are realizing the importance of pet dental health, and the industry is responding with products that offer more effective home care and enable veterinarians to perform dental procedures more accurately and efficiently. From dental chews to surgical instruments to anesthesia monitors, here are some of the latest and greatest dental products to have hit the market.

1. Digital sensor



New from Dentalaire is a sensor boot for the Dentalaire intraoral digital sensor. This boot helps place the sensor in the mouth more easily and provides added protection against bite trauma.

2. Mouth prop



Also from Dentalaire is an autoclavable mouth prop, available in small, medium and large sizes.

3. Dental chew



Working with a boarded veterinary nutritionist and a boarded dentist, Pets Best Life has introduced a new dental chew. Yummy Combs has a patented six-sided honeycomb shape to get between close teeth and aid oral hygiene.

4. Dental chew



New from Virbac, C.E.T. Veggiedent Fr3sh Tartar Control Chews for Dogs have earned the Veterinary Oral Health Council Seal of Acceptance. These vegetable-based chews offer the added benefit of decreasing oral malodor. They contain no animal proteins and are available in four sizes.



Grow Your Pet Segment with ECRM Programs

Discover the latest brands and products Gain insight into navigating the industry Connect with industry leaders

ECRM programs are the driving force for Pet buyers and suppliers. Participate in our upcoming programs:

Pet CBD Program | Nov 4-6, 2019 in Cape Coral, Florida
Pet Program | Apr 27-30, 2020 in Rosemont, Illinois

Contact our SVP of Retail to learn more about how you can partake in these programs: Wayne Bennett | (440) 528-4213 | WBennett@ECRM.MarketGate.com

ECRM.MarketGate.com



PRODUCTS | Dentistry

5. Warming blanket



Hot Dog warming blankets now offer a dual-port controller that allows for warming two patients at the same time using a single controller. Safe, effective, durable and reusable, these warming blankets are clinically proven to be more effective than competitive products.

6. Hot air warmer



Bair Hugger Warming Unit Model 675 from 3M incorporates updated software that accurately reflects the temperature at the end of the hose and displays on the LCD screen. The product is compatible with all Bair Hugger blanket styles.

7. Digital sensor



Midmark has introduced the first and only veterinary-specific, bite-resistant intraoral digital sensor with patented sensor housing to provide clear, crisp images that resist bite damage four times as well as the company's standard sensor. Midmark also provides free unlimited technical support and software upgrades for the life of the sensor.

8. Capnograph





Rad-97 with NomoLine Capnography from Masimo features an integrated sidestream gas analyzer for capnography, meeting continuous pulse carbon dioxide—oximetry and capnography needs in a single device with numeric, trend and waveform viewing options as well as fractional concentration of inspired carbon dioxide and respiration rate.

9. Endodontic motor



X-Smart IQ from Dentsply Sirona is a cordless endodontic motor controlled by a free Apple iOS IQ app. The monitor offers ease of use, virtually unbreakable NiTi rotary files tailor-made for dogs and cats, and the automatic reverse feature when a file binds. X-Smart IQ is a complete solution when shaping a root canal before cleaning and filling.

10. Physiologic monitor



Digicare's LifeWindow One is a multiparameter portable physiologic monitor engineered for veterinary anesthesia. Compact and user-friendly, LifeWindow offers optional Wi-Fi connectivity to allow users to connect to the product's iPad app for full control of the monitor, waveform display, printing and saving waveforms and patient records.

11. Periotome



Vet-Tome from iM3 is an automated periotome with foot pedal operation that facilitates precise tooth extraction with minimal or no alveolar bone loss and less trauma. The mechanical action and thin flexible blade allow easy insertion into the periodontal ligament space and alveolus coupled with the side-to-side movement by the operator cutting the ligament. The Vet-Tome decreases hand fatigue and speeds extraction time.

12. Catheter delivery system



Coltene's upgraded catheter delivery system delivers GuttaFlow to the apex of the cleaned root canal and can be cut to customize the length.

products





Medical Illumination International Air purification unit

Medical Illumination recently announced that it has completed its acquisition of the Vidashield product line from American Green Technology, including the UV24 Air Purification System. Built in the casing of a standardsize overhead light fixture (fluorescent or LED), the UV24 unit provides fast, continuous air purification that reduces bacteria, viruses and fungi in treated air without taking up floor or counter space. It also reduces the settling of airborne pathogens onto surfaces while reducing odors caused by bacteria and fungi. A single UV24 air purification unit can treat a volume of air equivalent to a room measuring 10 by 10 by 8 feet four times per hour. *For fastest response visit medillum.com*



Vetoquinol USA

Generic chewable NSAID

Flexprofen is a generic, beef-flavored chewable tablet that contains carprofen, a widely used, clinically proven nonsteroidal anti-inflammatory drug (NSAID) for dogs. The product is comparable to the leading brand name carprofen chewables that address symptoms of pain and inflammation typically associated with osteoarthritis. Flexprofen can also be used to treat dogs with postoperative pain resulting from soft-tissue and orthopedic surgeries. Flexprofen is available in 25-, 75- and 100-mg sizes in 180-count bottles. *For fastest response visit vetoquinolusa.com/flexprofen*

Smith Veterinary Consulting and Publishing

Book for relief, part-time work The fifth edition of *FlexVet: How to Be* One, How to Hire One, by Carin Smith, DVM, and Cindy Trice, DVM, is a practical guide for relief and part-time veterinarians. The book covers a wide range of resources to help practices as well as part-time and relief veterinarians navigate the business intricacies of flexible work. The 2019 edition includes updates on taxes, insurance and online resources. Other topics include choosing the right type of veterinarian for your practice, business plans, budgeting, marketing, social media and sample contracts and letters. For fastest response visit smithvet.com





Solutions Vetceterra Pet body bag

Euthabag is a practical solution for transportation, cremation and burial of euthanized pets that is respectful to both animal and caregiver. Euthabag features pleats on each side that create handles for easy transport. The waterproof fabric prevents leakage, is resistant to nails and tears, and expands to adjust to the animal's size. Animal identification information can be easily added with a pen or marker on the attached label, or an ID sticker may be added as a shipping tag. Available in five sizes, from extra-small, for pocket pets, to extra-large, for pets up to 190 lbs.

For fastest response visit euthabag.com





OF VETERINARY EXCELLENCE

EARS

Atlantic Coast Veterinary Conference[®] is celebrating 30 years this year in Atlantic City!

With over **250** sessions and **21** hours of RACE-approved CE, there will be something for everyone in the practice.

REGISTER TODAY AT ACVC.ORG

dvm360.com/products | Products & Services SHOWCASE



PRACTICE VALUATION SERVICES

What is your practice worth?

Contact us for a practice valuation today

William J. Roll, CPA Herring, Roll & Solomon, P.C. 570-286-5895 • wjroll@ptd.net



The product information you need at the click of a button.

Researching a purchase? Visit **dvm360.com** for hundreds more product listings.





Content licensing for every marketing strategy

Marketing solutions fit for:

- Tradeshow/POP Displays
 - dia
- Outdoor
- Social Media
- Direct Mail
- Radio & Television
- Print Advertising

Logo Licensing | Reprints | Eprints | Plaques

Leverage branded content from *DVM 360* to create a more powerful and sophisticated statement about your product, service or company in your next marketing campaign. Contact Wright's Media to find out more about how we can customize your acknowledgements and recognitions to enhance your marketing strategies.

For more information, call Wright's Media at 877.652.5295 or visit our website at www.wrightsmedia.com MEDICAL EQUIPMENT



MARKETPLACE | dvm360.com/products



Continuing education | CALENDAR

For a full listing of events in 2019, visit dvm360.com/calendar



August 21-23 HospitalDesign360 Conference (800) 255-6864, ext. 6 fetchdvm360.com/hd



August 23-26 Fetch dvm360 in Kansas City (800) 255-6864, ext. 6 fetchdvm360.com/kc



December 12-15 Fetch dvm360 in San Diego (800) 255-6864, ext. 6 fetchdvm360.com/sd

Here are the CE opportunities coming in the next few months

July 19-21

Pet Loss Professionals Alliance College Memphis, TN (800) 645-7700 myPLPA.org

July 19-21

PRIMA Move-Integrative Rehabilitation: **Canine Cranial Cruciate** Ligament Disease Fort Collins, CO (970) 818-0851 curacore.org

July 21-23

Great Lakes Veterinary Conference Traverse City, MI michvma.org

July 26-28

31st Fred Scott Feline Symposium Ithaca, NY (607) 253-3200 bit.ly/2Xe10DG

July 26

North Carolina **Regional Wildlife** Medicine Symposium Banner Elk, NC (828) 898-3521

August 1-4

Bluegrass Veterinary Conference Elizabeth, IN (252) 422-0943 vetmeetings.com August 2

20th Annual Hambletonian CE Seminar East Rutherford, NJ (908) 581-7673 firstchoice marketing.us

August 2-5 Southern Veterinary

Conference Birmingham, AL (205) 655-2320 thesvconline.com

August 2-6 AVMA Convention Washington, DC avma.org/events

August 3-4

Clinical Advantage-Technician's Workshop Baltimore, MD animaldentaltrainina com

August 7-9

Updates in Dentistry and Emergency **Critical** Care Mont Tremblant, QC (888) 488-3882 vetvacationce.com

August 9

How to Reduce Workplace Stress Through Communication & Leadership Skills Rosemont, IL (608) 265-5206

apps.vetmed.wisc. edu/cereg/

August 11-14

South Dakota VMA Annual Meeting Sioux Falls, SD (605) 688-6649 sdvetmed.org

August 11-14

Sun N Fun Veterinary Conference Myrtle Beach, FL (252) 422-0943 vetmeetings.com

August 15-18

13th Keystone Veterinary Conference Hershey, PA (888) 550-7862 pavma.org

August 21-23

HospitalDesign360 Conference Kansas City, MO (800) 255-6864, ext. 6 fetchdvm360.com/hd

August 21-24

Uncharted Veterinary Conference: Staff Drama Kansas City, MO unchartedvet.com

August 23-26 Fetch dvm360 in Kansas City Kansas City, MO (800) 255-6864, ext. 6 fetchdvm360.com

September 6-7

Sports Horse Medicine & Orthopedics Snohomish, WA (844) 870-6097

September 8-10

Pet Loss & Grief Companioning **Certification Course** Boston, MA (317) 966-0096 twoheartspetloss center.com

September 12-15

Colorado VMA Convention 2019 Denver, CO (303) 318-0447 colovma.ora

September 25-26

119th Penn Annual Conference Philadelphia, PA (215) 746-2421 vet.upenn.edu/ education

September 26-29

Southwest Veterinary Symposium 2019 San Antonio, TX (972) 664-9800 swvs.org

September 28-30

Pacific Northwest Veterinary Conference Tacoma, WA (800) 399-7862

October 4-6

Alaska State VMA Annual Symposium Anchorage, AK akvma.ora

October 4-6

2019 New York State Veterinary Conference Ithaca, NY cvent.me/xaxKg

Colorado VMA CE Southwest Durango, CO (303) 318-0447 colovma.org

October 14-17

The Atlantic Coast Veterinary Conference Atlantic City, NJ (609) 325-4915 acvc.org

acvssurgery

summit.org

dvm360[™] (Print ISSN: 2326-0688, Digital ISSN: 2326-070X) is published monthly by Multi/Media Healt care LLC, 325 W 1st St STE 300 Duluth MN 55802. Subscription rates: \$40 for one year in the United States & Possessions, Canada and Mexico; all other countries \$87.50. Single copies (prepaid only): \$11 in the United States; \$20 in Canada and Mexico; all other countries. Back issues, if available: U.S. \$23; Canada/Mexico \$28; all other countries \$46. International pricing includes air-expedited service. Include \$6.50 per order plus \$2 per additional copy for U.S. postage and handling. Periodicals postage paid at Duluth NN 55806 and additional mailing offices. POSTMASTER: Please send address change to dvm360, P. O. Box 6309, Duluth, NN 55806-6309. Canadian GST number. R-1242131387tO01, Publi ons Mail Agreement Number 40612608. Return undelive tions, P.O. Box 25542, London, ON N6C 6B2, Canada. Pr

© 2019 MultiMedia Healthcare LLC All rights reserved. No part of this publicati s instantia any form or by any means, electronic or part of this publication may be f smithetin in any form or by any means, electronic or mechanical including by photocop rmation storage and retrieval without permission in writing from the publisher. Auth to goy items for internal/educational or personal use, or the internal/educational or per c clients is granted by MultiMedia Healthcare LLC for libraries and other users regist opyright Clearance Center, 222 Rosewood Dr. Danvers, MA 01923, 978-750-8400 fax 978-646-8700 · visit http://www.copyright.com online. For uses beyond those listed above, please direct your writte quest to Permission Dept. fax 732-647-1104 or email: jfrommer@mmhgroup.com

MultiMedia Healthcare LLC provides certain customer contact data (such as customers' names, addresses, phone numbers, and e-mail addresses) to third parties who wish to promote relevant p ucts, services, and other opportunities which may be of interest to you. If you do not want MultiM Healthcare LLC to make your contact information available to third parties for marketing purpos simply call tol. Free (866) 529-2922 between the hours of 7:30 a.m. and 5 p.m. CST and a custome service representative will assist you in removing your name from MultiMedia Healthcare LLC's list simply call contract (coor) 327-2722 between the hours of 7.50 cm, and 5 pm, Cs1 and a costor service representative will assist you in removing your name from MultiMedia Healthcare LLC's1 Outside the United States, please call (218) 740-6477,dvm360 does not verify any claims or othe information appearing in any of the advertisements contained in the publication, and cannot ta responsibility for any losses or other damages incurred by readers in reliance on such content. dv not be held responsible for the safekeeping or return of unsolicited articles, manuscripts, photog illustrations, or other materials. Address correspondence to dvm360, 1140 Thompson Ave., Lene 66219, (913) 871-3800. To subscribe, call 888-527-7008. Outside the U.S. call 218-740-6477.

October 12-13

October 17-19

2019 ACVS Surgery Summit Las Vegas, NV (301) 916-0200

STAMPEDE | Bo Brock, DVM



His one weakness

I got a lot of great qualities from Joe Benny Brock, but I'm glad one small fear of his didn't get passed on in the genes.

oe Benny Brock. Most everyone called him Joe Benny, but I called him "Daddy."

He was a big man, 6 feet, 4 inches tall and about 250 pounds. But his size is not what defined him—it was his smile. When he truly smiled, his face changed completely. It was like his forehead got longer and his hairline moved back and away from his eyes. I have never seen a more amazing smile in my life. I loved that man, he took care of me, and I was his pride and joy.

We were a lot alike in many ways, but there are some things I got from my momma, and the "doctor" gene obviously came from her. Want to know how I know this? Well, here's the story.

When I was about 5 years old, we were at some occasion that brought about 60 family members to a farmhouse in the middle of nowhere. There was one batch of kids about my age I'd never seen. We were all out in the yard playing when a big German shepherdlooking dog came wandering onto the scene, seemingly full of bad intent.

Joe Benny was in the yard, and when he saw the animal and read its body language, he started rounding us all up and heading into the house. But instead of heading inside one little girl wouldn't listen. She ran toward that rascal, and it bit a chunk out of her shoulder. Joe Benny was screaming and making noise at the top of his lungs, trying to scare off the dog and slow the little girl down, but it didn't work. The damage was done, and now the child needed a trip to the doctor.

Looking back on it now, I'm not sure why they took me along, but they did. The girl was bleeding and crying, sitting in the back seat of a Dodge station wagon with her parents, while I sat in my momma's lap in the passenger seat and my daddy drove. (We didn't know what a car seat was back then.) We wound up at an old-timey doctor's office that smelled like alcohol and sick people. They took us all into the treatment room, and we waited awhile for the doctor. I remember seeing all that blood and I still her hear her crying like it was yesterday.

The room we were in was greenman, it was green. It had green asbestos tiles on the floor, the walls were a lighter shade of green, and even the old heater thing next to the wall was painted green. There were two chairs along one wall and one of those hard doctor beds with a piece of white paper pulled down over it in the center of the room. The girl's father was in one chair, while I was in my momma's lap on the other. The girl's mother was standing next to the doctor table, consoling her daughter with a nurse, and Joe Benny was perched in the window seat next to her looking a bit pale.

The doctor finally arrived and assessed the bite wound. He explained some things in grown-up talk to the parents and then told the nurse to prepare things to sew up the wound. I looked over and saw Joe Benny rub his face and noticed a bit of sweat forming on that forehead that expressed so much of his emotion.

The next few minutes were amazing to me, and I still remember them vividly 50 years later. First of all, looking back, how in the world was it all right for a little kid to be in the room to watch an arm sewing? Next, why did we take her to a doctor's office instead of an emergency room? And then, why was Joe Benny sitting so far away from the action?

There was a lot of screaming and crying as the doctor injected a local anesthetic before he sanitized and sutured. Then the sewing started. The crying and screaming had stopped, and I was enthralled as I watched the needle moving. It was just like my grandmother's sewing when she was making quilts in the den. I couldn't believe they did the same thing to skin.

Then about halfway through the sewing, I heard a thud behind me. My daddy was bent in two over the room's green heater. His hands were lying limp on the floor, and his feet weren't even touching the ground. It was like he'd suddenly fallen asleep, like a little kid in his high chair.

My momma screeched and put me on the floor as she scrambled across the room to assist him. The nurse left the doctor's side to check on him. I crawled back up into the chair and watched with great anticipation to find out why everyone was so concerned that my daddy had fallen asleep.

It was several years later that I finally laughed about this. And I still laugh. In fact, I'm cracking up as I write this. My dad, all 6-foot-4 of him, couldn't stand the sight of blood. He passed out in a doctor's office, draped over an oldtimey heater like laundry on a West Texas clothesline. He never did admit it, though. He always claimed it was because he hadn't eaten all day and was low on glucose.

I hope and pray that I got that man's sense of humor, compassion, wonderful smile and amazing intelligence, but I'm so glad I didn't get his weak stomach for sewing up tissue. I miss you, Joe Benny.

My momma reminded me of this story on the phone recently. We laughed and laughed and then laughed some more. Thank you, momma. Made my day.

Bo Brock, DVM, owns Brock Veterinary Clinic in Lamesa, Texas. His latest book is Crowded in the Middle of Nowhere: Tales of Humor and Healing From Rural America.



VETS MAKE TOUGH CHOICES EVERY DAY. DASUQUIN[®] ADVANCED IS AN EASY ONE.

RECOMMEND **DASUQUIN**[®] WITH CONFIDENCE.

- » ASU works with glucosamine & chondroitin sulfate to better protect cartilage than either of those ingredients alone.
- » Dasuquin[®] Advanced is not found online and is only available from veterinarians.

Become a member of our loyalty program at: loyalty.nutramaxlabs.com/DVM360 or to order please call Customer Service at 1-888-886-6442.





* Among veterinary brands in the US. Survey conducted among small animal veterinarians in the United States who recommended oral joint health supplements.

Available from all fine veterinarian product distributors.

What are their kidneys telling you?

Listen closer with **IDEXX SDMA®**

Detects

diseases of the kidney sooner¹⁻³

Reflects

other disease processes affecting the kidneys⁶

Learn more at idexx.com/dvmsdma

References available at idexx.com/SDMA



© 2019 IDEXX Laboratories, Inc. All rights reserved. • 2162925-00 All @/TM marks are owned by IDEXX Laboratories, Inc. or its affiliates in the United States and/or other countries. The IDEXX Privacy Policy is available at idexx.com.